

Multi-Ethnic Study of Atherosclerosis Monitoring Board Agenda

Conference Call

Phone (Audio)Connection:Dial 1-888-809-8852Pass Code: 134690

Internet (Visual) Connection: URL: <u>http://bbb.chscc.biostat.washington.edu/demo/mesa.jsp</u> Name: e-mail address Password: subclinical

Monday, November 3, 2014

11:00 am – 2:00 pm ET OSMB Meeting

Closed Session:		
11:00 am	Call to order	Dr. Hazuda
11:10 am	AnnouncementsDisclosure of conflicts	Ms. Sholinsky
11:15 am	Project Office Report	Dr. Olson
<u>General Session:</u> 11:30 am	 Steering Committee Report General remarks Responses to recommendations MESA III/Exam 6 Proposal update 	Dr. Burke
11:45 am	Coordinating Center Report	Mr. Johnson
12:00 pm	Participant Retention	Dr. Barr
12:15 pm	Events	Dr. Folsom
12:30 pm	Break	
12:45 pm	Radiation Exposure Update	Dr. Budoff
1:00 pm	Genetics Update	Dr. Rotter or Rich?
1:15 pm	P&P Report/Update on Recent Findings	Dr. Shea
Closed Session: 1:30 pm	Discussion and Recommendations	Board
2:00 pm	Adjourn	

Overview

MESA OSMB twice reviewed MESA Exam 6 ancillary study proposals earlier this year (Spring and Fall, 2014). The most recent OSMB review of MESA was by teleconference on September 30, 2013. Minutes from the September meeting are provided in Appendix A and the corresponding response to recommendations is provided in in the body of this executive summary.

Response to OSMB Recommendations (9/30/2013)

Recommendation 1: Enthusiastic endorsement of continuation of the MESA Study, highlighting these Study strengths and accomplishments:

- a. Continued outreach to non-MESA investigators and positioning MESA as a "population studies" laboratory
- b. Specimen usage policy
- c. Use of participant longitudinal summary report
- d. Outstanding publications record
- e. Successful involvement in NHLBI GO-Exome Sequencing Project

Response: Monitoring Board's recognition of the continuing scientific value of MESA is noted and appreciated.

Recommendation 2: Addition of a pulmonary disease expert to the Board, given likely funding of MESA COPD grant.

Response: NHLBI is pleased to welcome to the MESA OSMB Dr. Carlos Vaz Fragoso, from the VA-CT Clinical Epidemiology Research Center at Yale School of Medicine. Dr. Fragoso brings expertise in geriatrics and sleep disorders as well as pulmonary disorders. His membership will both complement and strengthen the Board as it provides oversight to MESA's expanding involvement in COPD and pulmonary related ancillary study activities.

Recommendation 3: Consideration of formal documentation/publication of MESA's experience with long-term retention and follow-up of a multi-ethnic, aging cohort.

Response: We very much appreciate the excellent publication topic. Several Coordinating Center Investigators are interested in this topic and are taking a leadership role in developing a manuscript.

Recommendation 4: Exploration of new venues for outreach to basic and translational scientists.

Response: To date, targeted outreach to basic and translational scientists has been somewhat limited. It should be noted that MESA resources and collaboration are available to virtually any interested researcher and that some ancillary studies currently being conducted have features that would be classified as basic or translational science. MESA is involved in the following noteworthy projects that might be classified as basic or translational science:

- COMBI-Bio a European / US collaboration in metabolomics.
- Epigenomics an epigenome-wide association study of DNA methylation and atherosclerosis.
- Arterial Elasticity measurement of pulse waveforms using novel equipment and analytic techniques.
- Markers for CKD a study of early kidney disease.

As part of overall outreach efforts, MESA will look for additional opportunities to engage basic and translational scientists.

Recommendation 5: NHLBI consideration of metrics comparing MESA to other cohorts of similar duration and complexity.

Response: The identification of metrics to evaluate the value and impact of large research studies has been an increasing focus of NHLBI. In 2013, the Institute established the NHLBI Advisory Council/Board of Extramural Experts Working Group on Epidemiology and Population Science to define how epidemiology and population research can be optimized, and in doing so is taking advantage of new evaluation methods and tools. The Working Group has just completed its deliberations and its draft report and recommendations can be found here:

http://nhlbiepi.wordpress.com/2014/10/22/recommendations-from-the-nhlbi-working-group-on-epidemiology/. NHLBI has begun to carefully consider these recommendations.

Over the past year, the Institute has been actively evaluating our research portfolio in new ways. Several portfolio analysis projects focusing on our epidemiology studies, including MESA, are underway to capture their productivity and assess their impact through biblioimetrics and other evaluation methodologies. Additionally, manuscripts are in the latter stages of development that will help NHLBI identify the contributions of Institute-supported research to the field of epidemiology and identify where gaps lie in its research portfolio. **Recommendation 6:** Radiation exposure – both per Exam and cumulative, noting that:

- Exact study procedure radiation dose is estimated per person
- Procedure radiation doses have come down considerably with technology advances
- Relatively few participants are nearing the MESA Study maximum threshold based on the Exam 5 report
- Risks of cumulative radiation exposure are not understood

Given the study threshold recommendations were made in 2009, the OSMB would like an update, including plans for managing radiation exposure going forward, should there be additional ancillary studies and/or exams.

Response:

Recommendation for Maximum Radiation Exposure

This report summarizes estimated radiation exposure for participants in MESA and presents recommendations for maximum radiation exposure for future examinations. These recommendations are most pertinent for MESA participants who received more radiation than expected due to protocol violations.

The MESA CT Committee still recommends the maximum total exposure for any MESA participant to be 25 milliSieverts for MESA research studies. This is more conservative than guidelines previously published regarding radiation safety limits including BIER VII¹ (<100 mSev) or annual doses for radiation workers² (<50 mSev/year). The MESA CT Committee felt it was both not feasible and outside the scope of the study to attempt to address or consider non-MESA clinical exposure to radiation. As shown in Table 3 below, no participant exceeded the recommended limit of 25 ms after completion of exam 5 at this time.

MESA CT Committee recommends that participants in the 21-25 mSev range be excluded from future studies that involve radiation. Since expected doses are <5 mSev for ancillary studies, no patients will exceed 25 mSev in MESA, inclusive of exam 6. Of special note is proposed study of CTA at Exam 6 which took into account this restriction when calculating sample sizes.

We are not aware of any updated data on radiation safety since 2009.

References:

- 1. Committee to Assess Health Risks from Exposure to Low Levels of Ionizing Radiation, National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2005.
- 2. 1990 Recommendations of the International Commission on Radiological Protection. ICRP Publication 60. Ann ICRP 1990;21.

Determining CT Radiation Exposure

Computed Tomography (CT) was performed during MESA exams, exposing participants to radiation. When Cardiac CT scans were acquired in exams 1 through 4, the protocol consisted of two scans during each examination. The Exam 5 Cardiac CT scan protocol consisted of one scan. For a select group of participants, Abdominal Aortic CT measurements (consisting of one scan) were completed once at either Exam 2 or 3, and a second time at Exam 4.

The estimated mean radiation exposure (per scan, in MilliSieverts), stratified by CT scanner model type and participant gender are presented below:

	Estimated Mean Radiation Exposure						
CT Scanner Model	(in MilliSieverts)						
	Ca	rdiac	Abd	lomen			
	Males	Females	Males	Females			
Aquilion	1.1	1.3	3	3			
Aquilion 64	1.1	1.3	3	3			
Imatron C-150	0.6	0.7	2.7	2.7			
Inner EBT	0.6	0.7	2.7	2.7			
Light Speed 16	1.1	1.3	2.6	2.6			
Light Speed Plus	1.5	1.9	2.4	2.4			
Light Speed Pro 16	1.5	1.9	2.4	2.4			
Light Speed QX/I	1.5	1.9	2.4	2.4			
Sensation 16	1.1	1.3	2.6	2.6			
Sensation Cardiac 64	0.9	1.1	2	2			
Volume Zoom	0.9	1.1	2.2	2.2			

Table 1a. Estimated per scan mean Radiation Exposure (mSv) by CT Scanner Model and Gender (E1-4)

CT Scanner Model	Estimated Mean Radiation Exposure (in MilliSieverts)						
	Ca	rdiac	Lung				
	Males	Females	Males	Females			
GE 64	1.2	1.1	3.9	3.7			
Siemens Definition 64	0.5	0.5	3.9	3.8			
Siemens Sensation 64	0.9	0.9	3.3	3.1			
Toshiba 320	1.3	1.2	3.3	3.0			

Table 1b. Estimated per scan mean Radiation Exposure (mSv) by CT Scanner Model and Gender (E5)

A dataset containing one case per participant has been created that combines all Cardiac, Lung, and Abdominal Aortic CT scan data from Exams 1 through 5. This file was used to summarize study radiation exposure in this report and will be used later on to track future total radiation exposure from participation in MESA. Also, this dataset will be used to identify study participants that may potentially exceed the study radiation exposure thresholds and, as a result, be recommended that they limit their participation in a future exam or not participate at all.

All Sites: Total CT Radiation Exposure

The following tables summarize the total radiation exposure from all MESA Cardiac CT (Exams 1 thru 5), Abdominal CT (Exams 2/3 and 4), and Lung CT (Exam 5 only) procedures. Protocol violations (where participants received more than the prescribed number of scans, or were scanned out of protocol, resulting in additional radiation exposure), are accounted in this summary.

Total MilliSieverts	Female	Male	Total
0.1 to 2.9 mSv	783	632	1415
3.0 to 5.9 mSv	701	701	1402
6.0 to 8.9 mSv	753	774	1527
9.0 to 11.9 mSv	767	667	1434
12.0 to 14.9 mSv	365	295	660
15.0 to 17.9 mSv	164	97	261
18.0 to 20.9 mSv	39	41	80
21.0 to 24.9 mSv	29	6	35
25.0 mSv or more	0	0	0
Total	3601	3213	6814

Table 2. Total Radiation Exposure from All MESA CT Procedures, Exams 1 – 5 (All Sites)

Exam Component	N	Mean (mSv)	SD	Min	25 th %ile	Median	75 th %ile	Max
Exam 1 Cardiac CT	6814	1.86	0.77	1.20	1.40	1.40	2.20	3.80
Exam 2 Cardiac CT	2955	1.86	0.78	1.20	1.40	1.40	2.20	3.80
Exam 3 Cardiac CT	2929	2.01	0.79	1.20	1.40	1.80	2.60	3.80
Exam 4 Cardiac CT	1412	2.14	0.75	1.20	1.40	2.20	2.60	3.80
Exam 5 Cardiac CT	3266	1.04	0.43	0.05	0.73	0.95	1.16	12.26
Exam 5 Lung CT	3124	4.10	0.89	0.11	3.49	3.80	4.77	10.04
Exam 2 Abd CT	780	2.54	0.20	2.20	2.40	2.70	2.70	2.70
Exam 3 Abd CT	1191	2.56	0.20	2.00	2.40	2.70	2.70	2.70
Exam 4 Abd CT	936	2.56	0.30	2.00	2.40	2.60	2.70	3.00
Cumulative Total (Ex1-5)	6814	7.44	4.34	1.20	3.60	7.12	10.22	23.33

Table 3. Total Radiation Exposure: Descriptive Summary (All Sites)

Variability in exposure shown in this table is based on scanner type and number of participants who received scans from different scanners, including protocol violations. Out of the 6814 MESA cohort, 376 participants have had a cumulative radiation exposure greater than 15 milliSieverts. No participant has reached or exceeded the cumulative radiation exposure threshold of 25 mSv.

Retention Report

Steering Committee Report Section 1 describes clinic exam and follow-up call retention rates in detail. Important highlights from the report follow.


Clinic Exam Retention

As of the end of Exam 5 (approximately 10 years post baseline) which was completed in February 2012, there are 4,655 participants who completed the exam which is approximately 76% of the cohort that was still enrolled (not deceased) as of Exam 5. Despite efforts emphasizing minority retention, Exam 5 minority retention rates were still lower than those observed for white participants.

	Exam 2		Exam 2 Exam 3		Exam 4		Exam 5					
	Enrolled	Done	%	Enrolled	Done	%	Enrolled	Done	%	Enrolled	Done	%
AFA	1872	1692	90%	1842	1607	87%	1806	1531	85%	1651	1233	75%
CHN	798	729	91%	790	699	88%	783	661	84%	750	541	72%
HIS	1476	1352	92%	1461	1257	86%	1444	1224	85%	1367	999	73%
CAU	2608	2466	95%	2575	2383	93%	2539	2288	90%	2381	1882	79%
Total	6754	6239	92%	6668	5946	89%	6572	5704	87%	6149	4655	76%

Follow-up Call retention

Follow-up call 14 was recently completed. Follow-up call 15 is currently underway and Follow-up call 16 is scheduled to begin by the end of October 2014. As would be expected, retention rates have decreased over time. Follow-up 10 difficulties (resources were directed to Exam 5 clinic exam efforts) were temporary and subsequent retention is more in line with expectations.



Appendix A: MESA OSMB Meeting Minutes (September 30, 2014)

MINUTES Observational Study Monitoring Board Multi-Ethnic Study of Atherosclerosis (MESA) Conference Call, 09/30/2013

PARTICIPANTS:

OSMB Members Present: Helen Hazuda (Chair), Ingrid Borecki, James Chesebro, Elisa Lee, L. Kristin Newby, Lewis Wexler

OSMB Members Absent: none

Investigators: Greg Burke (Steering Committee Chair), R. Graham Barr, Aaron Folsom, Susan Heckbert, Stephen Rich

Data Coordinating Center Staff: Craig Johnson, Richard Kronmal, Robyn McClelland

NHLBI Staff: Phyliss Sholinsky (Executive Secretary), Roxane Burkett, Cheryl Jennings, Jean Olson, Lorraine Silsbee

CALL TO ORDER: Dr. Hazuda convened this regularly scheduled annual meeting, being held as a conference call, at 11:00 am. Potential Board Member conflicts-of-interest were reviewed; there were no new ones to report.

The Project Office report included discussion of cohort follow-up and retention efforts. There have been 146 MESA manuscripts in press or published since the 2012 OSMB report. Thirty-five ancillary studies were approved. The current MESA contracts expire in 2015; proposed MESA renewal options are under consideration.

STUDY DESCRIPTIONS:

The MESA OSMB reviews the MESA Study along with its ancillary studies, including the MESA Air Study, which recruited new participants in addition to collecting data on consenting participants from the parent MESA study. The main MESA Study investigates the prevalence, correlates, and progression of subclinical cardiovascular disease (CVD) in a multi-ethnic cohort. The MESA Air Study prospectively examines the relationship between individual-level long-term air pollution exposures and progression of CVD. MESA Air is funded by the EPA, which convenes its own External Scientific Advisory Committee (ESAC), while the MESA OSMB provides oversight of participant burden and impact on the main MESA Study.

RESPONSES TO 2012 RECOMMENDATIONS:

The investigators presented their responses to the OSMB's September 2012 recommendations, which the OSMB accepted. Detailed follow-up information on participants with alert-level findings from MESA CT and MR exam components were provided in the OSMB report; relatively very few required urgent follow-up. The MESA Operations Committee, Participant Relations Committee and Field Center staff are working collaboratively to identify effective strategies for cohort retention, focusing on the older, possibly increasingly cognitively-impaired make-up of the cohort, along with on-going multi-ethnic considerations. MESA's outreach to non-MESA colleagues has resulted in the latter's involvement in 40% of ancillary studies and 25% of manuscripts as well as additional data access via BioLINCC and dbGaP.

ADVERSE EVENTS:

Not applicable; Examination 5 was completed prior to the 2012 OSMB report.

STUDY PROGRESS:

The investigators presented the progress made in the past year in cohort retention, follow-up data collection and events surveillance, longitudinal data availability, data analysis, publications (564 overall), and ancillary studies.

As part of ongoing efforts to position MESA as a "population laboratory", a Specimen Usage Policy was developed and incorporated into MESA's Ancillary Study Policy to optimize and prioritize use of specimens by MESA and non-MESA colleagues. In addition, an Analytic Opportunities Committee was established with expert contact persons assigned to promote collaborations in specific research areas. Ancillary studies proposed during the current contract period cover a wide range of research areas and achieved a high rate of funding success.

Based on Follow-Up 13, cohort retention is at 89% of target and showed improvement over past heterogeneity across sites. Follow-up 14 has begun. Challenges include those anticipated for an aging cohort, such as declining cognitive function, and cultural and immigration issues, such as participant return to country of origin. As noted above, there are ongoing efforts to improve retention efforts. The newly introduced Participant Summary Report, providing data feedback from the five Examinations, is anticipated to be an effective retention tool.

Although two centers are behind in follow-up activities, overall events surveillance continues to be up-to-date, with 94% of identified reports investigated and 91% classified. MESA surveillance remains an important activity as HMO-provided care is not represented in Medicare databases nor does the latter allow for validation. An average of 8.5 years of follow-up event data per participant is currently available for analyses; the next scheduled release is in 2014.

The NHLBI GO-Exome Sequencing Project, CHARGE-MESA ExomeChip and MESA's contributions to these programs were also discussed in depth.

MESA's overall focus will continue to be on: 1) maintenance of cohort retention; 2) follow-up calls and events surveillance; and 3) integration of ancillary studies. Analyses and publications will be emphasized, along with continued expansion of opportunities for engagement of "non-MESA" colleagues.

2013 Recommendations:

There were no issues of serious concern. The Board approved the request to oversee the MESA-related participant-burden aspects of the follow-up MESA COPD ancillary study.

The following recommendations were made:

- 1) Enthusiastic endorsement of continuation of the MESA Study, highlighting these Study strengths and accomplishments:
 - a. Continued outreach to non-MESA investigators and positioning MESA as a "population studies" laboratory
 - b. Specimen usage policy
 - c. Use of participant longitudinal summary report
 - d. Outstanding publications record
 - e. Successful involvement in NHLBI GO-Exome Sequencing Project

- Addition of a pulmonary disease expert to the Board, given likely funding of MESA COPD grant.
- 3) Consideration of formal documentation/publication of MESA's experience with long-term retention and follow-up of a multi-ethnic, aging cohort.
- 4) Exploration of new venues for outreach to basic and translational scientists.
- 5) NHLBI consideration of metrics comparing MESA to other cohorts of similar duration and complexity.

Next Meeting:

The meeting adjourned at 2:00 pm. The next in-person or conference call meeting will be scheduled for September 2014.

Respectfully submitted,

_/s 10/23/2013_____ Helen Hazuda, Ph.D. Chair, MESA OSMB __/s 10/23/2013____ Phyliss Sholinsky, M.S.P.H. Executive Secretary, MESA OSMB

SIGNATURES

<u>X</u> APPROVAL <u>DISAPPROVAL</u>

Sucar B. Shum

October 24, 2013

Susan B. Shurin, MD, Deputy Director, NHLBI

Date

Appendix B: Recent Publications

Published MESA Papers (4th Quarter 2013 – 3rd Quarter 2014) Chronological by Date published

- DeSantis AS, Diez Roux AV, Moore K, Baron KG, Mujahid MS, Nieto FJ. Associations of Neighborhood Characteristics with Sleep Timing and Quality: The Multi-Ethnic Study of Atherosclerosis. Sleep. 2013;36(10):1543-1551.
- Harhay MO, Tracy RP, Bagiella E, Barr RG, Pinder D, Hundley WG, Bluemke DA, Kronmal RA, Lima JA, Kawut SM. Relationship of CRP, IL-6 and fibrinogen with right ventricular structure and function: The MESA-Right Ventricle Study. *Int J Cardiol.* 2013;168(4):3818-3824.
- 3. <u>Blondon M, Sachs M, Hoofnagle AN, Ix JH, Michos ED, Korcarz C, Gepner AD, Siscovick DS, Kaufman JD, Stein JH, Kestenbaum B, de Boer IH. 25-hydroxyviatim d and parathyroid hormone are not associated with carotid intima-media thickness or plaque in the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2013;33(11):2639-2645.</u>
- Klein R, Li X, Kuo JZ, Klein BE, Cotch MF, Wong TY, Taylor KD, Rotter JI. Associations of candidate genes to age-related macular degeneration among racial/ethnic groups in the multiethnic study of atherosclerosis. *Am J Ophthalmol.* 2013;156(5):1010-1020.
- Jensky NE, Allison MA, Loomba R, Carnethon MR, de Boer IH, Budoff MJ, Burke GL, Criqui MH, Ix JH. Null association between abdominal muscle and calcified atherosclerosis in community-living persons without clinical cardiovascular disease: The multi-ethnic study of atherosclerosis. *Metabolism*. 2013;62(11):1562-1569.
- Elmariah S, Budoff MJ, Delaney JA, Hamirani Y, Eng J, Fuster V, Kronmal RA, Halperin JL, O'Brien KD. Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. *Am Heart J*. 2013;166(5):904-912.
- Hirsch JA, Diez Roux AV, Rodriguez DA, Brines SJ, Moore KA. Discrete land uses and transportation walking in two U.S. cities: The Multi-Ethnic Study of Atherosclerosis. *Health Place*. 2013;24:196-202.
- Steffen BT, Steffen LM, Liang S, Tracy R, Jenny NS, Tsai MY. n-3 and n-6 Fatty acids are independently associated with lipoprotein-associated phospholipase A2 in the Multi-Ethnic Study of Atherosclerosis. *Br J Nutr.* 2013;110(9):1664-1671.
- <u>Golden SH, Sanchez BN, Wu M, Champaneri S, Diez Roux AV, Seeman T, Wand GS.</u> <u>Relationship between the cortisol awakening response and other features of the diurnal cortisol</u> <u>rhythm: The Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology*. <u>2013;38(11):2720-2728.</u>
 </u>
- <u>Tomey K, Diez Roux AV, Clarke P, Seeman T. Associations between neighborhood</u> <u>characteristics and self-rated health: A cross-sectional investigation in the Multi-Ethnic Study of</u> <u>Atherosclerosis (MESA) cohort. *Health Place*. 2013;24:267-274.
 </u>
- Hicken MT, Adar SD, Diez Roux AV, O'Neill MS, Magzamen S, Auchincloss AH, Kaufman JD. Do psychosocial stress and social disadvantage modify the association between air pollution and blood pressure?: the multi-ethnic study of atherosclerosis. *Am J Epidemiol*. 2013;178(10):1550-1562.

- Hajat A, Diez-Roux AV, Adar SD, Auchincloss AH, Lovasi GS, O'Neill MS, Sheppard L, Kaufman JD. Air Pollution and Individual and Neighborhood Socioeconomic Status: Evidence from the Multi-Ethnic Study of Atherosclerosis (MESA). *Environ Health Perspect*. 2013;121(11-12):1325-1333.
- Soliman EZ, Alonso A, Misialek JR, Jain A, Watson KE, Lloyd-Jones DM, Lima J, Shea S, Burke GL, Heckbert SR. Reference ranges of PR duration and P-wave indices in individuals free of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis (MESA). *J Electrocardiol*. 2013;46(6):702-706.
- Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. *Heart*. 2013;99(24):1832-1836.
- 15. <u>Bansal N, Katz R, de Boer IH, Kestenbaum B, Siscovick DS, Hoofnagle AN, Tracy R, Laughlin GA, Criqui MH, Budoff MJ, Li D, Ix JH. Influence of Estrogen Therapy on Calcium, Phosphorus, and Other Regulatory Hormones in Postmenopausal Women: The MESA Study. J Clin Endocrinol Metab. 2013;98(12):4890-4898.</u>
- 16. <u>Kerr KF, Wang Z, Janes H, McClelland RL, Psaty BM, Pepe MS. Net reclassification indices for</u> evaluating risk prediction instruments: a critical review. *Epidemiology*. 2014;25(1):114-121.
- 17. <u>Al-Mallah MH, Nasir K, Katz R, Lima JA, Bluemke DA, Blumenthal RS, Mao S, Hundley WG, Budoff MJ. Relation of Thoracic Aortic Distensibility to Left Ventricular Area (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *Am J Cardiol.* 2014;113(1):178-182.</u>
- Tsai MY, Steffen BT, Guan W, McClelland RL, Warnick R, McConnell J, Hoefner DM, Remaley AT. New automated assay of small dense low-density lipoprotein cholesterol identifies risk of coronary heart disease: the multi-ethnic study of atherosclerosis. *Arterioscler Thromb* <u>Vasc Biol. 2014;34(1):196-201.</u>
- 19. <u>Gepner AD, Korcarz CE, Colangelo LA, Hom EK, Tattersall MC, Astor BC, Kaufman JD, Liu K, Stein JH. Longitudinal effects of a decade of aging on carotid artery stiffness: the multiethnic study of atherosclerosis. *Stroke*. 2014;45(1):48-53.</u>
- Smith BM, Austin JH, Newell JD Jr, D'Souza BM, Rozenshtein A, Hoffman EA, Ahmed F, Barr RG. Pulmonary Emphysema Subtypes on Computed Tomography: The MESA COPD Study. Am J Med. 2014;127(1):94.e7-94.e23.
- 21. <u>Armstrong AC, Gjesdal O, Almeida A, Nacif M, Wu C, Bluemke DA, Brumback L, Lima JA.</u> Left ventricular mass and hypertrophy by echocardiography and cardiac magnetic resonance: the multi-ethnic study of atherosclerosis. *Echocardiography*. 2014;31(1):12-20
- 22. <u>Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR,</u> <u>Blumenthal RS, Budoff MJ, Nasir K. Dyslipidemia, coronary artery calcium, and incident</u> <u>atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study</u> <u>of atherosclerosis. *Circulation*. 2014;129(1):77-86.</u>
- 23. Wheeler AL, Scherzer R, Lee D, Delaney JA, Bacchetti P, Shlipak M, Sidney S, Grunfeld C, Tien PC; Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). HIV/hepatitis

<u>C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection. *AIDS*. 2014;28(1):49-58.</u>

- <u>Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ,</u> <u>Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular</u> <u>events. JAMA. 2014;311(3):271-278.</u>
- 25. <u>Linefsky JP, O'Brien KD, Sachs M, Katz R, Eng J, Michos ED, Budoff MJ, de Boer I, Kestenbaum B. Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2014;233(2):331-337.</u>
- 26. <u>Bradley RD, Fitzpatrick AL, Jacobs DR Jr, Lee DH, Swords Jenny N, Herrington D. Associations</u> between y-glutamyltransferase (GGT) and biomarkers of atherosclerosis: The multi-ethnic study of atherosclerosis (MESA). *Atherosclerosis*. 2014;233(2):387-393.
- 27. Szpiro AA, Paciorek CJ. Measurement error in two-stage analyses, with application to air pollution epidemiology. *Environmetrics*. 2014;24:501-517. doi: 10.1002/env.2233
- Turkbey EB, Jain A, Johnson C, Redheuil A, Arai AE, Gomes AS, Carr J, Hundley WG, Teixido-Tura G, Eng J, Lima JA, Bluemke DA. Determinants and normal values of ascending aortic diameter by age, gender, and race/ethnicity in the Multi-Ethnic Study of Atherosclerosis (MESA). J Magn Reson Imaging. 2014;39(2):360-368.
- 29. Li X, Avery CL, Sitlani CM, Arking DE, Arnett DK, Bis JC, Boerwinkle E, Buckley BM, Chen IY, de Craen AJ, Eijgelsheim M, Enquobahrie D, Evans DS, Ford I, Garcia ME, Gudnason V, Harris TB, Heckbert SR, Hochner H, Hofman A, Hsueh WC Isaacs A, Jukema JW, Knekt P, Kors JA, Krijthe BP, Kristiansson K, Laaksonen M, Liu Y, Macfarlane PW, Newton-Cheh C, Nieminen MS, Oostra BA, Pelosa GM, Porthan K, Rice K, Rivadeneira FF, Rotter JI, Salomaa V, Sattar N, Siscovick DS, Slagboom PE, Smith AV, Sotoodehnia N, Stott DJ, Stricker BH, Sturmer T, Trompet S, Utterlinden AG, van Duijn C, Westerdorp RG, Witteman JC, Whitsel EA, Psaty BM. Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. *Pharmacogenomics J.* 2014;14(1):6-13.
- Pandey AK, Blaha MJ, Sharma K, Rivera J, Budoff MJ, Blankstein R, Al-Mallah M, Wong ND, Shaw L, Carr J, O'Leary D, Lima JA, Szklo M, Blumenthal RS, Nasir K. Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2014;232(2):369-376.
- 31. <u>Bittencourt MS, Blaha MJ, Blankstein R, Budoff M, Vargas JD, Blumenthal RS, Agatston A, Nasir K. Polypill Therapy, Subclinical Atherosclerosis, and Cardiovascular Events Implications for the Use of Preventive Pharmacotherapy: MESA (Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol. 2014;63(5):434-443.</u>
- Whelton SP, Narla V, Blaha MJ, Nasir K, Blumenthal RS, Jenny NS, Al-Mallah MH, Michos ED. Association Between Resting Heart Rate and Inflammatory Biomarkers (High-Sensitivity C-Reactive Protein, Interleukin-6, and Fibrinogen) (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol*. 2014;113(4):644-649.

- 33. <u>Manichaikul A, Hoffman EA, Smolonska, J, Gao W, Cho MH, Baumhauer H, Budoff M, Austin JH, Washko GR, Carr JJ, Kaufman JD, Pottinger T, Powel CA, Wijmenga C, Zanen P, Groen HJ, Postma DS, Wanner A, Rouhani FN, Brantly ML, Powell R, Smith BM, Rabinowitz D, Raffel LJ, Hinckley Stukovsky KD, Crapo JD, Beaty TH, Hokanson JE, Silverman EK, Dupuis J, O'Connor GT, Boezen HM, Rich SS, Barr RG. Genome-Wide Study of Percent Emphysema on Computed Tomography in the General Population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. *Am J Respir Crit Care Med*. 2014;189(4):408-418.</u>
- 34. Whitman IR, Patel VV, Soliman EZ, Bluemke DA, Praestgaard A, Jain A, Herrington D, Lima JA, Kawut SM. Validity of the Surface Electrocardiogram Criteria for Right Ventricular Hypertrophy: The MESA-RV Study (Multi-Ethnic Study of Atherosclerosis-Right Ventricle). J Am Coll Cardiol. 2014;63(7):672-681.
- 35. <u>Kanaya AM, Kandula NR, Ewing SK, Herrington D, Liu K, Blaha MJ, Srivastava S, Dave SS,</u> <u>Budoff MJ. Comparing coronary artery calcium among U.S. South Asians with four racial/ethnic</u> <u>groups: The MASALA and MESA studies. *Atherosclerosis.* 2014;234(1):102-107.</u>
- 36. Manichaikul A, Peloso GM, Auer PL, Bis JC, Voorman A, Morrison AC, Stitziel NO, Brody JA, Khetarpal SA, Crosby JR, Fornage M, Isaacs A, Jakobsdottir J, Feitosa MF, Davies G, Huffman JE, Davis B, Lohman K, Joon AY, Smith AV, Grove ML, Zanoni P, Redon V, Demissie S, Lawson K, Peters U, Carlson C, Jackson RD, Rvckman KK, Mackey RH, Robinson JG, Siscovick DS, Schreiner PJ, Mychaleckyj JC, Pankow JS, Hofman A, Uitterlinden AG, Harris TB, Taylor KD, Stafford JM, Reynolds LM, Marioni RE, Dehghan A, Franco OH, Patel AP, Lu Y, Hindy G, Gottesman O, Bottinger EP, Melander O, Orho-Melander M, Loos RJ, Duga S, Merlini PA, Farrall M, Goel A, Asselta R, Girelli D, Martinelli N, Shah SH, Kraus WE, Li M, Rader DJ, Reilly MP, McPherson R, Watkins H, Ardissino D; NHLBI GO Exome Sequencing Project, Zhang Q, Wang J, Tsai MH, Taylor HA, Correa A, Griswold ME, Lange LA, Starr JM, Rudan I, Eiriksdottir G, Launer LJ, Ordovas JM, Lew D, Chen YD, Reiner AP, Hayward C, Polasek O, Deary IJ, Borecki IB, Liu Y, Gudnason V, Wilson JG, van Duijn Cm, Kooperberg C, Rich SS, Psaty BM, Rotter JI, O'Donnell CJ, Rick K, Boerwinkle E, Kathiresan S, Cupples LA. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *Am J Hum Genet*. 2014;94(2):223-232.
- 37. Sturtz TM, Adar SD, Gould T, Larson TV. Constrained source apportionment of coarse particulate matter and selected trace elements in three cities from the multi-ethnic study of atherosclerosis. *Atmospheric Environment*. 2014;84:65-77.
- Ranchod YK, Diez Roux AV, Evenson KR, Sanchez BN, Moore K. Longitudinal associations between neighborhood recreational facilities and change in recreational physical activity in the multi-ethnic study of atherosclerosis, 2000-2007. *Am J Epidemiol*. 2014;179(3):335-343.
- <u>Castro-Diehl C, Diez Roux AV, Seeman T, Shea S, Shrager S, Tadros S. Associations of</u> socioeconomic and psychosocial factors with urinary measures of cortisol and catecholamines in the Multi-Ethnic Study of Atherosclerosis (MESA). *Psychoneuroendocrinology*. 2014;41:132-141.
- 40. <u>Hirsch JA, Diez Roux AV, Moore KA, Evenson KR, Rodriguez DA. Change in walking and</u> body mass index following residential relocation: the multi-ethnic study of atherosclerosis. *Am J* <u>*Public Health*</u>. 2014;104(3):e49-56.

- 41. <u>Kalyani RR, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, Becker D, Vaidya D. Sex</u> <u>differences in diabetes and risk of incident coronary artery disease in healthy young and middle-</u> <u>aged adults. *Diabetes Care*. 2014;37(3):830-838.</u>
- 42. <u>Szpiro AA, Sheppard L, Adar SD, Kaufman JD. Estimating acute air pollution health effects from cohort study data. *Biometrics*. 2014;70(1):164-174.</u>
- Manichaikul A, Rich SS, Perry H, Yeboah J, Law M, Davis M, Parker M, Ragosta M, Connelly JJ, McNamara CA, Taylor AM. A Functionally Significant Polymorphism in ID3 Is Associated with Human Coronary Pathology. *PLoS One*. 2014;9(3):e90222. doi: 10.1371/journal.pone.0090222. eCollection 2014.
- 44. Donekal S, Venkatesh BA, Liu YC, Liu CY, Yoneyama K, Wu CO, Nacif M, Gomes AS, Hundley WG, Bluemke DA, Lima JA. Interstitial Fibrosis, Left Ventricular Remodeling, and Myocardial Mechanical Behavior in a Population-Based Multiethnic Cohort: The Multi-Ethnic Study of Atherosclerosis (MESA) Study. *Circ Cardiovasc Imaging*. 2014;7(2)292-302.
- 45. <u>Remigio-Baker RA, Diez Roux AV, Szklo M, Crum RM, Leoutsakos JM, Franco M, Schreiner PJ, Carnethon MR, Nettleton JA, Mujahid MS, Michos ED, Gary-Webb TL, Golden SH. Physical environment may modify the association between depressive symptoms and change in waist circumference: the multi-ethnic study of atherosclerosis. *Psychosomatics*. 2014;55(2):144-154.</u>
- 46. <u>Ambale-Venkatesh B, Armstrong AC, Liu CY, Donekal S, Yoneyama K, Wu CO, Gomes AS, Hundley GW, Bluemke DA, Lima JA. Diastolic function assessed from tagged MRI predicts heart failure and atrial fibrillation over an 8-year follow-up period: the multi-ethnic study of atherosclerosis. *Eur Heart J Cardiovasc Imaging*. 2014;15(4):442-449.</u>
- Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, Maisel A, Peralta CA, Jacobs DR Jr. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: The Multi-Ethnic Study of Atherosclerosis. *Metabolism*. 2014;63(4):475-483.
- van Ballegooijen AJ, Kestenbaum B, Sachs MC, de Boer IH, Siscovick DS, Hoofnagle AN, Ix JH, Visser M, Brouwer IA. Association of 25-Hydroxyvitamin D and Parathyroid Hormone With Incident Hypertension: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(12):1214-1222.
- 49. Opdahl A, Ambale Venkatesh B, Fernandes VR, Wu CO, Nasir K, Choi EY, Almeida AL, Rosen B, Carvalho B, Edvardsen T, Bluemke DA, Lima JA. Resting Heart Rate as Predictor for Left Ventricular Dysfunction and Heart Failure: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(12):1182-1189.
- 50. <u>Bild DE, McClelland R, Kaufman JD, Blumenthal R, Burke GL, Carr JJ, Post WS, Register TC, Shea S, Szklo M. Ten-Year Trends in Coronary Calcification in Individuals without Clinical Cardiovascular Disease in the Multi-Ethnic Study of Atherosclerosis. *PLoS One.* 2014;9(4):e94916. doi: 10.1371/journal.pone.0094916. eCollection 2014.</u>
- 51. <u>Tota-Maharaj R, Blaha MJ, Zeb I, Katz R, Blankstein R, Blumenthal RS, Budoff MJ, Nasir K.</u> <u>Ethnic and sex differences in Fatty liver on cardiac computed tomography: the multi-ethnic study</u> <u>of atherosclerosis</u>. *Mayo Clin Proc.* 2014;89(4):493-503.

- 52. <u>Merkin SS, Karlamangla A, Roux AV, Shrager S, Seeman TE. Life course socioeconomic status</u> and longitudinal accumulation of allostatic load in adulthood: multi-ethnic study of atherosclerosis. *Am J Public Health*. 2014;104(4):e48-55.
- 53. <u>Lilly SM, Jacobs DR Jr, Kronmal R, Bluemke DA, Criqui M, Lima J, Allison M, Duprez D, Segers P, Chirinos JA. Arterial compliance across the spectrum of ankle-brachial index: the multiethnic study of atherosclerosis. *Atherosclerosis*. 2014;233(2):691-696.</u>
- 54. <u>Golden SH, Sanchez BN, DeSantis AS, Wu M, Castro C, Seeman TE, Tadros S, Shrager S, Diez Roux AV. Salivary cortisol protocol adherence and reliability by socio-demographic features:</u> <u>The Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology*. 2014;43:30-40.</u>
- 55. <u>Gepner AD, Colangelo LA, Blondon M, Korcarz CE, de Boer IH, Kestenbaum B, Siscovick DS, Kaufman JD, Liu K, Stein JH. 25-hydroxyvitamin d and parathyroid hormone levels do not predict changes in carotid arterial stiffness: the multi-ethnic study of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2014;34(5):1102-1109.</u>
- 56. Zavodni AE, Wasserman BA, McClelland RL, Gomes AS, Folsom AR, Polak JF, Lima JA, Bluemke DA. Carotid Artery Plaque Morphology and Composition in Relation to Incident Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA). *Radiology*. 2014;271(2):381-389.
- 57. Polak JF, Sacco RL, Post WS, Vaidya D, Arnan MK, O'Leary DH. Incident stroke is associated with common carotid artery diameter and not common carotid artery intima-media thickness. Stroke. 2014;45(5):1442-1446.
- Leary PJ, Kaufman JD, Barr RG, Bluemke DA, Curl CL, Hough CL, Lima JA, Szpiro AA, Van Hee VC, Kawut SM. Traffic-related Air Pollution and the Right Ventricle. The Multi-ethnic Study of Atherosclerosis. *Am J Respir Crit Care Med*. 2014;189(9):1093-1100.
- Fleishman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis. *World J Gastroenterol.* 2014;20(17):4987-4993.
- 60. <u>Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, Lima JA, Polak JF, Blondon M, Ruzinski J, Rock D, de Boer IH. Fibroblast growth factor-23 and cardiovascular disease in the general population: the multi-ethnic study of atherosclerosis. *Circ Heart Fail.* 2014;7(3):409-417.</u>
- 61. <u>Harkness JR, Silverman MG, Blankstein R, Budoff MJ, Agatston AS, Carr JJ, Lima JA,</u> <u>Blumenthal RS, Nasir K, Blaha MJ. Baseline subclinical atherosclerosis burden and distribution</u> <u>are associated with frequency and mode of future coronary revascularization: multi-ethnic study</u> <u>of atherosclerosis. *JACC Cardiovasc Imaging*. 2014;7(5):476-486.</u>
- 62. <u>Chrispin J, Jain A, Soliman EZ, Guallar E, Alonso A, Heckbert SR, Bluemke DA, Lima JA, Nazarian S. Association of Electrocardiographic and Imaging Surrogates of Left Ventricular Hypertrophy With Incident Atrial Fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2014;63(19):2007-2013.</u>

- 63. <u>McAuley PA, Chen H, Lee DC, Artero EG, Bluemke DA, Burke GL. Physical Activity,</u> <u>Measures of Obesity and Cardiometabolic Risk: The Multi-Ethnic Study of Atherosclerosis</u> (MESA). J Phys Act Health. 2014;11(4):831-837.
- 64. <u>Weiner SD, Ahmed HN, Jin Z, Cushman M, Herrington DM, Nelson JC, Di Tullio MR, Homma S. Systematic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). *Heart*. 2014;100(11):862-866.</u>
- 65. <u>Rifkin DE, Khaki AR, Jenny NS, McClelland RL, Budoff M, Watson K, Ix JH, Allison MA.</u> <u>Association of Renin and aldosterone with ethnicity and blood pressure: the multi-ethnic study of</u> <u>atherosclerosis. *Am J Hypertens*. 2014;27(6):801-810.</u>
- 66. <u>Arguelles W, Llabre MM, Penedo FJ, Daviglus ML, Sacco RL, Liu K, Szklo M, Polak JF, Eng J,</u> <u>Burke GL, Schneiderman N. Relationship of change in traditional cardiometabolic risk factors to</u> <u>change in coronary artery calcification among individuals with detectable subclinical</u> <u>atherosclerosis: The multi-ethnic study of atherosclerosis. *Int J Cardiol.* 2014;174(1):51-56.</u>
- 67. Ebong IA, Watson KE, Goff DC Jr, Bluemke DA, Srikanthan P, Horwich T, Bertoni AG. Age at menopause and incident heart failure: the Multi-Ethnic Study of Atherosclerosis. *Menopause*. 2014;21(6):585-591.
- 68. <u>Berardi C, Decker PA, Kirsch PS, de Andrade M, Tsai MY, Pankow JS, Sale MM, Sicotte H, Tang W, Hanson N, Polak JF, Bielinski SJ. Plasma and serum L-selectin and clinical and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). *Transl Res.* 2014;163(6):585-592.</u>
- 69. <u>Kanaya AM, Herrington D, Vittinghoff E, Ewing SK, Liu K, Blaha MJ, Dave SS, Qureshi F, Kandula NR. Understanding the High Prevalence of Diabetes in U.S. South Asians Compared with Four Racial/Ethnic Groups: The MASALA and MESA Studies. *Diabetes Care.* 2014;37(6):1621-1628.</u>
- 70. Smith BM, Hoffman EA, Basner RC, Kawut SM, Kalhan R, Barr RG. Not All Measures of Hyperinflation Are Created Equal: Lung Structure and Clinical Correlates of Gas Trapping and Hyperexpansion in COPD: The Multi-Ethnic Study of Atherosclerosis Study (MESA) COPD Study. Chest. 2014;145(6):1305-1315.
- 71. <u>Perng W, Villamor E, Shroff MR, Nettleton JA, Pislner JR, Liu Y, Diez-Roux AV. Dietary</u> <u>intake, plasma homocysteine, and repetitive element DNA methylation in the Multi-Ethnic Study</u> <u>of Atherosclerosis (MESA). *Nutr Metab Cardiovasc Dis.* 2014;24(6)614-622.</u>
- 72. <u>Habibi M, Chahal H, Opdahl A, Gjesdal O, Helle-Valle TM, Heckbert SR, McClelland R, Wu C, Shea S, Hundley G, Bluemke DA, Lima JA. Association of CMR-Measured LA Function With Heart Failure Development: Results From the MESA Study. *JACC Cardiovasc Imaging*. 2014;7(6):570-579.</u>
- Jenny NS, Blumenthal RS, Kronmal RA, Rotter JI, Siscovick DS, Psaty BM. Associations of pentraxin 3 with cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis. *J Thromb* <u>Haemost.</u> 2014;12(6):999-1005.

- 74. Leary PJ, Jenny NS, Barr RG, Bluemke DA, Harhay MO, Heckbert SR, Kronmal RA, Lima JA, Mikacenic C, Tracy RP, Kawut SM. Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study. *Pulm Circ*. 2014;4(2):250-259.
- 75. <u>Charles L, Fekedulegn D, Landsbergis P, Burchfiel C, Baron S, Kaufman J, Hinckley Stukovsy K, Fujishiro K, Foy C, Andrew M, Diez Roux A. 0101 Work Hours, Job Strain, and Occupation with Endothelial Function: The Multi-Ethnic Study of Atherosclerosis (MESA). Occup Environ Med. 2014;71 Suppl 1:A73.</u>
- 76. <u>Turin TC, Coresh J, Matsushita K, Sang Y, Ballew SH, Appel LJ, Arima H, Chadban SJ, Cirillo M, Djurdjev O, Green JA, Heine GH, Inder LA, Irie F, Ishani A, Ix JH, Kovesdy CP, Marks A, Ohkubo T, Shalev V, Shankar A, Wen CP, de Jong PE, Iseki K, Stengel B, Gansevoort RT, Levey AS; for the CKD Prognosis Consortium. Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End Stage Renal Disease and Mortality. JAMA. 2014;311(24):2518-2531.</u>
- 77. <u>Criqui MH, Denenberg JO, McClelland RL, Allison MA, Ix JH, Guerci A, Cohoon KP,</u> <u>Srikanthan P, Watson KE, Wong ND. Abdominal aortic calcium, coronary artery calcium, and</u> <u>cardiovascular morbidity and mortality in the multi-ethnic study of atherosclerosis. *Arterioscler* <u>Thromb Vasc Biol.</u> 2014;34(7):1574-1579.</u>
- 78. <u>Needham BL, Carroll JE, Diez Roux AV, Fitzpatrick AL, Moore K, Seeman TE. Neighborhood</u> <u>characteristics and leukocyte telomere length: The Multi-Ethnic Study of Atherosclerosis. *Health* <u>*Place*. 2014;28:167-172.</u></u>
- 79. <u>Hame Y, Angelini ED, Hoffman EA, Barr RG, Laine AF. Adaptive Quantification and Longitudinal Analysis of Pulmonary Emphysema With a Hidden Markov Measure Field Model.</u> *IEEE Trans Med Imaging.* 2014;33(7):1527-1540.
- Mahmoodi BK, Yatsuya H, Matsushita K, Sang Y, Gottesman RF, Astor BC, Woodward M, Longstreth WT Jr, Psaty BM, Shlipak MG, Folsom AR, Gansevoort RT, Coresh J. Associations of kidney disease measures with ischemic versus hemorrhagic stokes: pooled analyses of 4 prospective community-based cohorts. *Stroke*. 2014;45(7):1925-1931.
- 81. <u>Hoffman EA, Ahmed FS, Baumhauer H, Budoff M, Carr JJ, Kronmal R, Reddy S, Barr RG.</u> <u>Variation in the Percent of Emphysema-Like Lung in a Healthy, Nonsmoking Multiethnic</u> <u>Sample. The MESA Lung Study. *Ann Am Thorac Soc.* 2014;11(6):898-907.</u>
- 82. <u>Matthew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN, Alonso A, Chonchol M, Deo R, Ix JH, Siscovick DS, Kestenbaum B, de Boer IH. Fibroblast Growth Factor-23 and Incident Atrial Fibrillation: The Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). *Circulation*. 2014;130(4):298-307.</u>
- 83. <u>Unger E, Diez-Roux AV, Lloyd-Jones DM, Mujahid MS, Nettleton JA, Bertoni A, Badon SE, Ning H, Allen NB. Association of neighborhood characteristics with cardiovascular health in the multi-ethnic study of atherosclerosis. *Circ Cardiovasc Qual Outcomes.* 2014;7(4):524-531.</u>
- <u>Camacho A, Larsen B, McClelland RL, Morgan C, Criqui M, Cushman M, Allison MA.</u> <u>Association of subsyndromal and depressive symptoms with inflammatory markers among</u> <u>different ethnic groups: The multi-ethnic study of atherosclerosis (MESA). J Affect Disord.</u> <u>2014;164C:165-170.</u>

- 85. Doney B, Hnizdo E, Graziani M, Kullman G, Burchfiel C, Baron S, Fujishiro K, Enright P, Hankinson JL, Stukovsky KH, Martin CJ, Donohue KM, Barr RG. Occupational Risk Factors for COPD Phenotypes in the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. COPD. 2014;11(4):368-380.
- 86. Yeboah J, Delaney JA, Nance R, McClelland RL, Polak JF, Sibley CT, Bertoni A, Burke GL, Carr JJ, Herrington DM. Mediation of cardiovascular risk factor effects through subclinical vascular disease: the multi-ethnic study of atherosclerosis. *Aterioscler Thromb Vasc Biol.* 2014;34(8):1778-1783.
- 87. de Boer IH, Sachs MC, Chonchol M, Himmelfarb J Hoofnagle AN, Ix JH, Kremsdorf RA, Lin YS, Mehrotra R, Robinson-Cohen C, Siscovick DS, Steffes MW, Thummel KE, Tracy RP, Wang Z, Kestenbaum B. Estimated GFR and Circulating 24, 25-Dihydroxyvitamin D3 Concentration: A Participant-Level Analysis of 5 Cohort Studies and Clinical Trials. *Am J Kidney Dis.* 2014;64(2):187-197.
- <u>Chong EW, Guymer RH, Klein R, Klein BE, Cotch MF, Wang JJ, Shlipak MG, Wong TY. Is</u> renal function associated with early age-related macular degeneration? *Optom Vis Sci.* <u>2014;91(8):860-864.</u>
- Everson-Rose SA, Roetker NS, Lutsey PL, Kershaw KN, Longstreth WT Jr, Sacco RL, Diez Roux AV, Alonso A. Chronic stress, depressive symptoms, anger, hostility, and risk of stroke and transient ischemic attack in the multi-ethnic study of atherosclerosis. *Stroke*. 2014;45(8):2318-2323.
- 90. Zhang K, Larson TV, Gassett A, Szpiro AA, Daviglus M, Burke GL, Kaufman JD, Adar SD. Characterizing Spatial Patterns of Airborne Coarse Particulate (PM10-2.5) Mass and Chemical Components in Three Cities: The Multi-Ethnic Study of Atherosclerosis. *Environ Health Perspect.* 2014;122(8):823-830.
- 91. Sharma RK, Volpe G, Rosen BD, Ambale-Venkatesh B, Donekal S, Fernandes V, Wu CO, Carr J, Bluemke DA, Lima JA. Prognostic implications of left ventricular dyssynchrony for major adverse cardiovascular events in asymptomatic women and men: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2014;3(4). pii: e000975. doi: 10.1161/JAHA.114.000975.
- 92. <u>Roetker NS, Chen LY, Heckbert SR, Nazarian S, Soliman EZ, Bluemke DA, Lima JA, Alonso A.</u> <u>Relation of Systolic, Diastolic, and Pulse Pressures and Aortic Distensibility With Atrial</u> <u>Fibrillation (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol.* 2014;114(4):587-592.</u>
- Vaidya D, Bennett WL, Sibley CT, Polak JF, Herrington DM, Ouyang P. Association of parity with carotid diameter and distensibility: multi-ethnic study of atherosclerosis. *Hypertension*. 2014;64(2):253-258.
- 94. <u>Remigio-Baker RA, Allison MA, Schreiner PJ, Szklo M, Crum RM, Leoutsakos JM, Franco M, Carnethon MR, Nettleton JA, Mujahid MS, Diez Roux AV, Jensky N, Golden SH. Difference by sex but not by race/ethnicity in the visceral adipose tissue-depressive symptoms association: The Multi-Ethnic Study of Atherosclerosis. *Psychoneuroendocrinology*. 2014;47:78-87.</u>

- 95. <u>Ambale Venkatesh B, Volpe GJ, Donekal S, Mewton N, Liu CY, Shea S, Liu K, Burke G, Wu C, Bluemke DA, Lima JA. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the multi-ethnic study of atherosclerosis study. *Hypertension*. 2014;64(3):508-515.</u>
- 96. <u>Kamel H, Soliman EZ, Heckbert SR, Kronmal RA, Longstreth WT Jr, Nazarian S, Okin PM. P-wave morphology and the risk of incident ischemic stroke in the multi-ethnic study of atherosclerosis. *Stroke*. 2014;45(9):2786-2788.</u>
- 97. Polak JF, Post WS, Carr JJ, Szklo M, O'Leary DH. Associations of common carotid intimamedia thickness with coronary heart disease risk factors and events vary with distance from the carotid bulb. J Am Soc Echocardiogr. 2014;27(9):991-997.
- 98. <u>Silverman MG, Blaha MJ, Krumholz HM, Budoff MJ, Blankstein R, Sibley CT, Agatston A, Blumenthal RS, Nasir K. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. *Eur Heart J.* 2014;35(33):2232-2241.</u>
- 99. <u>Desai CS, Ning H, Soliman EZ, Burke GL, Shea S, Nazarian S, Lloyd-Jones DM, Greenland P.</u> <u>Electrocardiographic abnormalities and coronary artery calcium for coronary heart disease</u> <u>prediction and reclassification: The Multi-Ethnic Study of Atherosclerosis (MESA). *Am Heart J.* <u>2014;168(3):391-397.</u></u>
- 100. <u>Shea MK, Cushman M, Booth SL, Burke GL, Chen H, Kritchevsky SB. Associations</u> between vitamin K status and haemostatic and inflammatory biomarkers in community-dwelling adults. The Multi-Ethnic Study of Atherosclerosis. *Thromb Haemost*. 2014;112(3):438-444.
- 101. Fujiyoshi A, Miura K, Ohkubo T, Kadowaki T, Kadowaki S, Zaid M, Hisamatsu T, Sekikawa A, Budoff MJ, Liu K, Ueshima H; SESSA and MESA Research Groups. Crosssectional comparison of coronary artery calcium scores between caucasian men in the United States and Japanese men in Japan: the multi-ethnic study of atherosclerosis and the shiga epidemiological study of subclinical atherosclerosis. *Am J Epidemiol.* 2014;180(6):580-598.
- 102. <u>Kwon Y, Duprez DA, Jacobs DR, Nagayoshi M, McClelland RL, Shahar E, Budoff M, Redline S, Shea S, Carr JJ, Lutsey PL. Obstructive sleep apnea and progression of coronary artery calcium: the multi-ethnic study of atherosclerosis study. *J Am Heart Assoc.* 2014;3(5). pii: e001241. doi: 10.1161/JAHA.114.001241.</u>
- 103. <u>Yeboah J, Carr JJ, Terry JG, Ding J, Zeb I, Liu S, Nasir K, Post W, Blumenthal RS,</u> <u>Budoff MJ. Computed tomography-derived cardiovascular risk markers, incident cardiovascular</u> <u>events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of Atherosclerosis. *Eur J* <u>Prev Cardiol.</u> 2014;21(10):1233-1241.</u>
- 104. Driver TH, Shlipak MG, Katz R, Goldenstein L, Sarnak MJ, Hoofnagle AN, Siscovick DS, Kestenbaum B, de Boer IH, Ix JH. Low Serum Bicarbonate and Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Kidney Dis*. 2014;64(4):534-541.

- 105. <u>Ong KL, McClelland RL, Rye KA, Cheung BM, Post WS, Vaidya D, Criqui MH,</u> <u>Cushman M, Barter PJ, Allison MA. The relationship between insulin resistance and vascular</u> <u>calcification in coronary arteries, and the thoracic and abdominal aorta: The Multi-Ethnic Study</u> <u>of Atherosclerosis. *Atherosclerosis.* 2014;236(2):257-262.</u>
- 106. <u>Yeboah J, Erbel R, Delaney JC, Nance R, Guo M, Bertoni AG, Budoff M, Moebus S, Jockel KH, Burke GL, Wong ND, Lehmann N, Herrington DM, Mohlenkamp S, Greenland P. Development of a new diabetes risk prediction tool for incident coronary heart disease events: The Multi-Ethnic Study of Atherosclerosis and the Heinz Nixdorf Recall Study. *Atherosclerosis*. 2014;236(2):411-417.</u>
- 107. Kim SY, Sheppard L, Kaufman JD, Bergen S, Szpiro AA, Larson TV, Adar SD, Diez Roux AV, Polak JF, Vedal S. Individual-level concentrations of fine particulate matter chemical components and subclinical atherosclerosis: a cross-sectional analysis based on 2 advanced exposure prediction models in the multi-ethnic study of atherosclerosis. *Am J Epidemiol.* 2014;180(7):718-728.
- 108. <u>Cohen R, Budoff M, McClelland RL, Sillau S, Burke G, Blaha M, Szklo M, Uretsky S, Rozanski A, Shea S. Significance of a Positive Family History for Coronary Heart Disease in Patients With a Zero Coronary Artery Calcium Score (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol.* 2014;114(8):1210-1214.</u>
- 109. <u>Alonso A, Yin X, Roetker NS, Magnani JW, Kronmal RA, Ellinor PT, Chen LY, Lubitz SA, McClelland RL, McManus DD, Soliman EZ, Huxley RR, Nazarian S, Szklo M, Heckbert SR, Benjamin EJ. Blood lipids and the incidence of atrial fibrillation: the multi-ethnic study of atherosclerosis and the framingham heart study. J Am Heart Assoc. 2014;3(5). pii: e001211. doi: 10.1161/JAHA.114.001211.</u>
- 110. <u>Hu T, Rianon NJ, Nettleton JA, Hyder JA, He J, Steffen LM, Jacobs DR, Criqui MH,</u> <u>Bazzano LA. Protein intake and lumbar bone density: the Multi-Ethnic Study of Atherosclerosis</u> (MESA). *Br J Nutr.* 2014;112(8):1384-1392.
- 111. Jones MR, Diez-Roux AV, Hajat A, Kershaw KN, O'Neill MS, Guallar E, Post WS, Kaufman JD, Navas-Acien A. Race/Ethnicity, Residential Segregation, and Exposure to Ambient Air Pollution: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Public Health. 2014;104(11):2130-2137.
- 112. <u>Almeida AL, Teixido-Tura G, Choi EY, Opdahl A, Fernandes VR, Wu CO, Bluemke</u> DA, Lima JA. [Metabolic Syndrome, Strain, and Reduced Myocardial Function: Multi-Ethnic Study of Atherosclerosis.] *Arq Bras Cardiol.* 2014 Mar 25 [Epub ahead of print]
- 113. <u>Hsu JJ, Katz R, Ix JH, de Boer IH, Kestenbaum B, Shlipak MG. Association of fibroblast</u> growth factor-23 with arterial stiffness in the Multi-Ethnic Study of Atherosclerosis. *Nephrol Dial Transplant*. 2014 Apr 29. [Epub ahead of print]
- 114. <u>Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, Blankstein</u> <u>R, Budoff MJ, Greenland P, Folsom AR. Use of Coronary Artery Calcium Testing to Guide</u> <u>Aspirin Utilization for Primary Prevention: Estimates From the Multi-Ethnic Study of</u> <u>Atherosclerosis. *Circ Cardiovasc Oual Outcomes.* 2014 May 6. [Epub ahead of print]</u>
- 115. <u>Hughes-Austin JM, Wassel CL, Jimenez J, Criqui MH, Ix JH, Rasmussen-Trovik LJ,</u> Budoff MJ, Jenny NS, Allison MA. The relationship between adiposity-associated inflammation

and coronary artery and abdominal aortic calcium differs by strata of central adiposity: The Multi-Ethnic Study of Atherosclerosis (MESA). Vasc Med. 2014 Jun 6. [Epub ahead of print]

- 116. Smith BM, Hoffman EA, Rabinowitz D, Bleecker E, Christenson S, Couper D, Donohue KM, Han MK, Hansel NN, Kanner RE, Kleerup E, Rennard S, Barr RG. Comparison of spatially matched airways reveals thinner airway walls in COPD. The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study and the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). *Thorax.* 2014 Jun 13. [Epub ahead of print]
- 117. <u>Garimella PS, Ix JH, Katz R, Shlipak MG, Criqui MH, Siscovick DS, Kramer H, Sibley CT, Sarnak MJ. Association of Albumin-Creatinine Ratio and Cystatin C With Change in Ankle-Brachial Index: The Multi-Ethnic Study of Atherosclerosis (MESA). *Am J Kidney Dis.* 2014 Jul 3. [Epub ahead of print]</u>
- 118. <u>Shah RV, Murthy VL, Abbasi SA, Eng J, Wu C, Ouyang P, Kwong RY, Goldfine A, Bluemke DA, Lima J, Jerosch-Herold M. Weight loss and progressive left ventricular remodeling: The Multi-Ethnic Study of Atherosclerosis (MESA). *Eur J Prev Cardiol.* 2014 Jul 9. [Epub ahead of print]</u>
- 119. Ko YA, Mukherjee B, Smith JA, Park SK, Kardia SL, Allison MA, Vokonas PS, Chen J, Diez-Roux AV. Testing departure from additivity in Turkey's model using shrinkage: application to a longitudinal setting. *Stat Med.* 2014 Aug 11. [Epub ahead of print]
- 120. <u>Hirsch JA, Moore KA, Barrientos-Gutierrez T, Brines SJ, Zagorski MA, Rodriguez DA,</u> <u>Diez Roux AV. Built Environment change and change in BMI and waist circumference: Multi-Ethnic Study of Atherosclerosis. *Obesity*. 2014 Aug 18. [Epub ahead of print]</u>
- 121. Zemaitis P, Liu K, Jacobs DR Jr, Cushman M, Durazo-Arvizu R, Shoham D, Palmas W, Cooper R, Kramer H. Cumulative Systolic BP and Changes in Urine Albumin-to-Creatinine Ratios in Nondiabetic Participants of the Multi-Ethnic Study of Atherosclerosis. *Clin J Am Soc Nephrol.* 2014 Sep 8. [Epub ahead of print]
- 122. <u>Tattersall MC, Gassett A, Korcarz CE, Gepner AD, Kaufman JD, Liu KJ, Astor BC, Sheppard L, Kronmal RA, Stein JH. Predictors of Carotid Thickness and Plaque Progression During a Decade: The Multi-Ethnic Study of Atherosclerosis. *Stroke*. Sep 11. [Epub ahead of print]</u>
- 123. <u>Fujishiro K, Diez Roux AV, Kaufman J, Landsbergis P, Kaufman JD, Korcarz CE, Stein</u> <u>JH. Occupational characteristics and the progression of carotid artery intima-media thickness over</u> <u>9 years: The Multi-Ethnic Study of Atherosclerosis (MESA). Occup Environ Med. 2014 Sep 12.</u> [Epub ahead of print]
- 124. <u>Yeboah J, Bluemke DA, Hundley WG, Rodriguez CJ, Lima JA, Herrington DM. Left</u> <u>Ventricular Dilation and Incident Congestive Heart Failure in Asymptomatic Adults without</u> <u>Cardiovascular Disease. MESA. J Card Fail. 2014 Sep 12. [Epub ahead of print]</u>
- 125. <u>O'Neal WT, Efird JT, Dawood FZ, Yeboah J, Alonso A, Heckbert SR, Soliman EZ.</u> <u>Coronary Artery Calcium and Risk of Atrial Fibrillation (from the Multi-Ethnic Study of Atherosclerosis). *Am J Cardiol.* 2014 Sep 16. [Epub ahead of print]</u>

- 126. Koo BB, Sillau S, Dean DA 2nd, Lutsey PL, Redline S. Periodic Limb Movements During Sleep and Prevalent Hypertension in the Multi-Ethnic Study of Atherosclerosis. *Hypertension*. 2014 Oct 6. [Epub ahead of print]
- 127. <u>Ebong IA, Watson KE, Goff DC Jr, Bluemke DA, Srikanthan P, Horwich T, Bertoni AG.</u> <u>Association of menopause age and N-terminal pro brain natriuretic peptide: the Multi-Ethnic</u> <u>Study of Atherosclerosis. *Menopause*. 2014 Oct 6. [Epub ahead of print]</u>
- 128. Leary PJ, Barr RG, Bluemke DA, Bristow MR, Kronmal RA, Lima JA, Ralph DD, Ventetuolo CE, Kawut SM. H2 receptor antagonists and right ventricular morphology: The MESA Right Ventricle Study. *Ann Am Thorac Soc.* 2014 Oct 8. [Epub ahead of print]
- 129. <u>Adar SD, Kaufman JD, Diez-Roux AV, Hoffman EA, D'Souza J, Hinckley Stukovsky</u> <u>KD, Rich SS, Rotter JI, Guo X, Raffel LJ, Sampson PD, Oron AP, Raghunathan T, Barr RG. Air</u> <u>Pollution and Percent Emphysema Identified by Computed Tomography in the Multi-Ethnic</u> <u>Study of Atherosclerosis. *Environ Health Perspect*. 2014 Oct 10. [Epub ahead of print]</u>
- 130. Yeboah J, Gibson AO, Blaha MJ, Arnan MK, Sacco RL, Szklo M, Herrington DM. Coronary Artery Calcium and Incident Cerebrovascular Events in an Asymptomatic Multi Ethnic Cohort. MESA. *JACC Imaging*. (In press)
- 131. Needham BL, Bird C, Bradley R, Fitzpatrick A, Jacobs Jr D, Ouyang P, Seeman T, Thurston R, Vaidya D, Wang SL, Diez Roux AV. Gender Differences in Telomere Length: The Multi-Ethnic Study of Atherosclerosis. *Biodemography and Social Biology*. (In press)
- 132. Shah RV, Murthy VL, Abbasi SA, Blankstein R, Kwong RY, Goldfine A, Jerosch-Herold M, Lima JA, Ding J, Allison MA. Visceral adiposity and the risk of metabolic syndrome across body-mass index: The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol*. (In press)
- 133. Hirsch JA, Moore KA, Clarke PJ, Rodriguez DA, Evenson KR, Brines SJ, Zagorski MA, Diez Roux AV. Changes in the built environment and walking trajectories: longitudinal results from the Multi-Ethnic Study of Atherosclerosis. *American Journal of Epidemiology*. (In press)
- 134. Oelsner EC, Hoffman EA, Folsom AR, Carr JJ, Enright P, Kawut SM, Kronmal R, Lederer D, Lima JA, Lovasi GS, Shea S, Barr RG. Pulmonary emphysema is associated with increased all-cause mortality in adults: the Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. *Annals of Internal Medicine*. (In press)
- 135. Chahal J, Bluemke DA, Wu CO, McClelland R, Liu K, Shea SJ, Burke G, Balfour P, Herrington D, Shi PB, Post W, Olson J, Watson KE, Folsom AR, Lima AC. Heart Failure Risk Prediction In the Multi-Ethnic Study Of Atherosclerosis Study. *Heart*. (In press)
- 136. Ambale-Venkatesh B, Donekal S, Yoneyama K, Wu C, Fernandes VR, Rosen BD, Shehata ML, McClelland R, Bluemke DA, Lima JA. Regional myocardial functional patterns: Quantitative tagged magnetic resonance imaging in an adult population free of cardiovascular risk factors: The multi-ethnic study of atherosclerosis (MESA). *Journal of Magnetic Resonance Imaging*. (In press)
- 137. Rieke K, Durazo-Arvizu R, Liu K, Michos ED, Luke A, Kramer H. Association between Anxiety Levels and Weight Change in the Multi-Ethnic Study of Atherosclerosis. *Journal of Obesity*. (In press)

- 138. Whang W, Peacock J, Soliman EZ, Alcantara C, Nazarian S, Shah AJ, Davidson KW, Shea S, Munter P, Shimbo D. Relations between Depressive Symptoms, Anxiety, and T Wave Abnormalities in Subjects without Clinically-apparent Cardiovascular Disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). *American Journal of Cardiology*. (In press)
- 139. Dean II DA, Wang R, Jacobs Jr DR, Duprez D, Punjabi NM, Zee PC, Shea S, Watson K, Redline S. A Systematic Assessment of the Association of Polysomnographic Indices with Blood Pressure: The Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep*. (In press)
- 140. Aaron CP, Schwartz JE, Bielinski SJ, Hoffman EA, Austin JH, Oelsner EC, Donohue KM, Kalhan R, Berardi C, Kaufman JD, Jacobs Jr DR, Tracy RP, Barr RG. Intercellular Adhesion Molecule (ICAM) 1 and Longitudinal Change In Percent Emphysema and Lung Function: The MESA Lung Study. *Respir Med.* (In press)
- 141. Park SK, Adar SD, O'Neill MS, Auchincloss AH, Szpiro A, Bertoni AG, Navas-Acien A, Kaufman JD, Diez-Roux AV. Long-term exposure to air pollution and type 2 diabetes in a multiethnic cohort. *American Journal of Epidemiology*. (In press)
- 142. Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alcantara C, Jackson CL, Williams MA, Redline S. Racial/Ethnic Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA). *SLEEP*. (In press)

Appendix C: Steering Committee Report



Multi-Ethnic Study of Atherosclerosis

MESA Master Draft Agenda September 17-18, 2014

Hilton Crystal City Hotel 2399 Jefferson Davis Highway Arlington, VA 22202 Telephone: 703-418-6800 Fax: 703-418-3763

Tuesday,	Sep	tember	16,	2014
----------	-----	--------	-----	------

Meeting rooms in italics

5:00 pm – 7:00 pm	TBD Subcommittee or Working Group Meeting – <i>Blue Ridge</i>
5:30 pm – 7:30 pm	Genetics Committee Meeting – Adams Dr. Rotter
7:00 pm – 8:00 pm	Operations Committee Meeting – <i>Blue Ridge</i> Dr. Barr
7:30 pm – 9:30 pm	HIV-CVD Working Group Meeting – <i>Adams</i> Dr. Delaney
8:00 pm – 9:00 pm	Lab Committee Meeting – <i>Blue Ridge</i> Dr. Tracy

Wednesday, September 17, 2014

Meeting rooms in italics

7:30 am – 8:30 am	Cognition Working Group Meeting – Relish RestaurantDr. Fitzpatrick
8:30 am – 5:00 pm	MESA Steering Committee Meeting – MadisonDr. Burke
5:00 pm – 7:00 pm	COPD 2 Meeting – Madison Dr. Barr
7:00 pm – 9:00 pm	PI Working Meeting – Madison Dr. Burke

Thursday, September 18, 2014

Meeting rooms in italics

8:30 am – 12:00 pm MESA Steering Committee Meeting – MadisonDr. Burke

Wednesday, September 17, 2014 Meeting rooms in italics

7:30 am – 8:30 am	Cognition Working Group Meeting – Relish Restaurant	Dr. Fitzpatrick
8:30 am – 5:00 pm	MESA Steering Committee Meeting – Madison	Dr. Burke
8:30 am	Call to Order and meeting overview	Dr. Burke
8:45 am	Project Office Report	Dr. Olson
9:15 am	Operations Committee Report	Dr. Barr
9:45 am	Participant Relations Committee Report	Dr. Post
10:00 am	Break	
10:45 am	Genetics Genetics Committee Report	Dr. Rotter
11:30 am	Lunch	
1:00 pm	Ancillary Studies Committee Report	
1:30 pm	Scientific Presentations MASALA Predictors of Incident Heart Failure with Preserved Ejection Fraction Use of Coronary Artery Calcium Testing to Guide Aspirin Utilization The association of neighborhood characteristics with cardiovascular health 	Dr. Blaha Dr. Miedema
3:30 pm	Break	
3:40 pm	Publication and Presentation Committee Report	Dr. Shea
3:50 pm	Morbidity & Mortality Committee Report	Dr. Folsom
4:00 pm	Scientific Presentations Findings from the MESA Kidney ancillary study Abdominal Aortic Calcium, Coronary Artery Calcium 	
5:00 pm	Adjourn	

	-		e			
7:00 pm – 9:	:00 pm	PI Working Me	eeting – Madison	••••••	••••••	. Dr. Burke

Thursday, September 18, 2014

Meeting rooms in italics

8:30 am – 12:00 pn	MESA Steering Committee Meeting – <i>Madison</i> Dr. Burke
8:30 am	Scientific Presentations • Sleep Architecture: A Novel Marker in Cardiovascular Risk: Findings from MESA Dr. Kwon • Genetic predictors of sleep apnea
11:00 am	MESA III and Exam 6Dr. Burke
11:30 am	Review action items, next steps, future meetingsDr. Burke
12:00 pm	Adjourn

BLANK

Table of Contents

ME	MESA Steering Committee Agendai				
Tab	ole of Contents	v			
Sec	tion 1: Retention	1			
1.1	Exam Retention – All MESA Exams	3			
	1.1.1 Exam Retention – All MESA Exams	4			
1.2	Follow-up Calls	5			
	1.2.1 Follow-up Retention Overall	5			
	1.2.2 Follow-up 9-15 Retention by Site	6			
	1.2.3 Follow-up 14 Retention as of 8/12/2014				
	1.2.4 Follow-up 15 Retention as of 8/12/2014	9			
	1.2.5 MESA Air Family and New Recruits Follow-up	10			
Sec	tion 2: Follow-up Calls and Events	11			
Intr	oduction	13			
2.1	Participants Available for Events Surveillance	14			
2.2	Participant Reports from General Health Questions (Follow-Ups 1 - 13)	15			
2.3	Initiated Investigations, by Source	16			
2.4	Participant Status, from Follow-up	17			
	2.4.1 Air Pollution Ancillary Study Participant Status, from Follow-up	19			
2.5	Investigation Tracking Summary	21			
2.6	Stroke Investigations	22			
2.7	MD Reviews	23			
	2.7.1 Review Completion	23			
	2.7.2 Death Investigation and Classification	23			
	2.7.3 Events Data Release Update: Participants with CHD & CVD Combination Endpoints	26			
2.8	Investigations Ineligible for Review Due to "Insufficient Data to Classify"	31			

Sec	tion 3: Publications and Presentations	33
3.1.	P&P and Genetics P&P Membership	
	3.1.1. P&P Members	
	3.1.2. Genetics P&P Members	
3.2.	Recent P&P Activities	
3.3.	Recent Genetics P&P Activities	
3.4.	Summary of MESA Authorship: Approved Proposals as of August 14, 2014	39
3.5.	Summary of Genetics P&P Authorship: Approved Proposals as of August 11, 2014	
3.6.	Central and Local Analyst Activities	40
3.7.	Accounting of Paper Status	40
	3.7.1. Table: Summary of Manuscripts as of August 14, 2014	40
	3.7.2. Table: Summary of Genetics Manuscripts as of August 11, 2014	40
	3.7.3. Table: Time from Manuscript Approval – Main Study Papers Pending	41
	3.7.4. Table: Time from Manuscript Approval – Ancillary Study Papers Pending	
	3.7.5 Table: Time from Manuscript Approval – Genetics Papers Pending	56
3.8.	MESA Manuscripts and Papers	64
3.9	CARe Manuscript Proposals	65
	tion 4: Laboratory Repository Inventory	
Intr	oduction	69
4.1	MESA Lab Variables and Current Completion Status as of 8.28.2014	
	4.1.1 Table: Baseline Visit Assays	
	4.1.2 Table: Visit 2 Assays	71
	4.1.3 Table: Visit 3 Assays	
	4.1.4 Table: Visit 4 Assays	
	4.1.5 Table: Visit 5 Assays	
	4.1.6 Table: Ancillary Study Assays, Funded	
4.2	MESA Repository Summary as of August, 2014	
	4.2.1 Baseline	
	4.2.2 Exam 2	
	4.2.3 Exam 3	
	4.2.4 Exam 4	
	4.2.5 Exam 5	
4.3	MESA Repository Report, as of August, 2014	89
	4.3.1 MESA Repository Availability, by Category	
	4.3.2 MESA DNA Repository Availability, by Category	
Sec	tion 5: Datasets	101

Introduction		. 103
5.1	Exam 1 Data	. 103
	5.1.1 Update Status	. 103
5.2	Exam 2 Data	. 104
	5.2.1 Posted Exam 2 Datasets	. 104
	5.2.2 Update Status	. 104
5.3	Exam 3 Data	. 105
	5.3.1 Posted Exam 3 Datasets	. 105
	5.3.2 Update Status	. 105
5.4	Exam 4 Data	. 106
	5.4.1 Posted Exam 4 Datasets	. 106
	5.4.2 Update Status	. 106
5.5	Ancillary Study Data	. 107
5.6	Events Datasets	. 107
5.7	Exam 5 Data	. 108
	5.7.1 Posted Exam 5 Datasets	. 108
	5.7.2 Update Status	. 108
	5.7.3 Exam 5 Descriptive Summary	. 109
5.8	Longitudinal Data Availability (select variables)	. 111

Sec	Section 6: Ancillary Studies	
6.1	New and Revised Proposals	115
6.3	Ancillary Study Proposals of Ancillary Studies (none)	116
6.6	MESA Ancillary Studies Status Tables	117

BLANK

Section 1: Retention

1.1 Exam	Retention – All MESA Exams	. 3
1.1.1	Exam Retention – All MESA Exams	. 4
1.2 Follow	w-up Calls	. 5
1.2.1	Follow-up Retention Overall	. 5
1.2.2	Follow-up 9-15 Retention by Site	. 6
1.2.3	Follow-up 14 Retention as of 8/12/2014	. 8
1.2.4	Follow-up 15 Retention as of 8/12/2014	. 9
1.2.5	MESA Air Family and New Recruits Follow-up	10

SEPTEMBER 17-18, 2014

BLANK

Introduction

MESA began enrolling participants in July of 2000, and is now well into the fourteenth year of data collection. Of the 6814 originally enrolled participants, 989 have died since enrolling. The remaining 5825 participants constitute the set of participants from which we calculate the retention rate. Although there are 492 participants who have asked to be dropped from the study, they are nevertheless considered to be part of the living cohort for the purpose of calculating the true retention in MESA.

Retention continues to be a high priority in MESA. Since the conclusion of Exam 5, the focus of retention strategies has shifted to successful completion of the surveillance phone calls.

1.1 Exam Retention – All MESA Exams

The MESA field centers began the fifth MESA visit in mid-April of 2010 and completed all exam components by mid-February, 2012. The overall retention rate of 76% reflects clinic visits for all enrolled participants.

Table 1.1.1 is a summary of MESA retention for all exams by site and race. This table shows a comparison of retention rates across time. Some participants cannot be located and others refused the exam. There are numerous no-shows. All sites made every effort to schedule and examine as many of the enrolled participants as possible.

1.1.1 Exam Retention – All MESA Exams

Site	Daaa	Exam 2		E	Exam 3			Exam 4			Exam 5		
Site	Race	Enrolled	Do	one	Enrolled	Do	ne	Enrolled	Do	one	Enrolled	Do	ne
	African American	493	447	91%	483	423	88%	476	405	85%	438	351	80%
WFU	Hispanic	3	3	100%	3	2	67%	3	3	100%	3	2	67%
WFU	White	570	539	95%	563	534	95%	552	490	89%	513	399	78%
	Total	1066	989	93%	1049	959	91%	1031	898	87%	954	752	79%
	African American	376	354	94%	369	335	91%	358	322	90%	327	260	80%
	Chinese	2	2	100%	2	2	100%	2	2	100%	2	2	100%
COL	Hispanic	491	459	93%	485	434	89%	478	435	91%	452	374	83%
	White	221	214	97%	219	208	95%	218	207	95%	204	174	85%
	Total	1090	1029	94%	1075	979	91%	1056	966	91%	985	810	82%
	African American	552	474	86%	544	458	84%	532	425	80%	480	315	66%
JHU	White	528	482	91%	518	456	88%	510	435	85%	481	343	71%
	Total	1080	956	89%	1062	914	86%	1042	860	83%	961	658	68%
	Hispanic	454	402	89%	449	392	87%	444	369	83%	427	323	76%
UMN	White	601	567	94%	595	554	93%	585	534	91%	540	448	83%
	Total	1055	969	92%	1044	946	91%	1029	903	88%	967	771	80%
	African American	297	272	92%	293	265	90%	288	253	88%	268	207	77%
	Chinese	301	278	92%	300	277	92%	297	273	92%	285	246	86%
NWU	Hispanic	0	0		0	0		1	1	100%	0	0	
	White	553	531	96%	547	509	93%	543	498	92%	519	423	82%
	Total	1151	1081	94%	1140	1051	92%	1129	1025	91%	1072	876	82%
	African American	154	145	94%	153	126	82%	152	126	83%	138	100	72%
	Chinese	495	449	91%	488	420	86%	484	386	80%	463	293	63%
UCLA	Hispanic	528	488	92%	524	429	82%	518	416	80%	485	300	62%
	White	135	133	99%	133	122	92%	131	124	95%	124	95	77%
	Total	1312	1215	93%	1298	1097	85%	1285	1052	82%	1210	788	65%
	African American	1872	1692	90%	1842	1607	87%	1806	1531	85%	1651	1233	75%
	Chinese	798	729	91%	790	699	88%	783	661	84%	750	541	72%
Total	Hispanic	1476	1352	92%	1461	1257	86%	1444	1224	85%	1367	999	73%
	White	2608	2466	95%	2575	2383	93%	2539	2288	90%	2381	1882	79%
	Total	6754	6239	92%	6668	5946	89%	6572	5704	87%	6149	4655	76%


1.2 Follow-up Calls

Follow-up phone interviews are administered to participants in order to identify potential events that may require investigation. (Please see Section 2 of this Steering Committee Report for information on the number of potential events requiring investigation). These telephone interviews have been administered at the time of each exam and between exams. During time periods when clinic exams are not taking place, these follow-up calls are performed approximately every nine months. Since the interview is administered by phone, retention for follow-up calls should not be affected significantly by participants who have relocated or cannot come to the clinic because of illness or time constraints. The clinics are expected to complete a final follow-up call interview with a proxy when the participant has passed away.

The status of the follow-up call is recorded on a Contact Cover Sheet, indicating if the interview was performed, was unable to be done, or was refused. A Contact Cover Sheet is expected for each enrolled participant, regardless of whether or not the interview was successfully completed.

1.2.1 Follow-up Retention Overall

The table below is a graphic illustration of retention for follow-up calls since the first follow-up. As could be expected, retention rates have gradually decreased over time in a consistent manner. However, Follow-up 10 has a noticeably lower retention rate than the previous follow-up, followed by a return to the consistent pattern. This occurred because implementation of Exam 5 took place during the Follow-up 10 period, and due to the demands of Exam 5 start-up, the sites fell behind on Follow-up 10 completion. To allow Follow-up 11 to proceed on schedule, it was recommended that Follow-up 10 be skipped and coded as "Unable," resulting in an unusually low completion rate.



1.2.2 Follow-up 9-15 Retention by Site

This table shows retention by site for recent follow-up contacts. The number enrolled at each contact period is adjusted for the number of participants who were deceased or transferred to another clinic. The follow-up retention rate for each clinic and overall is shown in the "Completed" line. Study dropouts are included under "Not Completed."

Since Follow-ups 14 and 15 are still underway, there is an additional line item in Table 1.2.2 showing the number expected at this time. The percent completed for this contact is based on the number expected instead of the total number enrolled.

This report reflects data received through 8/22/2014.

		WFU	Col.	JHU	UMN	NWU	UCLA	Total
F9	Transferred	0	0	0	0	0	0	0
	Deceased	13	12	10	8	4	6	53
	Enrolled	1005	1035	1015	1014	1115	1271	6455
	Completed	910 (91%)	856 (83%)	902 (89%)	918 (90%)	1028 (92%)	1060 (83%)	5674 (88%)
	Not Completed	95	179	113	96	87	211	781
F10	Transferred	0	0	0	0	0	0	0
	Deceased	17	13	14	15	10	24	93
	Enrolled	988	1022	1001	999	1105	1247	6362
	Completed	901 (91%)	516 (50%)	831 (83%)	831 (83%)	836 (76%)	971 (78%)	4886 (77%)
	Not Completed	87	506	170	168	269	276	1476
F11	Transferred	1	-3	0	1	0	1	0
	Deceased	35	33	40	33	33	36	210
	Enrolled	953	989	961	966	1072	1211	6152
	Completed	870 (91%)	829 (84%)	823 (86%)	863 (89%)	939 (88%)	921 (76%)	5245 (85%)
	Not Completed	83	160	138	103	133	290	907
F12	Transferred	0	0	0	0	0	0	0
	Deceased	0	22	11	0	2	33	68
	Enrolled	953	967	950	966	1070	1178	6084
	Completed	868 (91%)	801 (83%)	786 (83%)	809 (84%)	967 (90%)	924 (78%)	5155 (85%)
	Not Completed	85	166	164	157	103	254	929
F13	Transferred	0	0	0	0	0	0	0
	Deceased	41	12	12	25	24	20	134
	Enrolled	912	955	938	941	1046	1158	5950
	Completed	807 (88%)	786 (82%)	736 (78%)	803 (85%)	925 (88%)	917 (79%)	4974 (84%)
	Not Completed	105	169	202	138	121	241	976
F14	Transferred	0	0	0	0	0	0	0
	Deceased	6	11	9	9	18	13	66
	Enrolled	906	944	929	932	1028	1145	5884
	Expected	785	834	801	815	982	1006	5133
	Completed	690 (88%)	697 (84%)	628 (78%)	657 (81%)	778 (79%)	770 (77%)	4220 (82%)
	Not Completed	95	137	173	158	204	236	913
F15	Transferred	0	0	0	0	0	0	0
	Deceased	2	4	10	10	12	10	48
	Enrolled	904	940	919	922	1016	1135	5836
	Expected	311	327	322	323	353	395	2031
	Completed	235 (76%)	221 (68%)	243 (75%)	266 (82%)	297 (84%)	291 (74%)	1553 (76%)
	Not Completed	76	106	79	57	56	104	478

- Expected: Enrolled and FU14/FU15 window has closed (denominator for FU14/FU15 retention)

Completed: General Health Interview data received
Not completed: Includes study dropouts as well as other reasons interview could not be completed

1.2.3 Follow-up 14 Retention as of 8/12/2014

Section 1.2.3 provides more detailed information about retention in Follow-up 14, which is 89% complete. Follow-up 14 began in mid-2013 and will continue through September 2014. The first table includes all participants who are not deceased, and gives the true retention rate. In the second table, participants who have dropped out are also excluded to show progress among participants who are actually expected to respond.

To calculate true retention at a given time period, the numbers in the first two tables are based only on participants whose windows have closed. Participants whose windows have not closed are not included in these tables, even if interviews were completed or follow-up was closed out.

Site Name	Follow-up Due	Contact	s Made		Completed etention)	Not Completed	Contact not made
Wake Forest	757	732	97%	679	90%	53	25
Columbia	807	722	89%	682	85%	40	85
Johns Hopkins	776	645	83%	618	80%	27	131
Minnesota	790	699	88%	643	81%	56	91
Northwestern	854	788	92%	753	88%	35	66
UCLA	964	859	89%	753	78%	106	105
Total	4948	4445	90%	4128	83%	317	503

All participants not deceased, including study dropouts (true retention rate)

All participants not deceased OR dropped out (completion rate of those expected)
--

Site Name	Follow-up Due	Contact	s Made	Interviews	Completed	Not Completed	Contact not made
Wake Forest	732	732	100%	679	93%	53	0
Columbia	760	722	95%	682	90%	40	38
Johns Hopkins	658	645	98%	618	94%	27	13
Minnesota	757	699	92%	643	85%	56	58
Northwestern	801	788	98%	753	94%	35	13
UCLA	863	859	100%	753	87%	106	4
Total	4571	4445	97%	4128	90%	317	126

All participants, not deceased OR dropped out (regardless of contact window)

Site Name	Follow-up 14 Due	Contact	s Made	Interviews	Completed	Not Completed	Contact not made
Wake Forest	879	736	84%	683	78%	53	143
Columbia	900	831	92%	784	87%	47	69
Johns Hopkins	793	675	85%	643	81%	32	118
Minnesota	893	724	81%	668	75%	56	169
Northwestern	960	876	91%	838	87%	38	84
UCLA	1033	1014	98%	883	85%	131	19
Total	5458	4856	89%	4499	82%	357	602

Follow-up Due: Not Deceased and Follow-up window has closed

Contacts Made: Follow-up status obtained (regardless of window)

Interview Completed: General Health Questionnaire data received (% calculated from Follow-ups Due)

Interview Not Completed: Contact Cover indicates interview will not be done

Contact Not Made: No data or status has been received

1.2.4 Follow-up 15 Retention as of 8/12/2014

Section 1.2.4 provides more detailed information about retention in Follow-up 15, which began in January 2014 and will continue through June 2015. The first table includes all participants who are not deceased, and gives the true retention rate. In the second table, participants who have dropped out are also excluded to show progress among participants who are actually expected to respond.

To calculate true retention at a given time period, the numbers in the first two tables are based only on participants whose windows have closed. Participants whose windows have not closed are not included in these tables, even if interviews were completed or follow-up was closed out.

An participants not deceased with closed windows, including study dropouts (true recention rate)												
	Follow-up	Contacts Made		Interviews Completed		Not	Contact not					
Site Name	Due	Contact	s made	(F15 Re	etention)	Completed	made					
Wake Forest	289	218	218 75%		71%	14	71					
Columbia	306	207	68%	202	66%	5	99					
Johns Hopkins	297	238	80%	227	76%	11	59					
Minnesota	298	262	88%	247	83%	15	36					
Northwestern	329	263	80%	259	79%	4	66					
UCLA	369	322	87%	270	73%	52	47					
Total	1888	1510	80%	1409	75%	101	378					

All participants not deceased with closed windows, including study dropouts (true retention rate)

All participants not deceased OR dropped out with closed windows (completion rate of those expected)

	Follow-up	Contact	a Mada	Interv	views	Not	Contact not
Site Name	Due	Contact	s made	Com	oleted	Completed	made
Wake Forest	274	218	80%	204	74%	14	56
Columbia	283	207	73%	202	71%	5	76
Johns Hopkins	246	238	97%	227	92%	11	8
Minnesota	285	262	92%	247	87%	15	23
Northwestern	308	263	85%	259	84%	4	45
UCLA	325	322	99%	270	83%	52	3
Total	1721	1510	88%	1409	82%	101	211

All participants (regardless of contact window), not deceased OR dropped out (total completion rate of those expected)

Site Name	Follow-up 15 Due	Contact	s Made	Interviews	Completed	Not Completed	Contact not made
Wake Forest	870	240	28%	226	26%	14	630
Columbia	889	330	37%	321	36%	9	559
Johns Hopkins	770	277	36%	265	34%	12	493
Minnesota	881	377	43%	357	41%	20	504
Northwestern	946	354	37%	347	37%	7	592
UCLA	1014	575	57%	502	50%	73	439
Total	5370	2153	40%	2018	38%	135	3217

Follow-up Due: Not Deceased and Follow-up window has closed

<u>Contacts Made:</u> Follow-up status obtained (with closed window)

<u>Interview Completed</u>: General Health Questionnaire data received (with closed window, % calculated from Follow-ups Due) <u>Interview Not Completed</u>: Contact Cover indicates interview will not be done

Contact Not Made: No data or status has been received

1.2.5 MESA Air Family and New Recruits Follow-up

The MESA Air grant ended July 31, 2014. MESA Air Family and New Recruit Follow-up 14 calls were prioritized to be completed by the end of the grant period.

	Follow-up	Contact	a Mada	Interv	views	Not	Contact not
Site Name	Due	Contact	s made	Com	oleted	Completed	made
Wake Forest	44	44	100%	40	91%	4	0
Columbia	136	136	100%	107	79%	29	0
Johns Hopkins	43	40	93%	35	81%	5	3
Minnesota	78	68	87%	55	71%	13	10
Northwestern	144	144	100%	114	79%	30	0
UCLA	16	16	100%	13	81%	3	0
Total	461	448	97%	364	79%	84	13

MESA Family Follow-up 14

Air New Recruits Follow-up 14

	Follow-up	Contact	a Mada	Interv	views	Not	Contact not
Site Name	Due	Contact	siviaue	Com	oleted	Completed	made
Coastal LA	74	74 100%		70	95%	4	0
Riverside LA	76	76	100%	68	89%	8	0
Rockland NY	95	95	100%	86	91%	9	0
Total	245	245	100%	224	91%	21	0

Follow-up Due: Not Deceased and Follow-up window has closed

<u>Contacts Made: Follow-up status obtained (regardless of window)</u>

Interview Completed: General Health Questionnaire data received (percent calculated from Follow-ups Due)

Interview Not Completed: Contact Cover indicates interview will not be done

Contact Not Made: No data or status has been received

Section 2: Follow-up Calls and Events

Intr	oduction	13
2.1	Participants Available for Events Surveillance	14
2.2	Participant Reports from General Health Questions (Follow-Ups 1 - 13)	15
2.3	Initiated Investigations, by Source	16
2.4	Participant Status, from Follow-up	17
	2.4.1 Air Pollution Ancillary Study Participant Status, from Follow-up	19
2.5	Investigation Tracking Summary	21
2.6	Stroke Investigations	22
2.7	MD Reviews	23
	2.7.1 Review Completion	23
	2.7.2 Death Investigation and Classification	23
	2.7.2.1 Death Investigation, underlying cause by ICD-10 category	24
	2.7.2.2 Death Investigation, underlying cause, most common ICD-10 codes	25
	2.7.3 Events Data Release Update: Participants with CHD & CVD Combination Endpoints (Average of 8.5 years of surveillance)	26
	2.7.3.1 Participants with CHD & CVD Combination Endpoints (Baseline to Present)	27
	2.7.3.2 Events Data Release Update: Participants with Endpoints from Completed Reviews (Average of 8.5 years of surveillance)	28
	2.7.3.3 Participants with Endpoints from Completed Reviews (Baseline to Present)	29
	2.7.3.4 Endpoints from Completed Reviews (Baseline to Present)	30
2.8	Investigations Ineligible for Review Due to "Insufficient Data to Classify"	31

BLANK

Introduction

Progress in follow-up calls and events has continued since the October 2013 Steering Committee Meeting.

Highlights include the following:

- The 2012 Events data set (for events dated through 12/31/2012) will be posted in September.. Work will begin on the 2013 dataset in October 2014.
- The abstractors have initiated a QC review of the more problematic data they collect, led by Cynthia Jones and beginning with enzyme values.
- The annual Abstraction QC review has been split into two sessions, in the fall and the spring.
- With the completion of the MESA Air study, investigation of events for Family and Air participants formally ceased, though some sites may choose to complete their few remaining investigations.
- We continue to discover new efficiencies that the EDC makes possible. Sites are no longer shipping physical records to the central Stroke abstractor now that she can view them online, and we match medical record scans to investigations centrally (freeing up site staff from this task).

Conversion from Follow-up call based cumulative clinical events datasets to calendar year based clinical events datasets

Starting with our last data set (for 2011 events), the Coordinating Center began to produce cumulative clinical events datasets to correspond to a calendar year. The rationale for this change is to better align the datasets produced by the study with data obtained from CMS or other sources (NDI) that are based on calendar year. Release of Calendar year based cumulative events datasets will occur approximately 15 months after the end of the calendar year (e.g. Calendar Year 2013 clinical events dataset release is expected 2nd quarter, 2015). This delay is necessary in order to allow for completion of follow-up calls after the end of the calendar year (up to 9 months) that would include surveillance of the time period of interest and to allow sufficient time for processing potential events, obtaining medical records, and adjudication.

2.1 Participants Available for Events Surveillance

The table below shows the number of participants still available for events surveillance in August 2014. Participants who have left the study voluntarily (i.e., made a hard refusal—"Do Not Contact") are dropped from the "Available" column, but participants who returned to the study after a previous absence are considered available and included in the "Available" column.

Due primarily to Field Center resources being directed at completing Exam 5, Follow-up 10 was not completed for 1132 participants, many of whom are reported below as available. Since then, all but 141 of the participants still enrolled have completed at least one of the followup interviews.

Note: the number of deceased listed in this table differs slightly from the number in the "Death Investigation and Classification" table (Section 2.7.2) because the latter table includes deaths still pending confirmation.

SiteName	Baseline	Deceased	Do Not Contact	Transfers	Available for Events
3: Wake Forest	1077	-178	-34	2	867
4: Columbia	1102	-154	-60	-5	881
5: Johns Hopkins	1086	-172	-150	3	768
6: Minnesota	1066	-145	-47	-1	873
7: Northwestern	1164	-140	-70	-8	946
8: UCLA	1319	-195	-130	9	1004
Total	6814	-984	-491	0	5339

2.2 Participant Reports from General Health Questions (Follow-Ups 1 - 15)

This is an updated version of an abbreviated summary of a larger dataset posted in August 2011 in the Events subsection of the Exam Datasets section of the <u>MESA Internal web site</u>; the full dataset includes detailed data for each participant. Multiple 'Yes' responses to the same question by the same participant at different Follow-ups are counted only once in the table below. The table summarizes affirmative participant responses to inquiries regarding new diagnoses and/or procedures since their previous MESA Follow-up. The diagnoses/procedures reported by the participants were NOT necessarily confirmed by physicians or MESA reviewers. This is <u>not</u> MESA endpoint data.

It is recommended that MESA Investigators confirm the raw data in this table before any public presentation or publication. Participant surveillance time varies widely for the raw data below.

		al of ticipants
Follow-Up General Health Question	#	%
Chest Pain or Discomfort *	2860	42%
Shortness of Breath *	3212	47%
Leg Pain*	4852	71%
Doctor Visit or Hospital Stay	6715	99%
High Blood Pressure	4733	69%
High Blood Pressure: New Diagnosis since baseline	1823	27%
Diabetes	1782	26%
Diabetes: New Diagnosis since baseline	883	13%
High Cholesterol Level	4665	68%
High Cholesterol Level: New Diagnosis since baseline	2232	33%
New/Different Doctor Treatment Recommendations *	4582	67%
MESA Test Results Received **	4282	63%
MESA Results Discussed with Doctor **	3652	54%
New Doctor Diagnosis/Tests Due to MESA Results **	863	13%
MI or Heart Attack	262	4%
Angina	198	3%
Heart Failure or CHF	186	3%
PVD/Intermittent Claudication/Pain in Legs Due to Artery Blockage	155	2%
Atrial Fibrillation	367	5%
Deep Vein Thrombosis/Leg Blood Clot	172	3%
TIA or Mini-Stroke	264	4%
Stroke	162	2%
Carotid Artery Blockage	172	3%
Lung Abnormality/Nodule	426	6%
Cancer	1056	15%
Hospital Stay	3347	49%
Nursing Home or Rehab Center Stay	534	8%
Exercise Treadmill or Bicycle Test *	2410	35%
Coronary Angiography or Heart Catheterization *	538	8%
Echocardiogram *	2683	39%
Coronary Bypass Surgery	133	2%
Angioplasty: Open Up Arteries to Heart	216	3%
Angioplasty: Open Up Arteries in Legs	79	1%
Carotid Ultrasound or Carotid Angiogram	781	11%
X-Ray/CAT scan/MRI/Other Study of Chest	3971	58%
Other Procedure/Surgery Related to Heart or Blood Vessels ***	2567	38%

Report Generated 8/1/2014

* These questions were removed after Followup 12

** MESA test result questions were only asked at Follow-Ups 1 and 2

*** Early in MESA, some field centers recorded ECGs in this category and other field centers did not.

2.3 Initiated Investigations, by Source

The information in the following table was obtained from submitted *Initial Notification of Potential Event/Death* forms and therefore represents the number of investigations that originated from different sources of information. Due to a time lag between potential events detection at Follow-Up and the submission of an *Initial Notification of Potential Event/Death* form, some events may not yet be captured in this table. This table illustrates that follow-up calls remain the primary source for obtaining information on potential events, though field centers differ in the percentage of investigations initiated from other sources.

Report Generated 8/1/2014

Site Name	Follo telepho con	ne/mail	and	tigating other vent	cli init	ther nic- iated ntact	Clini	c visit	spo cont	ot or ouse acted center		tuary/ I news	Other		Total
3: WFU	1707	54.4%	978	31.2%	141	4.5%	65	2.1%	42	1.3%	119	3.8%	81	2.6%	3139
4: COL	2223	84.8%	290	11.1%	41	1.6%	16	0.6%	18	0.7%	0	0.0%	33	1.3%	2621
5: JHU	1945	91.6%	67	3.2%	35	1.6%	6	0.3%	20	0.9%	31	1.5%	17	0.8%	2123
6: UMN	1803	79.4%	262	11.5%	23	1.0%	13	0.6%	27	1.2%	15	0.7%	127	5.6%	2272
7: NWU	1696	89.5%	100	5.3%	33	1.7%	9	0.5%	28	1.5%	11	0.6%	17	0.9%	1894
8: UCLA	1874	95.1%	59	3.0%	10	0.5%	2	0.1%	6	0.3%	0	0.0%	18	0.9%	1971
Total	11248	80.2%	1756	12.5%	283	2.0%	111	0.8%	141	1.0%	176	1.3%	293	2.1%	14020

16

2.4 Participant Status, from Follow-up

After clinic exam 4, some of the key questions from the Medical History Form were added to the Followup 8 General Health form to provide the ability to track new onset of risk factor conditions. In addition, a set of trigger questions was added to identify MESA Air participants who need to have a new Air Questionnaire administered, though Follow-up 13. Contacts from Follow-up 8 through the start of Follow-up 15 were jointly supported by MESA and the MESA Air ancillary study.

Unlike clinic exams, these interviews should not be affected significantly by participants who cannot come to the clinic because of illness or who have relocated (unless new contact info was not provided to MESA). The clinics are required to complete a final Follow-up call interview with a proxy when the participant has passed away.

The following tables show the participant status ascertained at the three surveillance calls regardless of the contact window.

Reports Generated 8/1/2014

Follow-up 13

Site Name	Followup Expected	Contac	Contact Made		view oleted	Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	892	892	100%	811	91%	80	69	11	0	0
4: COL	910	910	100%	801	88%	109	97	12	0	0
5: JHU	810	810	100%	748	92%	50	32	18	0	0
6: UMN	907	907	100%	817	90%	89	75	14	0	0
7: NWU	981	981	100%	925	94%	55	53	2	0	0
8: UCLA	1055	1055	100%	917	87%	138	133	5	0	0
Total	5555	5555	100%	5019	90%	521	459	62	0	0

Follow-up 14

Site Name	Followup Expected	Contac	ct Made	Interview Completed		Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	879	754	86%	701	80%	53	51	2	0	125
4: COL	900	837	93%	787	87%	50	41	9	0	63
5: JHU	793	675	85%	643	81%	31	26	5	0	118
6: UMN	893	754	84%	688	77%	63	58	5	0	139
7: NWU	960	903	94%	860	90%	43	39	4	0	57
8: UCLA	1033	1017	99%	884	86%	131	121	10	0	16
Total	5458	4940	91%	4563	84%	371	336	35	0	518

Site Name	Followup Expected	Contac	ct Made	Interview Completed		Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	871	278	32%	257	30%	21	19	2	0	593
4: COL	889	366	41%	357	40%	9	8	1	0	523
5: JHU	770	277	36%	265	34%	12	12	0	0	493
6: UMN	881	397	45%	375	43%	21	16	5	0	484
7: NWU	949	440	46%	430	45%	10	6	4	0	509
8: UCLA	1015	615	61%	542	53%	71	66	5	0	400
Total	5375	2373	44%	2226	41%	144	127	17	0	3002

Follow-up 15

Summary for all follow-ups

Followup (dates)	Followup Expected	Conta	ct Made		rview pleted	Interview Not Completed	Unable	Refused	Unknown	Contact Not Made
FU 1 (8/01-5/03)	6772	6771	99.99%	6631	97.92%	140	124	16	0	1
FU 2 (9/02-1/04)	6763	6756	99.90%	6576	97.20%	180	114	65	1	7
FU 3 (6/03-12/04)	6740	6702	99.40%	6313	93.70%	389	301	88	0	38
FU 4 (3/04-7/05)	6673	6672	100.00%	6383	95.70%	289	186	101	2	1
FU 5 (1/05-6/06)	6581	6576	99.90%	6080	92.40%	496	403	86	7	5
FU 6 (9/05-4/07)	6484	6473	99.80%	6097	94.00%	376	272	102	2	11
FU 7 (9/06-5/08)	6343	6338	99.90%	5874	92.60%	464	368	86	10	5
FU 8 (6/07-1/09)	6236	6227	99.90%	5875	94.20%	352	287	56	9	9
FU 9 (8/08-2/10)	6166	6152	99.80%	5674	92.00%	478	408	70	0	14
FU 10 (4/09-11/10)	6043	6018	99.60%	4886	80.90%	1132	1083	47	2	25
FU 11 (3/10-8/11)	5952	5950	100.00%	5244	88.10%	706	587	119	0	2
FU 12 (8/11-1/13)	5781	5771	99.80%	5202	90.00%	569	497	72	0	10
FU 13 (5/12-10/13)	5555	5555	100.00%	5019	90.40%	521	459	62	0	0
FU 14 (3/13-9/14)	5458	4940	90.50%	4563	83.60%	371	336	35	0	518
FU 15 (1/14-6/15)	5375	2373	44.10%	2226	41.40%	144	127	17	0	3002

These tables describe the status of all participants for whom a Follow-up Contact Cover Sheet is expected. Columns include:

-Follow-ups Expected: Number of participants not deceased or lost to Follow-up

-Contacts Made: Total number of Contact Cover sheets submitted regardless of interview completion

-Interviews Completed: Interview fully or partially completed by participant or proxy

-Interviews Not Completed: Interview not completed because participant was Unable or Refused

-Unable: Participant unable to complete interview (could not locate participant, participant reported deceased or had health issue)

-Refused: Participant contacted but refused to complete interview

- Unk.: Unknown -- Participant contacted but did not compete interview for unknown reason

-Contacts Not Made: Participant not deceased or lost to Follow-up, but no Contact Cover sheet received

2.4.1 Air Pollution Ancillary Study Participant Status, from Follow-up

The status of the additional MESA Family participants recruited for MESA Air is summarized below. The following table shows the participant status ascertained at the three surveillance calls regardless of the contact window. Contacts from Follow-up 8 through the start of Follow-up 15 were jointly supported by MESA and the MESA Air ancillary study.

Unlike clinic exams, these interviews should not be affected significantly by participants who cannot come to the clinic because of illness or who have relocated (unless new contact info was not provided to MESA). The clinics are required to complete a final Follow-up call interview with a proxy when the participant has passed away.

From the completed Follow-up calls (and other sources), 426 investigations have been opened for possible events. Three hundred and ninety nine investigations have so far been completed; of these 87 are eligible for review, and 42 have been reviewed.

As of August 1, 2014, there were 9 Family and Air investigations not initiated, and 29 Family and Air investigations initiated but not completed. One of the uninitiated cases and 6 of the uncompleted cases were likely to be eligible. While the MESA Air Pollution study no longer supports this work, sites are free to complete these cases at their own discretion.

Reports Generated 8/1/2014

Follow-up	Follow- up Expected	Conta	act Made		terview mpleted	Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
4: COL	95	38	40%	36	38%	1	1	0	0	57
8: UCLA	151	61	40%	61	40%	0	0	0	0	90
Total	246	99	40%	97	39%	1	1	0	0	147

MESA Air New Recruits Follow-up 14:

MESA Air New Recruits Follow-up 15:

Follow-up	Follow- up Expected	Conta	act Made		terview mpleted	Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
4: COL	94	7	7%	7	7%	0	0	0	0	87
8: UCLA	149	147	99%	121	81%	26	26	0	0	2
Total	243	154	63%	128	53%	26	26	0	0	89

These tables describe the status of all participants for whom a Follow-up Contact Cover Sheet is expected. Columns include:

-Follow-ups Expected: Number of participants not deceased or lost to Follow-up

-Contacts Made: Total number of Contact Cover sheets submitted regardless of interview completion

-Interviews Completed: Interview fully or partially completed by participant or proxy

-Interviews Not Completed: Interview not completed because participant was Unable or Refused

-Unable: Participant unable to complete interview (could not locate participant, participant reported deceased or had health issue)

-Refused: Participant contacted but refused to complete interview

- Unk.: Unknown -- Participant contacted but did not compete interview for unknown reason

-Contacts Not Made: Participant not deceased or lost to Follow-up, but no Contact Cover sheet received

Reports Generated 8/1/2014 MESA Air Family Follow-up 13:

Follow-up	Follow-up Expected	Conta	act Made	Interview Completed		Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	44	44	100%	41	93%	3	3	0	0	0
4: COL	137	130	95%	95	69%	34	33	1	0	7
5: JHU	48	48	100%	33	69%	14	11	3	0	0
6: UMN	77	77	100%	47	61%	30	30	0	0	0
7: NWU	145	145	100%	123	85%	22	22	0	0	0
8: UCLA	16	16	100%	12	75%	4	4	0	0	0
Total	467	460	99%	351	75%	107	103	4	0	7

MESA Air Family Follow-up 14:

Follow-up	Follow-up Expected	Contact Made		Interview Completed		Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	44	0	0%	0	0%	0	0	0	0	44
4: COL	137	36	26%	36	26%	0	0	0	0	101
5: JHU	48	17	35%	16	33%	1	1	0	0	31
6: UMN	77	20	26%	20	26%	0	0	0	0	57
7: NWU	145	28	19%	25	17%	1	1	0	0	117
8: UCLA	16	0	0%	0	0%	0	0	0	0	16
Total	467	101	22%	97	21%	2	2	0	0	366

MESA Air Family Follow-up 15:

Follow-up	Follow-up Expected	Cont	act Made	Interview Completed		Interview Not Completed	Unable	Refused	Unk.	Contact Not Made
3: WFU	40	2	5.0%	2	5.0%	0	0	0	0	38
4: COL	134	12	9.0%	12	9.0%	0	0	0	0	122
5: JHU	44	2	4.5%	2	4.5%	0	0	0	0	42
6: UMN	77	27	35.1%	25	32.5%	2	2	0	0	50
7: NWU	142	2	1.4%	1	0.7%	1	1	0	0	140
8: UCLA	16	16	100.0%	10	62.5%	6	6	0	0	0
Total	453	61	13.5%	52	11.5%	9	9	0	0	392

These tables describe the status of all participants for whom a Follow-up Contact Cover Sheet is expected. Columns include:

-Follow-ups Expected: Number of participants not deceased or lost to Follow-up

-Contacts Made: Total number of Contact Cover sheets submitted regardless of interview completion

-Interviews Completed: Interview fully or partially completed by participant or proxy

-Interviews Not Completed: Interview not completed because participant was Unable or Refused

-Unable: Participant unable to complete interview (could not locate participant, participant reported deceased or had health

issue)

-Refused: Participant contacted but refused to complete interview

- Unk.: Unknown -- Participant contacted but did not compete interview for unknown reason

-Contacts Not Made: Participant not deceased or lost to Follow-up, but no Contact Cover sheet received

2.5 Investigation Tracking Summary

The following table summarizes the progress that each field center is making toward initiating and completing investigations, as well as whether the completed and eligible investigations have been reviewed by the M&M Committee.

This table is sorted by follow-up (i.e., the follow-up phone interview that generated the event investigation, regardless of event date). To see a breakdown of "MD Review Not Yet Completed," please see Section 2.7.1

Report Generated 8/1/2014

FU	Status	N	/FU	Colu	umbia	J	HU	м	inn	N	wu	U	CLA	Т	otal
	Investigations Indicated	2860		2314		1842		1968		1635		1761		12380	
	Investigations Not Yet Initiated	0	0%	0	0%	0	0%	0	0%	0	0%	11	1%	11	0%
	Investigations Initiated	2860	100%	2314	100%	1842	100%	1968	100%	1635	100%	1750	99%	12369	100%
	Investigations Not Yet Complete	0	0%	11	0%	26	1%	0	0%	0	0%	23	1%	60	0%
	Investigations Not Yet Complete - OVERDUE	0	0%	9	0%	26	1%	0	0%	0	0%	22	1%	57	0%
1- 12	Investigations Complete	2860	100%	2303	100%	1816	99%	1968	100%	1635	100%	1727	99%	12309	100%
	MD Review Not Indicated due to Insufficient Data	54	2%	93	4%	131	7%	72	4%	65	4%	69	4%	484	4%
	MD Review Not Indicated per MESA Protocol	2035	71%	1703	74%	1259	69%	1208	61%	1239	76%	1217	70%	8661	70%
	MD Review Indicated	771	27%	507	22%	426	23%	688	35%	331	20%	441	26%	3164	26%
	MD Review Not Yet Complete	20	3%	14	3%	4	1%	23	3%	13	4%	26	6%	100	3%
	MD Review Complete	751	97%	493	97%	422	99%	665	97%	318	96%	4 15	94%	3064	97%
FU	Status	N	/FU	Colu	umbia	J	HU	М	inn	N	wu	U	CLA	Т	otal
	Investigations Indicated	155		155		163		159		159		102		893	
	Investigations Not Yet Initiated	0	0%	0	0%	0	0%	0	0%	1	1%	1	1%	2	0%
	Investigations Initiated	155	100%	155	100%	163	100%	159	100%	158	99%	10 1	99%	891	100%
	Investigations Not Yet Complete	4	3%	19	12%	26	16%	5	3%	3	2%	41	4 1%	98	11%
	Investigations Not Yet Complete - OVERDUE	3	2%	12	8%	25	15%	2	1%	2	1%	41	4 1%	85	10%
13	Investigations Complete	15 1	97%	136	88%	137	84%	154	97%	155	98%	60	59%	793	89%
	MD Review Not Indicated due to Insufficient Data	6	4%	13	10%	1	1%	0	0%	4	3%	9	15%	33	4%
	MD Review Not Indicated per MESA Protocol	100	66%	84	62%	119	87%	96	62%	115	74%	25	42%	539	68%
	MD Review Indicated	45	30%	39	29%	17	12%	58	38%	36	23%	26	43%	221	28%
	MD Review Not Yet Complete	33	73%	27	69%	11	65%	41	71%	27	75%	25	96%	164	74%
	MD Review Complete	12	27%	12	31%	6	35%	17	29%	9	25%	1	4%	57	26%
FU	Status	N	/FU	Colu	umbia	J	HU	М	inn	N	wu	U	CLA	Т	otal
	Investigations Indicated	81		125		120		112		97		95		639	
	Investigations Not Yet Initiated	5	6%	7	6%	22	18%	5	4%	12	12%	1	1%	61	10%
	Investigations Initiated	76	94%	118	94%	98	82%	107	96%	85	88%	94	99%	578	90%
	Investigations Not Yet Complete	18	24%	54	46%	71	72%	23	21%	11	13 %	60	64%	237	41%
	Investigations Not Yet Complete - OVERDUE	8	11%	34	29%	55	56%	5	5%	6	7%	38	40%	146	25%
14	Investigations Complete	58	76%	64	54%	27	28%	84	79%	74	87%	34	36%	341	59%
	MD Review Not Indicated due to Insufficient Data	0	0%	6	9%	0	0%	0	0%	4	5%	9	26%	19	6%
	MD Review Not Indicated per MESA Protocol	43	74%	41	64%	26	96%	51	61%	55	74%	20	59%	236	69%
	MD Review Indicated	15	26%	17	27%	1	4%	33	39%	15	20%	5	15%	86	25%
	MD Review Not Yet Complete	15	100%	17	100%	1	100%	33	100%	13	87%	5	100%	84	98%
	MD Review Complete	0	0%	0	0%	0	0%	0	0%	2	13 %	0	0%	2	2%

Table continues on the following page

FU	Status	v	/FU	Columbia JHU		м	inn	N	NWU UCLA		CLA	Total			
	Investigations Indicated	58		47		36		42		49		35		267	
	Investigations Not Yet Initiated	14	24%	13	28%	17	47%	4	10%	33	67%	10	29%	91	34%
	Investigations Initiated	44	76%	34	72%	19	53%	38	90%	16	33%	25	7 1%	176	66%
	Investigations Not Yet Complete	19	43%	26	76%	18	95%	16	42%	7	44%	22	88%	108	61%
	Investigations Not Yet Complete - OVERDUE	1	2%	3	9%	1	5%	2	5%	1	6%	12	48%	20	11%
15	Investigations Complete	25	57%	8	24%	1	5%	22	58%	9	56%	3	12%	68	39%
	MD Review Not Indicated due to Insufficient Data	0	0%	0	0%	0	0%	0	0%	0	0%	1	33%	1	1%
	MD Review Not Indicated per MESA Protocol	24	96%	6	75%	1	100%	16	73%	8	89%	2	67%	57	84%
	MD Review Indicated	1	4%	2	25%	0	0%	6	27%	1	11%	0	0%	10	15%
	MD Review Not Yet Complete	1	100%	2	100%	0	-	6	100%	1	100%	0	-	10	100%
	MD Review Complete	0	0%	0	0%	0	-	0	0%	0	0%	0	-	0	0%
FU	Status	v	/FU	Colu	umbia	J	HU	М	inn	N	wu	U	CLA	Т	otal
	Investigations Indicated	3 158		2641		2162		2281		1940		1994		14185	
	Investigations Not Yet Initiated	19	1%	20	1%	39	2%	9	0%	46	2%	23	1%	165	1%
	Investigations Initiated	3 139	99%	2621	99%	2123	98%	2272	100%	1894	98%	1971	99%	14020	99%
	Investigations Not Yet Complete	45	1%	110	4%	142	7%	44	2%	21	1%	147	7%	509	4%
	Investigations Not Yet Complete - OVERDUE	12	0%	58	2%	107	5%	9	0%	9	0%	113	6%	308	2%
TOTAL	Investigations Complete	3094	99%	2511	96%	1981	93%	2228	98%	1873	99%	1824	93%	135 11	96%
	MD Review Not Indicated due to Insufficient Data	60	2%	112	4%	132	7%	72	3%	73	4%	88	5%	537	4%
			71%	1834	73%	1405	7 1%	1371	62%	14 17	76%	1264	69%	9493	70%
	MD Review Not Indicated per MESA Protocol	2202	71%	.001											
		2202 832	27%	565	23%	444	22%	785	35%	383	20%	472	26%	3481	26%
	Protocol				23% 11%	444 16	22% 4%	785 103	35% 13%	383 54	20% 14%	472 56	26% 12%	3481 358	26% 10%

2.6 Stroke Investigations

As of August 2014, 569 investigation of potential cerebrovascular events have been designated eligible for review, 460 of which have been reviewed and classified by the physician reviewers. The remaining investigations are pending assignment or review.

	Eligible f					
Site	Cerebro Only Events	Cerebro / Cardiac Combination Events	Cerebro Reviews Completed			
3: WFU	98	33	114			
4: COL	55	17	55			
5: JHU	42	21	60			
6: UMN	117	29	118			
7: NWU	49	12	41			
8: UCLA	67	21	72			
Total	428	133	460			

2.7 MD Reviews

2.7.1 Review Completion

The following table documents the rate at which completed investigations are assigned to and reviewed by the M&M subcommittee physicians. At any given period in time there will be outstanding reviews that are pending information or final decisions. Unassigned investigations include those to be assigned in the coming months, as well as those pending field center collection of records for same-participant investigations with earlier event dates (or those within 30 days).

Report Generated 8/1/2014

	-	out Spital	In Hospital		То	tal
MD Review Indicated	852	-	2705	-	3557	-
MD Review Not Yet Complete	65	8%	323	12%	388	11%
Pending Review Assignment	52	80%	237	73%	289	74%
Assigned, Pending Reviewer Completion	13	20%	86	27%	99	26%
MD Review Complete	787	92%	2382	88%	3169	89%

2.7.2 Death Investigation and Classification

The following table summarizes the investigation and review status of all deaths. The classifications for reviewed deaths listed here are also included in Section 2.7.3.3 below (Participants with Endpoints from Completed Reviews).

	Total	Wake Forest	Columbia	Johns Hopkins	Minnesota	North western	UCLA
All Deaths (Pending and Completed)	1027	190	158	187	146	148	198
Death Pending Investigation	194	36	45	27	21	22	43
Review Ineligible (Non-CVD)	544	100	72	98	83	101	90
Review Complete	296	55	43	63	43	27	65
CHD Death	93	21	9	19	8	13	23
Stroke Death	35	9	2	6	5	7	6
Other Athero Death	8	0	3	2	3	0	0
Other CVD Death	45	8	11	9	6	3	8
Non-CVD Death	111	17	17	27	19	4	27
Unknown Cause Death	4	0	1	0	2	0	1

2.7.2.1 Death Investigation, underlying cause by ICD-10 category

The following table summarizes the deaths counted above by the major ICD-10 classification categories.

Class	Description	Num
А, В	Certain infectious and parasitic diseases	29
С	Neoplasms	322
D	Neoplasms or blood-related diseases	9
E	Endocrine, nutritional and metabolic diseases	41
F	Mental and behavioural disorders	41
G	Diseases of the nervous system	33
I	Diseases of the circulatory system	232
J	Diseases of the respiratory system	76
К	Diseases of the digestive system	39
М	Diseases of the musculoskeletal system and connective tissue	7
Ν	Diseases of the genitourinary system	24
R	Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	8
V-Y	External causes of morbidity and mortality	33
	Events Eligibility form not yet completed	133

2.7.2.2 Death Investigation, underlying cause, most common ICD-10 codes

The following table lists the most common underlying causes of death among the deaths counted above, by ICD-10 code.

ICD-10	Count	Description
C34.9	88	BRONCHUS OR LUNG, UNSPECIFIED
125.1	39	ATHEROSCLEROTIC HEART DISEASE
F03.	34	UNSPECIFIED DEMENTIA
125.0	33	ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, SO DESCRIBED
C25.9	29	PANCREAS, UNSPECIFIED
121.9	27	ACUTE MYOCARDIAL INFARCTION, UNSPECIFIED
J44.9	23	CHRONIC OBSTRUCTIVE PULMONARY DISEASE, UNSPECIFIED
C18.9	21	COLON, UNSPECIFIED
164.	18	STROKE, NOT SPECIFIED AS HEMORRHAGE OR INFARCTION
J18.9	17	PNEUMONIA, UNSPECIFIED
E14.9	17	WITHOUT COMPLICATIONS
G30.9	16	ALZHEIMER'S DISEASE, UNSPECIFIED
C61.	15	MALIGNANT NEOPLASM OF PROSTATE
C56.	13	MALIGNANT NEOPLASM OF OVARY
C22.0	12	LIVER CELL CARCINOMA
150.0	12	CONGESTIVE HEART FAILURE
C16.9	11	STOMACH, UNSPECIFIED
J84.1	10	OTHER INTERSTITIAL PULMONARY DISEASES WITH FIBROSIS
C92.0	10	ACUTE MYELOID LEUKEMIA
A41.9	10	SEPTICEMIA, UNSPECIFIED
Other	572	

2.7.3 Events Data Release Update: Participants with CHD & CVD Combination Endpoints (Average of 9.5 years of surveillance)

The following table summarizes combination endpoints from the Events dataset update released in December 2013 and available in the Events subsection of the Exam Datasets section of the <u>MESA</u> Internal web site.

The table displays the number of participants with an endpoint. In other words, unlike in Section 2.7.3.4, multiple instances of the same endpoint occurring in the same participant are counted only once in the table below. "Definite" and "probable" classifications are combined for each endpoint. The rate of combination endpoint events is per 10,000 person-years.

	CHD	Hard	СН	D All	CVD	Hard	CVE) All
Site Name	Ppts	Rate	Ppts	Rate	Ppts	Rate	Ppts	Rate
3: Wake Forest	63	61.5	101	101.0	98	96.9	139	140.7
4: Columbia	38	37.2	64	63.5	62	61.2	94	94.0
5: Johns Hopkins	44	44.2	67	68.4	71	72.1	102	105.2
6: Minnesota	53	53.2	77	78.3	90	91.7	118	121.9
7: Northwestern	35	31.8	63	58.3	51	46.8	80	74.7
8: UCLA	51	41.6	77	63.5	78	64.1	106	88.1
Total	284	44.6	449	71.7	450	71.5	639	103.1

Report Generated 12/30/2013

Definition of Combination Endpoints

Endpoint Combination	MI	Angina	Resusc. Cardiac Arrest	Stroke	CHD Death	Stroke Death	Other Athero. Death	Other CVD Death
CHD Hard	Х		Х		Х			
CHD All	Х	X *	Х		Х			
CVD Hard	Х		Х	Х	Х	Х		
CVD All	Х	X *	Х	Х	Х	Х	Х	Х

* Note: If Angina was classified "probable" rather than "definite," it is included in CHD All and CVD All only if a coronary revascularization was performed at the same time or afterwards.

2.7.3.1 Participants with CHD & CVD Combination Endpoints (Baseline to Present)

The following table displays the number of participants with an endpoint. In other words, multiple instances of the same endpoint occurring in the same participant are counted only once in the table below. "Definite" and "probable" classifications are combined for each endpoint.

<u>Note</u>: The table below includes all data classified to date; surveillance time varies widely for participants whose data are included here. For data derived from uniform surveillance time, please see tables specifying an average surveillance time.

Site Name	CHD Hard	CHD AII	CVD Hard	CVD AII
3: Wake Forest	65	101	100	139
4: Columbia	41	69	64	100
5: Johns Hopkins	46	69	73	106
6: Minnesota	53	80	92	123
7: Northwestern	41	71	57	89
8: UCLA	53	81	78	111
Total	299	471	464	668

Report Generated 8/1/2014

Definition of Combination Endpoints

Endpoint Combination	MI	Angina	Resusc. Cardiac Arrest	Stroke	CHD Death	Stroke Death	Other Athero. Death	Other CVD Death
CHD Hard	Х		Х		Х			
CHD All	Х	X *	Х		Х			
CVD Hard	Х		Х	Х	Х	Х		
CVD All	Х	X *	Х	Х	Х	Х	Х	Х

* Note: If Angina was classified "probable" rather than "definite," it is included in CHD All and CVD All only if a coronary revascularization was performed at the same time or afterwards.

2.7.3.2 Events Data Release Update: Participants with Endpoints from Completed Reviews (Average of 9.5 years of surveillance)

The following table summarizes endpoints from the Events dataset update released in December 2013 and available in the Events subsection of the Exam Datasets section of the <u>MESA Internal web site</u>.

The table displays the number of participants with an endpoint (as in Section 2.7.3.1). Multiple instances of the same endpoint occurring in the same participant are counted only once in the table below. "Definite" and "probable" classifications are combined for each endpoint. The rate of endpoint events is per 10,000 person-years. The "Death: Non-CVD – Inelig. for Review" category includes only deaths that have been finalized; non-CVD deaths pending investigation or review are not included.

Report Generated 12/30/2013

Site Nam	ıe	MI	Resusc. Cardiac Arrest	Angina	CHF	PVD	Coro. Revasc.	Stroke	TIA	Death: CHD	Death: Stroke	Death: Other Athero	Death: Other CVD	Death: Non-CVD	Death: Unknown	Death: Non-CVD - Inelig. for Review
3: WFU	Ppts	41	10	57	63	9	68	37	22	21	9	0	8	13	0	75
5. WFO	Rate	40.1	9.6	56.5	61.8	8.7	67.6	35.9	21.3	19.9	8.5	0.0	7.6	12.3	0.0	71.1
4: COL	Ppts	27	3	53	38	9	49	24	5	9	3	2	7	13	1	65
4. COL	Rate	26.4	2.9	52.7	37.2	8.7	48.3	23.4	4.8	8.3	2.8	1.9	6.5	12.1	0.9	60.3
5: JHU	Ppts	27	6	36	33	18	42	31	13	17	6	1	8	26	0	88
5. JHU	Rate	27.1	6.0	36.7	33.3	18.1	42.9	31.2	13.0	16.3	5.8	1.0	7.7	24.9	0.0	84.3
6: UMN	Ppts	51	2	47	42	26	63	38	17	7	5	3	6	17	2	71
O. UIVIIN	Rate	51.2	2.0	47.5	42.1	26.0	63.8	38.1	17.0	6.7	4.8	2.9	5.8	16.3	1.9	68.1
7: NWU	Ppts	26	5	37	26	7	52	19	3	10	4	0	2	3	0	75
7. INVV U	Rate	23.6	4.5	33.9	23.7	6.3	48.0	17.2	2.7	8.7	3.5	0.0	1.7	2.6	0.0	65.2
0.1101.4	Ppts	33	1	43	35	12	41	31	7	21	7	0	5	25	1	73
8: UCLA	Rate	26.9	0.8	35.4	28.5	9.7	33.6	25.2	5.7	16.0	5.3	0.0	3.8	19.0	0.8	55.5
Total	Ppts	205	27	273	237	81	315	180	67	85	34	6	36	97	4	447
lolai	Rate	32.2	4.2	43.4	37.3	12.7	50.1	28.2	10.5	12.7	5.1	0.9	5.4	14.5	0.6	66.9

2.7.3.3 Participants with Endpoints from Completed Reviews (Baseline to Present)

The following table displays the number of participants with an endpoint. In other words, unlike in Section 2.7.3.4, multiple instances of the same endpoint occurring in the same participant are counted only once in the table below. "Definite" and "probable" classifications are combined for each endpoint. The "Death: Non-CVD – Inelig. for Review" category includes only deaths that have been finalized; non-CVD deaths pending investigation or review are not included.

<u>Note</u>: The table below includes all data classified to date; surveillance time varies widely for participants whose data are included here. For data derived from uniform surveillance time, please see tables specifying an average surveillance time.

Site Name	мі	Resusc. Cardiac Arrest	Angina	CHF	PVD	Coro. Revasc.	Stroke	TIA	Death: CHD	Death: Stroke	Death: Other Athero	Death: Other CVD	Death: Non- CVD	Death: Unkno wn	Death: Inelig. For Review
3: WFU	43	10	57	65	9	68	38	22	21	9	0	8	16	0	101
4: COL	30	3	56	42	13	51	24	5	9	2	3	11	16	1	71
5: JHU	27	6	36	33	19	42	31	13	19	6	2	9	27	0	98
6: UMN	51	2	51	43	28	66	40	17	8	5	3	6	19	2	82
7: NWU	29	6	41	28	7	59	19	3	13	4	0	3	4	0	99
8: UCLA	33	1	45	36	13	44	31	7	23	6	0	8	27	1	89
Total	213	28	286	247	89	330	183	67	93	32	8	45	109	4	540

2.7.3.4 Endpoints from Completed Reviews (Baseline to Present)

The following table shows the results from all finalized reviews. Unlike in Sections 2.7.3 through 2.7.3.3, multiple endpoints occurring more than once in the same participant are included here (e.g., if a participant had two MIs, they are both recorded here).

<u>Note</u>: The table below includes all data collected to date; surveillance time varies widely for participants whose data are included here. For data derived from uniform surveillance time, please see tables specifying an average surveillance time.

	Site	N	11	Rescusitated Cardiac Arrest		Angina		CHF		P١	/D	Coro.	Stroke	TIA			De	eath		
	Name	def	prob	def	prob	def	prob	def	prob	def	prob	Revasc.	Shoke		CHD	Stroke	Other Athero	Other CVD	Non- CVD	Unknown
	3: WFU	2	0	1	0	10	9	7	7	7	0	7	4	4	17	4	0	6	8	0
	4: COL	0	0	0	0	9	11	2	1	4	0	4	1	1	8	1	2	6	7	1
	5: JHU	0	1	0	0	3	8	2	3	13	1	3	6	1	17	3	1	7	7	0
Out of Hospital	6: UMN	0	0	0	0	9	12	4	4	15	3	3	4	6	5	3	1	3	6	1
	7: NWU	0	0	0	0	9	4	0	0	7	3	2	3	0	10	2	0	3	2	0
	8:UCLA	0	1	0	0	4	5	1	2	6	0	0	3	1	20	3	0	6	4	1
	Total	2	2	1	0	44	49	16	17	52	7	19	21	13	77	16	4	31	34	3
	3: WFU	29	18	8	1	41	11	79	24	11	0	76	40	22	4	5	0	2	9	0
	4: COL	14	20	2	1	46	17	34	22	15	1	66	30	4	1	1	1	3	10	0
	5: JHU	19	9	5	1	20	10	29	6	18	1	44	26	13	2	3	1	2	20	0
In Hospital	6: UMN	42	19	1	1	39	10	51	11	28	2	80	42	15	3	2	2	3	13	1
nospitui	7: NWU	26	15	6	0	41	7	30	6	7	0	72	17	3	3	2	0	0	2	0
	8:UCLA	19	16	1	0	33	18	23	15	8	1	49	30	6	3	3	0	2	23	0
	Total	149	97	23	4	220	73	246	84	87	5	387	185	63	16	16	4	12	77	1
Tot	al	151	99	24	4	264	122	262	101	139	12	406	206	76	93	32	8	43	111	4

2.8 Investigations Ineligible for Review Due to "Insufficient Data to Classify"

The following table shows the initial participant-reported event type for investigations ultimately ending as ineligible for review because there was "Insufficient Data to Classify." Potential events receive this designation only after several attempts have been made to obtain sufficient records. The most common reasons for this designation are the following: participant refusal to provide/renew consent for release of records, participant failure to sign/return consent form, inability to locate participant to obtain/renew consent, hospital/physician failure to respond to record requests. Investigations initially reported as a cardiac/cerebrovascular combination case are counted twice in the total column.

The number of investigations classified as 'Insufficient Data to Classify' has generally decreased steadily since the early Follow-ups. Events investigations are estimated at about 99% complete through Follow-up 13, about 59% from Follow-up 14 and 39% from Follow-up 15 (Follow-ups 14 and 15 are currently underway).

Reports Generated 8/1/2014

	FU-1	FU-2	FU-3	FU-4	FU-5	FU-6	FU-7	FU-8	FU-9	FU-10	FU-11	FU-12	FU-13	FU-14	FU-15
Insufficient Data to Classify	79	46	64	36	46	32	24	25	36	23	41	42	36	21	5

				Car	diac	;					С	erebro	vaso	ular			Non	-CVD										
		Hosp	oitaliz	ed		Out of	f Hosp	ital		Hosp	oitalize	d		Out of	Hos	pital	Non-CVD Non-Fatal		Non-Fatal		Non-Fatal		Non-CVD Death		Unknown		Total	
	De	eath	Non	-Fatal	De	eath	Non-	Fatal	D	eath	Non	Fatal	De	eath	Nor	n-Fatal	Hosp	italized										
Site	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%				
3: WFU	1	2%	10	17%	0	0%	9	15%	0	0%	2	3%	0	0%	6	10%	31	53%	0	0%	0	0%	59	100%				
4: COL	0	0%	19	17%	0	0%	19	17%	0	0%	4	3%	0	0%	9	8%	57	50%	5	4%	2	2%	115	100%				
5: JHU	0	0%	14	11%	0	0%	34	26%	0	0%	9	7%	0	0%	11	8%	63	47%	1	1%	1	1%	133	100%				
6: UMN	0	0%	8	11%	0	0%	12	16%	0	0%	1	1%	0	0%	1	1%	52	70%	0	0%	0	0%	74	100%				
7: NWU	0	0%	5	7%	0	0%	19	25%	0	0%	3	4%	0	0%	3	4%	39	51%	5	7%	2	3%	76	100%				
8: UCLA	0	0%	11	12%	1	1%	15	17%	0	0%	2	2%	1	1%	8	9%	47	52%	5	6%	0	0%	90	100%				
Total	1	0%	67	12%	1	0%	108	20%	0	0%	21	4%	1	0%	38	7%	289	53%	16	3%	5	1%	547	100%				

Note: The table below includes all data finalized to date; surveillance time varies widely for participants whose data are included here.

BLANK

32

Section 3: Publications and Presentations

3.1.	P&P and Genetics P&P Membership	35
	3.1.1. P&P Members	35
	3.1.2. Genetics P&P Members	36
3.2.	Recent P&P Activities	37
3.3.	Recent Genetics P&P Activities	38
3.4.	Summary of MESA Authorship: Approved Proposals as of August 14, 2014	39
3.5.	Summary of Genetics P&P Authorship: Approved Proposals as of August 11, 2014	39
3.6.	Central and Local Analyst Activities	40
3.7.	Accounting of Paper Status	40
	3.7.1. Table: Summary of Manuscripts as of August 14, 2014	40
	3.7.2. Table: Summary of Genetics Manuscripts as of August 11, 2014	40
	3.7.3. Table: Time from Manuscript Approval – Main Study Papers Pending	41
	3.7.4. Table: Time from Manuscript Approval – Ancillary Study Papers Pending	48
	3.7.5 Table: Time from Manuscript Approval – Genetics Papers Pending	56
3.8.	MESA Manuscripts and Papers	64
3.9	CARe Manuscript Proposals	65

BLANK

3.1. P&P and Genetics P&P Membership

3.1.1.P&P Members

Member	Site/Affiliation	E-mail address
Moyses Szklo, MD, DrPH	Johns Hopkins University Field Center	mszklo1@jhu.edu
Steven Shea, MD, MS	Columbia University Field Center	ss35@columbia.edu
David Bluemke, MD, PhD	MRI Reading Center, NIH/CC/DRD	bluemke@nih.gov
Kiang Liu, PhD	Northwestern University Field Center	kiangliu@northwestern.edu
Robyn McClelland, PhD	Coordinating Center, Univ. of Washington	rmcclell@u.washington.edu
Alain Bertoni, MD	Wake Forest University Field Center	abertoni@wakehealth.edu
Karol Watson, MD, PhD	UCLA Field Center	kwatson@mednet.ucla.edu
Joseph Polak, MD, MPH	Tufts-NEMC Ultrasound Reading Center	jpolak@tuftsmedicalcenter.org
Michael Tsai, PhD	Blood Laboratory, Univ. of Minnesota	tsaix001@tc.umn.edu
Joao Lima, MD	MRI Reading Center	jlima@jhmi.edu
Ian de Boer, MD, MS	University of Washington	deboer@u.washington.edu
Michael Blaha, MD	Johns Hopkins Hospital	mblaha1@jhmi.edu
Norrina B. Allen, PhD	Northwestern University	norrina-allen@northwestern.edu;

The Coordinating Center has a Program Coordinator, Karen Hansen (hansenk3@u.washington.edu), to assist the main P&P Committee. Any procedural questions related to P&P should be directed to her.

3.1.2. Genetics P&P Members

Member	Site/Affiliation	E-mail address
Wendy Post, MD, MS	Johns Hopkins University Field Center	wpost@jhmi.edu
Stephen Rich, PhD	University of Virginia	ssr4n@virginia.edu
Xiuqing Guo, PhD	LA BioMed/Harbor UCLA	xguo@labiomed.org
Nancy Swords Jenny, PhD	Blood Laboratory (Univ. of Vermont)	nancy.jenny@uvm.edu
Yongmei Liu, PhD	Wake Forest University	Yoliu@wfubmc.edu
James Pankow, PhD, MPH	Minnesota Field Center	pankow@epi.umn.edu
Christina Wassel, PhD	University of Pittsburgh	cwassel@pitt.edu

Procedural questions related to Genetics P&P should be directed to genpp@uw.edu.

3.2. Recent P&P Activities

- ✓ Review and approval of proposals, abstracts, and penultimate drafts
 - MESA now has 1,285 approved paper proposals:
 - 664 papers published or in press
 - 185 penultimate drafts approved for submission
 - 19 penultimate drafts in revision and review process
 - 417 papers in progress
 - 24 MESA abstracts were submitted to the AHA Scientific Sessions 2014 meeting scheduled for November 15-19, 2014.
 - 46 MESA abstracts were submitted to 16 different conferences other than the AHA meeting. These 16 conferences will be held between May and December 2014.
- ✓ Complete and up-to-date website listing
 - It is the responsibility of all first and Senior MESA authors to maintain accurate author lists and to notify P&P of any changes to these.
- ✓ Website updates and changes
 - Published papers additions
 - P&P policy and procedural information updated
 - o Presentations (from approved abstracts) added online
- ✓ Conducted a large audit follow-up project in May-July 2014

3.3. Recent Genetics P&P Activities

- ✓ Review and approval of proposals, abstracts, and penultimate drafts, as of August 11, 2014
 - Genetics P&P now has 326 paper proposals:
 - 70 papers published or in press
 - 34 penultimate drafts approved for submission
 - 8 penultimate drafts in revision and review process
 - 8 proposals withdrawn
 - 214 approved proposals with paper in progress
 - Genetics P&P approved 10 MESA Genetics abstracts between January 3, 2014 and August 11, 2014:
 - 1 abstract was submitted to the International Society for Environmental Epidemiology, August 24-24, 2014 in Seattle, WA.
 - 1 abstract was submitted to the American Society of Nephrology, November 11-16, 2014 in Philadelphia, PA.
 - 1 abstract was submitted to the American Society of Hemotology, December 6-9, 2014 in San Francisco, CA.
 - 7 abstracts were submitted to the American Society of Human Genetics, October 18-22, 2014 in San Diego, CA.
- ✓ Complete and up-to-date website listing
 - It is the responsibility of all first and Senior MESA authors to maintain accurate author lists and to notify Genetics P&P of any changes to these.
 - A comprehensive list of MESA Genetics papers can be found on the MESA SHARe website (http://www.mesa-nhlbi.org/MesaInternal/MESASHARe/PublicationsPres.aspx)

3.4. Summary of MESA Authorship: Approved Proposals as of August 14, 2014

	Number of first authors		Number of authors		Number of papers on which	
	represented		represented		site is represented	
	Main papers	All papers	Main papers	All papers	Main papers	All papers
	(N = 591)	(N = 1,318)	(N = 591)	(N = 1,318)	(N = 591)	(N = 1,318)
Coordinating Center	17	24	40	51	228	472
Project Office	1	1	9	9	31	81
Field Centers Wake Forest Columbia Johns Hopkins Minnesota Northwestern UCLA	19 13 45 15 31 6	29 37 70 19 43 14	40 42 94 31 58 24	65 78 163 36 85 38	245 146 257 169 184 48	414 353 525 295 326 153
Reading Centers CT MRI Tufts-NEMC Ultrasound Wisc. Ultrasound Blood USC Nutrition ECG Retinal	5 12 1 5 0 2 1	10 26 1 8 0 2 4	12 29 3 10 1 3 4	22 45 3 13 1 3 8	118 197 51 105 6 38 10	261 401 101 230 6 57 53
Other*	191	381	563	992	525	1,211

"Site is represented" counts papers with authors, coauthors, sponsors, and analysts from a site; "authors represented" counts only first authors and coauthors from a site.

*Not affiliated with above.

3.5. Summary of Genetics P&P Authorship: Approved Proposals as of August 11, 2014

"Site is represented" counts papers with authors, coauthors, sponsors, and analysts from a site; "authors represented" counts only first authors and coauthors from a site.

	Number of first authors represented	Number of authors represented	Number of papers on which site is represented
	G papers (N = 326)	G papers (N = 326)	G papers (N = 326)
Coordinating Center	11	22	78
Project Office	2	3	18
Field Centers			
Wake Forest	19	25	85
Columbia	16	19	72
Johns Hopkins	16	26	86
Minnesota	13	12	63
Northwestern	5	13	34
UCLA	1	3	10
Reading Centers			
СТ	6	2	16
MRI	11	9	37
Ultrasound	1	1	10
Blood	15	9	79
Nutrition	0	0	0
ECG	1	2	4
Retinal	6	4	14
Other*	59	248	286

*Not affiliated with above.

3.6. Central and Local Analyst Activities

	Central Analyst	Local Analyst
Main Study	387	198
Ancillary Studies	458	264
Genetics	279	27

3.7. Accounting of Paper Status

3.7.1. Table: Summary of Manuscripts as of August 14, 2014

	Total Main & Ancillary	Main Study	Ancillary Studies
Papers Published or In Press	664	311	353
Pen Drafts Approved	185	81	104
Pen Drafts in Review	19	11	8
Pen Drafts Pending	417	167	250
0 – 3 months (from approval) >3 – 6 months >6 – 9 months >9 – 12 months >12 months	47 42 41 43 224	20 11 16 13 107	27 31 25 30 137
Total Papers Approved	1,285	570	715

3.7.2. Table: Summary of Genetics Manuscripts as of August 11, 2014

	Approved Genetics Paper Proposals
Papers Published or In Press	70
Pen Drafts Approved	34
Pen Drafts in Review	2
Pen Drafts Pending (paper in progress)	214
0-3 months (from approval)	13
>3-6 months	10
>6-9 months	12
>9 – 12 months	17
>12 months	166
Total Papers Approved	326

3.7.3.Table: Time from Manuscript Approval – Main Study Papers Pending

Information is sorted by manuscript approval date. Table continues on the following seven pages.

Over 12 months

Manuscript Number	Title	First Author	Approval Date
ME 006	Neighborhood characteristics and CVD risk in a multi-ethnic sample	Mujahid, Mahasin S.	08/24/2006
ME 020	Value of coronary artery calcium and carotid IMT in predicting cardiovascular disease events among individuals with family history of heart diseases: Multiethnic Study of Atherosclerosis.	Nasir, Khurram	09/20/2007
MC 163	Association between features of the radial artery pulse pressure waveform and diabetes: The Multi-Ethnic Study of Atherosclerosis.	Brumback, Lyndia	04/04/2008
MC 185	Association between Sleep Duration and Sub-clinical Cardiovascular Disease Risk Status: The Multi-Ethnic Study of Atherosclerosis (MESA)	Kwon, Jeff	01/30/2009
ME 049	DASH Diet Adherence and Incident Heart Failure: Multi-Ethnic Study of Atherosclerosis	Nguyen, Ha T	08/21/2009
ME 050	CONFORMITY WITH PRINCIPLES OF THE DASH DIET AND RISK OF INCIDENT TYPE 2 DIABETES IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)	Nguyen, Ha T	09/15/2009
ME 052	The Relationship Between Global Left Ventricular Diastolic Function Determined by Magnetic Resonance Imaging and Incident Cardiovascular Disease – The Multi-Ethnic Study of Atherosclerosis	Yan, Raymond T	10/20/2009
ME 054	Is the association of hypertension with cardiovascular events stronger among the lean and normal weight than among the overweight and obese? The Multi-Ethnic Study of Atherosclerosis	Colangelo, Laura	12/04/2009
ML 079	Timing of Ambient Particulate Matter Exposure and Blood pressure/Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)	Chen, Yeh-Hsin	12/22/2009
MC 208	Association of the Mediterranean diet pattern with left ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis	Levitan, Emily B.	03/12/2010
ML 082	Racial/ ethnic differences in physical activity mode and longitudinal associations with body mass index and depression in a population-based cohort: The Multi-Ethnic Study of Atherosclerosis	Echeverria, Sandra E.	03/12/2010
ML 088	Place of Birth and Age Trajectories of Health Status: Results from the Multiethnic Study of Atherosclerosis	Le-Scherban, Felice Z.	05/14/2010
ME 062	Quantification of Left Atrial Myocardial Deformation for Prediction of Incident Atrial Fibrillation: The Multiethnic Study of Atherosclerosis	Opdahl, Anders	05/17/2010

ME 040	Prognosis of Coronary Calcium based upon location of CAC: The Multi-Ethnic Study of Atherosclerosis (MESA)	Blaha, Michael	06/11/2010
ME 065	Use of Coronary Calcium Score to Reclassify Coronary Heart Disease Risk in those with Metabolic Syndrome and Diabetes : Results from the Multi-ethnic Study of Atherosclerosis (MESA)	Malik, Shaista	06/17/2010
ME 036	Association between Physical Activity and Cardiovascular Events in the Multi-Ethnic Study of Atherosclerosis (MESA)	Turkbey, Evrim Bengi	01/28/2011
ML 102	Aortic biomechanics by MRI: Relation with age, gender, ethnicity and traditional cardiovascular risk factors. A cross-sectional and longitudinal study: The Multi-Ethnic Study of Atherosclerosis (MESA)	Teixido-Tura, Gisela	01/28/2011
ML 107	Reproducibility of the radial artery pulse waveform: The Multi- Ethnic Study of Atherosclerosis	Brumback, Lyndia	04/29/2011
ME 087	Quantifying Zero Coronary Artery Calcium as a Negative Risk Factor: Risk-Adjusted Likelihood Ratios – MESA	Blaha, Michael	04/29/2011
ML 109	Comparison of anthropometrics in individuals with and without HIV in two large national cohorts: The Multi-Ethnic Study of Atherosclerosis (MESA) and AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT)	Atkinson, Benjamin E	06/10/2011
ME 088	Differences in traditional risk factors and lipid particle size and number in individuals with HDL-C > 80mg/dL with and without coronary and carotid atherosclerosis: The Multi-Ethnic Study of Atherosclerosis	Wilkins, John T	06/23/2011
ME 095	Association of Ideal Cardiovascular Health with Baseline Subclinical Cardiovascular Disease and Incident Events: the Multi-Ethnic Study of Atherosclerosis	Polonsky, Tamar	06/26/2011
ME 097	The Association of Calcium Supplementation and Incident Cardiovascular Events: Multi-Ethnic Study of Atherosclerosis.	Agarwal, Subhashish	08/04/2011
ME 098	Prevalence and prognostic implications of coronary artery calcium in low risk women: a meta-analytic study of MESA and three additional cohorts	Desai, Chintan S	08/10/2011
ML 114	The Biomechanical Relationship between Left Ventricular Torsion, Circumferential Strain and Aortic Stiffness: A Combined Risk Factor Parameter	Chugh, Atul R	10/03/2011
ML 118	Physical activity, insulin sensitivity, and blood pressure: findings from the Multi-Ethnic Study of Atherosclerosis (MESA)	Foy, Capri G	12/08/2011
MC 241	Arterial Aging Chronic Kidney Patients as a Marker of Accelerated Atherogenesis– a Comparison to the Multiethnic Study of Atherosclerosis	Rizzi, Patricia Belfort	12/08/2011
MC 245	Prevalence and Degree of Vertebral Fractures of the Thoracic Spine from Cardiac CT Images of the Multi Ethnic Study of Atherosclerosis	Li, Dong	01/03/2012
ME 109	Use of 12-lead electrocardiogram as an index of myocardial scar: relationship with demographic characteristics, traditional cardio- vascular risk factors and prognostic value in the Multi-Ethnic Study of Atherosclerosis.	Mewton, Nathan	01/03/2012

MC 242	Work Hours and Coronary Artery Calcium: the Multi-Ethnic Study of Atherosclerosis (MESA)	Baughman, Penelope	01/03/2012
ME 110	Reclassification of coronary heart disease events with coronary artery calcium score versus a multiple biomarker approach: Multi- Ethnic Study of Atherosclerosis	Rana, Jamal S	01/03/2012
MC 244	Association between PR Interval and measure of left ventricular structure and function in the Multi-Ethnic Study of Atherosclerosis (MESA)	Husby, Michael	01/03/2012
ML 123	Neighborhood Socioeconomic Status and Longitudinal Cumulative Biological Risk: The Multi-Ethnic Study of Atherosclerosis	Merkin, Sharon Stein	02/15/2012
ME 119	Cardiovascular Disease Risk Prediction in Combined Cohort Studies	D'Agostino, Sr., Ralph B.	02/22/2012
MC 249	Does Social Support Moderate the Effects of Socioeconomic Status on Subclinical Atherosclerosis?: The Multi-Ethnic Study of Atherosclerosis	Abedin, Zameer	03/09/2012
ML 121	Traditional Ethnic Diet and Type 2 Diabetes, Prevalence and Incidence: The Multi-Ethnic Study of Atherosclerosis (MESA)	Mercado, Carla I.	03/22/2012
ME 123	The relationship of HDL size, particles and subclasses to carotid atherosclerosis and cardiovascular events: The Multi-Ethnic Study of Atherosclerosis	Mackey, Rachel H	03/22/2012
ML 125	Clinical and Imaging Risk Factors for Myocardial Scar in MESA Study	Nacif, Marcelo Souto	04/13/2012
MC 250	The Relationship of Bone Mineral Density to Aortic Valve Calcium in the Multi Ethnic Study of Atherosclerosis	Tandon, Karman	04/27/2012
MM 028	Impact of Methods Used to Determine Net Reclassification Improvement on Perceived Value of Biomarkers Used to Identify Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA)	Blankstein, Ron	05/11/2012
ME 127	Comparison of Small Artery Elasticity, Large Artery Elasticity, Aortic Distensibility, Carotid Artery Distensibility, and Young's Modulus at the Carotid Artery in Prediction of Congestive Heart Failure Cardiovascular Events in An Asymptomatic Population: The Multi-Ethnic Study of Atherosclerosis (MESA)	Hom, Elizabeth K	05/11/2012
MC 251	Relationship Between Cardiovascular Risk Factors With Small Artery Elasticity, Large Artery Elasticity, Aortic Distensibility, Carotid Artery Distensibility, and Young's Modulus at the Carotid Artery: The Multi-Ethnic Study of Atherosclerosis (MESA)	Hom, Elizabeth K	05/11/2012
MC 252	A comparison of sex differences in the atherosclerotic burden in those with and without diabetes: The Multi Ethnic Study of Atherosclerosis (MESA)	Huxley, Rachel R.	05/11/2012
ME 135	Coronary Artery Calcium and High-Sensitivity C-reactive Protein as Predictors of Incident Coronary Heart Disease Events at Different Stages of Hypertension: The Multi-Ethnic Study of Atherosclerosis.	Tota-Maharaj, Rajesh	05/18/2012
ME 137	The Hypertriglyceridemic state of Chronic kidney Disease and its association with Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis.	Lamprea, Julio A	05/18/2012

ME 139	Dose Response of Cigarette Smoking on Cardiac Function In the Multiethnic Study of Atherosclerosis	Gjesdal, Ola	05/30/2012
ME 141	Association of New Generation Antidepressants with Cardiovascular Morbidity and Mortality: Results from the Multi- Ethnic Study of Atherosclerosis (MESA)	Camacho, Alvaro	05/30/2012
MC 254	The impact of race/ethnicity on infection and telomere shortening: The Multi-Ethnic Study of Atherosclerosis	Aiello, Allison E.	05/30/2012
ME 133	Inflammatory markers, family history, and lifestyle habits as predictors of cardiovascular events	Klonoff-Cohen, Hillary Sandra	06/21/2012
ML 127	Low-carbohydrate diets and incidence, prevalence, and progression of coronary artery calcium in the Multi-Ethnic Study of Atherosclerosis (MESA)	Hu, Tian	06/21/2012
ML 129	Electrocardiographic models for estimating serial change in left ventricular mass in the Multi-Ethnic Study of Atherosclerosis (MESA)	Soliman, Elsayed Z.	07/26/2012
ME 142	Cardiovascular Disease Risk Prediction with a Multiple Biomarker Strategy: The Multi Ethnic Study of Atherosclerosis (MESA).	Agarwal, Subhashish	07/26/2012
ME 112	Outcomes and Structural Associations of Baseline ST Elevation in the Multi-Ethnic Study of Atherosclerosis	Tian, David G	08/04/2012
ME 143	Correlates of Bradycardia and its impact on incident CVD: The Multi-ethnic Study of Atherosclerosis (MESA)	Dharod, Ajay	08/09/2012
ML 131	Ten-year trends in Cardiovascular Risk Factors in the Multi- Ethnic Study of Atherosclerosis	Burke, Gregory	08/24/2012
ME 146	Predictors of Intermediate-term Events in Subjects with a Low Lifetime Risk of Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA).	Joshi, Parag H.	08/31/2012
MC 256	Chronic stress, personality traits, and endothelial dysfunction: The Multi-Ethnic Study of Atherosclerosis	Kershaw, Kiarri N.	08/31/2012
MM 032	Cardiovascular exposures, cognitive decline and depression in whites and blacks	Zeki Al Hazzouri, Adina	09/05/2012
ME 149	Association of Comorbid Depression and Diabetes with Mortality: A Pooled Cohort Analysis	Carnethon, Mercedes	09/05/2012
ME 151	CardioRS: Toward a New Methodology for Predicting Cardiovascular Events	Kakadiaris, Ioannis A	10/02/2012
MC 261	Incidence, Prevalence, and basic predictors of diagnosed type 2 diabetes at the Chicago MESA field center; a comparison study	Rasmussen-Torvik, Laura J.	10/02/2012
ML 136	Associations between medication use and left ventricular mass, volume, and systolic function in a multi-ethnic cohort	Delaney, Joseph Chris	10/02/2012
ML 137	Statin use and risk for depressive symptoms in the Multi-Ethnic Study of Atherosclerosis	Colangelo, Laura	10/02/2012
MM 033	Regression methods using parametric two-part models, with application to Coronary Artery Calcium progression: The Multi- Ethnic Study of Atherosclerosis	Mercer, Laina D	10/02/2012
MC 262	Association of R wave to Radial pulse Delay with Subclinical Cardiovascular Disease and Risk Factors: The Multi-Ethnic Study of Atherosclerosis	Duprez, Daniel A.	10/26/2012

ML 139	Impact of the Objective and Perceived Healthy Food Environment on Diet: A Longitudinal Analysis of the Multi-Ethnic Study of Atherosclerosis	Zhang, Yun	11/08/2012
ME 155	Inflammatory Markers and Incident Atrial Fibrillation in the Multi-Ethnic Study of Atherosclerosis	Verma, Nishant	11/30/2012
ME 156	Abnormal P-wave indices and Incident Atrial Fibrillation in the Multi-Ethnic Study of Atherosclerosis	Verma, Nishant	11/30/2012
ML 140	The Association of Changes in Transport and Leisure Walking with Perceived Safety and Police-Reported Crime: The Multi- Ethnic Study of Atherosclerosis	Kerr, Zachary Y	11/30/2012
MM 035	Methods of handling missing data for Coronary Artery Calcium: a comparison of multiple imputation, weighting and complete case analysis	Young, Rebekah	11/30/2012
ME 160	Developing a NASA/NSBRI Integrated Risk Calculator to Estimate the Short Term Risk of an Acute Coronary Event in Astronauts	Khera, Amit	12/13/2012
ME 159	Aortic stiffness determined by MRI as a predictor of cardiovascular events in the Multi-Ethnic Study of Atherosclerosis	Kim, Jang Young	12/28/2012
MC 264	Association between acculturation and overweight or obesity in Mexican ancestry adults: The Multi-Ethnic Study of Atherosclerosis	Moran, Andrew	01/09/2013
ML 141	Latent Transition Analysis of Anxious-Depression among different Ethnic groups: The Multi Ethnic Study of Atherosclerosis.	Camacho, Alvaro	01/24/2013
MC 265	Everyday discrimination and markers of inflammation in the Multi-Ethnic Study of Atherosclerosis (MESA): A test of the Stress Process Model	Mitchell, Uchechi A.	01/24/2013
ME 161	Predictors of change in ankle brachial index over time and incident peripheral arterial disease: Are there racial/ethnic differences?	Wassel, Christina	02/08/2013
ML 100	Stratifying severity for metabolic syndrome features by clustering individuals on their VLDL, LDL and HDL cholesterol diameters in the Multi-ethnic Study of Atherosclerosis	Frazier-Wood, Alexis C.	02/12/2013
ME 165	Cardiovascular Risk Factor Control in Diabetes Pooling Project: Multiethnic Study of Atherosclerosis, Atherosclerosis Risk in Communities Study, and Jackson Heart Study	Wong, Nathan	02/27/2013
MC 267	Association of minor ECG abnormalities and bundle branch block (BBB) with subclinical myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA)	Mitchell, Adam	03/01/2013
ML 144	Dietary Diversity and Quality and Weight Gain and Incident Type II Diabetes in the Multi-Ethnic Study of Atherosclerosis	de Oliveira Otto, Marcia C.	03/01/2013
ME 164	Dietary Diversity and Quality and Incident Cardiovascular Disease in a Multi-Ethnic America - the Multi-Ethnic Study of Atherosclerosis	de Oliveira Otto, Marcia C.	03/01/2013
ME 075	Role of GFR-estimation and Age in Cardiovascular Event-free Survival: The Multi-Ethnic Study on Atherosclerosis	Puzantian, Houry	03/07/2013
MC 268	Association between short-term and long-term PM2.5 and NOx air pollution and cross-sectional measurement of arterial stiffness measures in the Multi-Ethnic Study of Atherosclerosis (MESA)	Hom, Elizabeth K	03/15/2013

ML 146	Association between long-term PM2.5 and NOx air pollution and longitudinal change in arterial stiffness measures in the Multi- Ethnic Study of Atherosclerosis (MESA)	Hom, Elizabeth K	03/15/2013
ML 147	Examining the role of neighborhood-level foreclosure on changes in health behaviors and mental health	Crawford, Natalie D	03/15/2013
ME 166	Longitudinal Association of Self-reported Sleep-Disordered Breathing and Peripheral Arterial Disease: The Multi-Ethic Study of Atherosclerosis.	Nagayoshi, Mako	03/15/2013
ME 168	Anxiety and Incident Cardiovascular Disease in the Multi-Ethnic Study of Atherosclerosis (MESA)	Alcantara, Carmela	04/12/2013
ME 169	Left ventricular mass and volume in relationship to traditional risk factors and cardiovascular events at 10 years of follow-up: the MESA study	Bluemke, David A.	04/12/2013
ML 149	Cholesterol Ester Transfer Protein Activity, HDL Subclasses, and the Progression of Coronary Artery Calcification: The Multi- Ethnic Study of Atherosclerosis (MESA)	Silverman, Michael G	04/12/2013
ME 167	A 10-year Stroke Risk Prediction Model: Multi-ethnic Study of Atherosclerosis (MESA)	Arnan, Martinson Kweku	05/17/2013
ME 173	Left Ventricular Remodeling Index (Assessed using MRI) and Incident Atrial Fibrillation in a Multi-Ethnic Cohort. The Multi- Ethnic Study of Atherosclerosis (MESA).	Cammarata, Michael W	05/17/2013
ML 152	The association of Non-alcoholic Fatty Liver Disease with carotid Arterial compliance, Carotid Initimal Media Thickness and coronary artery calcification. The Multi-Ethnic Study of Atherosclerosis	Oni, Ebenezer T.	05/17/2013
ML 151	Adherence to a Mediterranean-like diet and incident hypertension among normotensives in a racially diverse population: The Multi- Ethnic Study of Atherosclerosis	Aneni, Ehimen C	05/17/2013
MC 272	Effect of migration and acculturation on refractive error in the US: The Multi-Ethnic Study of Atherosclerosis	Chua, Sharon Yu Lin	05/17/2013
ME 172	Implications of Coronary artery calcium score on Sample Size Calculations in Cardiovascular Primary Prevention Trials: The Multi-Ethnic Study of Atherosclerosis (MESA)	Bittencourt, Márcio Sommer	05/17/2013
ML 153	Persistent Coronary Artery Calcium Scores of Zero: Long-Term Non-Progressors in the Multi-Ethnic Study of Atherosclerosis	Whelton, Seamus	05/17/2013
ME 175	Impact of Cholesterol Ester Transfer Protein Activity on Cardiovascular Disease in a Multi-Ethnic Cohort: The Multi- Ethnic Study of Atherosclerosis (MESA)	Silverman, Michael G	05/17/2013
ML 097	Establishing Temporality Amongst Correlated Metabolic Variables: Multi-Ethnic Study of Atherosclerosis Joining in a Multi-Cohort Study	Vaidya, Dhananjay	05/22/2013
ME 176	Predictors of Incident Heart Failure with Preserved Ejection Fraction in a Multi-Ethnic Cohort: The Multi-Ethnic Study of Atherosclerosis (MESA)	Silverman, Michael G	05/30/2013
ME 178	Do retinal microvascular markers improve cardiovascular risk assessment in intermediate-risk individuals? The Multi-Ethnic Study of Atherosclerosis	Cheung, Carol Y	06/20/2013
ME 177	Change in Allostatic Load and the Prediction of Cardiovascular Disease and Mortality: The Multi-Ethnic Study of Atherosclerosis	Merkin, Sharon Stein	06/20/2013

ML 155	Association between Baseline Use of Antidepressant Medications with Coagulation Factors and Inflammatory Markers: The Multi- Ethnic Study of Atherosclerosis (MESA)	Stojanovic, Danijela	06/20/2013
MC 273	VALIDATION OF A RISK SCORE TO DETECT OCCULT CKD IN THE GENERAL COMMUNITY: THE MULTI- ETHNIC STUDY OF ATHEROSCLEROSIS	Peralta, Carmen A.	06/20/2013
ML 156	Longitudinal association of psychological variables and subclinical atherosclerosis in US Latino group: Evidence from the Multi-Ethnic Study of Atherosclerosis (MESA).	Ortiz, Manuel	06/20/2013
MM 036	Common Spatial-Temporal Factor Analysis of Measured Neighborhood Level Characteristics: The Multi-Ethnic Study of Atherosclerosis	Nethery, Rachel	07/02/2013
ME 179	Central pressure and incident cardiovascular disease: An individual participant meta-analysis	Ben-Shlomo, Yoav	07/10/2013
ME 183	Past progression of kidney dysfunction and mortality: A collaborative meta-analysis	Naimark, David MJ	07/10/2013

End table.

3.7.4. Table: Time from Manuscript Approval – Ancillary Study Papers Pending

Information is sorted by manuscript approval date. Table continues on the following eight pages.

Over 12 months

Manuscript Number	Title	First Author	Approval Date
AC 025	Prevalence And Risk Factors of Visual Impairment and Blindness And Its Relationship To Retinal Diseases in A Multi-Ethnic Population	Cotch, Mary Frances	08/26/2004
AC 069	Carotid artery wall thickness and associations with cardiovascular risk factors: A comparison between measurements by MRI vs. Ultrasound.	Zhang, Yiyi	01/27/2006
AL 008	Fatty Liver and the Risk of Calcific Atherosclerosis: The Multi- Ethnic Study of Atherosclerosis	Remigio-Baker, Rosemay A	05/03/2007
AC 147	Association of thrombotic factors with exogenous and endogenous sex hormone levels (The Multi-Ethnic Study of Atherosclerosis)	Williams, Marlene S	05/16/2007
AC 150	Features of the Metabolic Syndrome and/or Diabetes Mellitus as Predictors of Thoracic Aortic Calcification as Detected by Cardiac Computed Tomography: The Multi-Ethnic Study of Atherosclerosis	Katz, Ronit	06/29/2007
AL 019	The Association of Neighborhood Measures on Longitudinal Changes in Walking: The Multiethnic Study of Atherosclerosis	Evenson, Kelly	08/29/2008
AC 248	Relation of Carotid Intima Media Thickness, Aortic Distensibility, Calcification and Coronary Wall Thickness to Coronary Artery Calcification (from the Multi-Ethnic Study of Atherosclerosis [MESA])	Ahmadi, Naser	09/15/2009
AC 259	The association of catecholamines with CHD risk factors in the Multi-Ethnic Study of Atherosclerosis (MESA)	Horwich, Tamara	12/22/2009
AC 268	Ethnicity and Gender Differences in the Prevalence of Rheumatic Disease Associated Autoantibodies: The CARDIA and MESA Cohorts	Majka, Darcy S.	03/12/2010
AE 025	Fetuin-A and Incident Cardiovascular Disease in MESA	St-Jules, David E	04/30/2010
AE 026	Association of NT-proBNP and Cardiac Troponin T with Subclinical Atherosclerosis and Incident Coronary Heart Disease: the Multi-Ethnic Study of Atherosclerosis	Daniels, Lori	05/14/2010
AC 280	Association of long-term exposure to ambient particulate matter and telomere length: Results from the Multi-Ethnic Study of Atherosclerosis.	Liu, Chih-Chin	07/09/2010
AL 054	Contribution of the neighborhood environment to waist size among Hispanics and Chinese immigrants to the United States: Results from the Multi-ethnic Study of Atherosclerosis (MESA)	Albrecht, Sandra S.	11/26/2010
AE 041	The Association between Amino Terminal Pro-Brain Natriuretic Peptide, Diabetes, and Incident Heart Failure- The Multi-Ethnic Study of Atherosclerosis.	Balfour, Pelbreton C	12/21/2010
AL 091	Long-term exposures to ambient coarse particulate matter (PM10- 2.5) and lung function and lung density: The Multi-Ethnic Study of Atherosclerosis (MESA)	Zhang, Kai	01/28/2011

AL 055	The Use of Baseline Traditional Cardiovascular Risk Factors to Predict Right Ventricular Structure and Function: The MESA- Right Ventricle Study	Ventetuolo, Corey E.	02/11/2011
AC 313	BK Viruria and Risk of Chronic Kidney Disease: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Johnson, Catherine Owens	02/11/2011
AC 316	Air Pollution, Walking Behaviors, and Neighborhood Environment: A Cross-Sectional Analysis in the Multi-Ethnic Study of Atherosclerosis	Chen, Yeh-Hsin	02/25/2011
AC 322	Long-term exposures to airborne coarse particulate matter and in- vivo retinal images of the microvasculature: The Multi-Ethnic Study of Atherosclerosis	Adar, Sara D.	03/08/2011
AC 320	Occupation, Obesity, and Work and Leisure Time Physical Activity in the Multi-ethnic Study of Atherosclerosis (MESA) cohort	Baron, Sherry	03/11/2011
AC 318	The Association of Serum Vitamin D Concentrations and Non Alcoholic Fatty Liver Disease (NAFLD):The Multi-Ethnic Study of Atherosclerosis	Foster, Temitope	03/11/2011
AC 325	Coronary Calcium Scans and Radiation Exposure in the Multi- Ethnic Study of Atherosclerosis	Messenger, Bradley	04/29/2011
AE 049	QRS dispersion as a predictor of ventricular dyssynchrony and cardiovascular events	Jain, Rahul	04/29/2011
AC 326	Association of Urine Albumin Excretion with Cardiometabolic Risk Factors and Subclinical Atherosclerosis: Comparison of Rheumatoid Arthritis Patients to MESA Controls	Giles, Jon Tyler	04/29/2011
AL 064	B-Type Natriuretic Peptide (BNP) and Prevalent and Incident Hypertension with a Focus on Obesity: Results from the Multi- Ethnic Study of Atherosclerosis (MESA)	Marney, Annis M	05/17/2011
AC 328	A Reproducibility Study of Renal Artery Calcium Measured Using Non-enhanced Computed Tomography Scans: The Multiethnic Study of Atherosclerosis	Prabhu, Sachinand	05/17/2011
AC 329	Impact of Nonalcoholic Fatty Liver Disease, Metabolic Syndrome, and Obesity on Systemic Inflammation and Subclinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)	Silverman, Michael G	05/17/2011
AC 332	Endogenous sex hormone levels and mitral annular calcification: results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Garcia-Ruiz, Jose Manuel	06/10/2011
AC 333	Relationship of Myocardial T1, Extracellular Volume Fraction to Obesity: the Multi-Ethnic Study of Atherosclerosis (MESA)	Liu, Songtao	06/23/2011
AL 066	Race, Neighborhood Characteristics and Early Kidney Function Decline: The Multi-Ethnic Study of Atherosclerosis	Crews, Deidra	06/23/2011
AM 033	Selecting Optimal Neighborhoods for Community Survey 3 in the Multi-Ethnic Study of Atherosclerosis	Hu, Tianle	07/08/2011
AL 069	Cardiovascular Disease Screening and Detection Costs: Results from the NIH-NHLBI-Sponsored Multi-Ethnic Study of Atherosclerosis	Shaw, Leslee J	08/31/2011
AC 340	Plasma phospholipid long-chain monounsaturated fatty acids and cardiac structure and function	Imamura, Fumiaki	10/03/2011

AC 346	The Relationship Between Central Adiposity, Adipokines, and Arterial Elasticity: The Multi-Ethnic Study of Atherosclerosis (MESA)	Forbang, Nketi Innocent	10/12/2011
AE 055	Distribution and Prognostic Implications of Segmental and Regional Left Ventricular Mass in the Multi-Ethnic Study of Atherosclerosis (MESA)	Kenchaiah, Satish	10/12/2011
AC 347	Is Myocardial T1 Fibrosis Index, a marker of Diffuse Myocardial Fibrosis, related to Left Ventricular Mass Hypertrophy in the Multi-Ethnic Study of Atherosclerosis (MESA)?	Mewton, Nathan	10/12/2011
AL 070	Association of Phosphorus Metabolism Biomarkers with Subclinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA)	Kestenbaum, Bryan	10/25/2011
AC 351	Impact of Insulin Resistance (IR) on RV Structure & Function in Healthy Adults without Significant Cardiovascular Disease	Zamanian, Roham	10/25/2011
AC 353	The relationship between anthropometry and visceral fat mass from computed tomography: The Multi-Ethnic Study of Atherosclerosis	Mongraw-Chaffin, Morgana	11/07/2011
AC 465	Comparison of myocardial fibrosis using contrast enhanced T1 mapping in chemotherapy recipients to subjects in the Multi- ethnic Study of Atherosclerosis (MESA): a cross-sectional analysis.	Vasu, Sujethra	11/08/2011
AC 356	Prediction equations for visceral fat mass by sex: The Multi- Ethnic Study of Atherosclerosis	Mongraw-Chaffin, Morgana	12/08/2011
AC 355	Is BMI associated with shorter telomere length? A meta-analysis of over 60 observational studies	Nettleton, Jennifer	12/08/2011
AC 359	Fetuin-A and Lumbar Spine Bone Mineral Density in MESA	Ix, Joachim H.	01/03/2012
AC 364	Associations of self-reported sleep and daytime sleepiness with telomere length: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Prather, Aric	01/31/2012
AC 367	The association of oral contraceptive use with right ventricular structure and function: The MESA-Right Ventricle Study	Ventetuolo, Corey E.	02/01/2012
AE 057	Aorto-Iliac Bifurcation Position and Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis (MESA)	Forbang, Nketi Innocent	02/01/2012
AL 073	Angiotensin II Receptor Blockers and ACE Inhibitors and Risk of COPD/Emphysema. The MESA Lung Study.	Parikh, Megha	02/15/2012
AE 058	Association of Subclinical measures of Atherosclerosis with GFR decline and Incident Chronic Kidney Disease: Results from the Multi-ethnic Study of Atherosclerosis (MESA)	Rosas, Sylvia E.	02/15/2012
AL 074	Neighborhood physical environment and changes in BMI and waist circumference over time: the Multi-Ethnic Study of Atherosclerosis	Barrientos- Gutierrez, Tonatiuh	02/15/2012
AL 075	Relation between retinopathy and progression of coronary artery calcium (CAC) score: The Multi-Ethnic Study of Atherosclerosis	Khazai, Bahram	03/09/2012
AC 373	Thoracic aortic calcification, central pulse pressure and Left Ventricular Hypertrophy: the Multi-Ethnic Study of Atherosclerosis	Khan, Abigail DeFrees May	03/09/2012

AE 060	The association of pericardial fat and fatty liver with incident atrial fibrillation in the Jackson Heart Study and Multi-Ethnic Study of Atherosclerosis	Heckbert, Susan	03/09/2012
AC 374	The association between leukocyte telomere length and right ventricular structure and function: The MESA-RV Study	Harhay, Michael Oscar	03/09/2012
AC 377	Long-term exposures to ambient coarse particulate matter (PM10- 2.5) and right ventricle ejection fraction and mass: The Multi- Ethnic Study of Atherosclerosis (MESA)	Elkayam, Laura R.	03/22/2012
AC 375	Associations between neighborhood characteristics and cognitive functioning: A cross-sectional investigation in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort	Tomey, Kristin	03/22/2012
AL 078	Role of Inflammatory Markers and Lipoprotein Particle subclasses in the Progression of Coronary Artery Calcium: The Multi-Ethnic Study of Atherosclerosis	Zeb, Irfan	03/22/2012
AC 378	Correlation between bi-dimensional and three-dimensional Right Ventricular measures and airflow obstruction in The MESA COPD Study	Corona-Villalobos, Celia Pamela	03/22/2012
AE 064	Non-alcoholic Fatty Liver Disease is Independent Predictor of Long-term Incident Cardiovascular Events-The Multi-Ethnic Study of Atherosclerosis	Zeb, Irfan	03/22/2012
AL 081	Methodological considerations in the study of kidney function decline	Sachs, Michael C	04/11/2012
AM 038	3D Left ventricular wall thickness and thickening by cardiac MRI: the Multi-Ethnic Study of Atherosclerosis (MESA)	Yang, Eunice	04/13/2012
AL 079	The role of pronounced socioeconomic neighborhood change on cardiovascular risk behaviors and acute health outcomes	Crawford, Natalie D	04/13/2012
AE 061	Association between Brain Natriuretic Peptide (BNP) Levels, Glomerular Filtration Rate, and CHF in the Multi-ethnic Study of Atherosclerosis (MESA).	Pesenko, Stephanie	04/24/2012
AC 178	The effects of acute and chronic exposure to ambient particulate matter on cardiopulmonary function in the Multiethnic Study of Atherosclerosis (MESA)	Chervona, Yana	04/25/2012
AL 080	Renal and Retinal Microvascular Changes and Chronic Kidney Disease: The Multi-Ethnic Study of Atherosclerosis	Chacko, Billy G.	04/27/2012
AE 069	Association of Fetuin-A with All-Cause Mortality: A Multiple Cohort Approach	Ix, Joachim H.	05/09/2012
AC 384	Determinants of interstitial fibrosis evaluated by MR T1 mapping in Multi-Ethnic Study of Atherosclerosis (MESA)	Volpe, Gustavo J	05/11/2012
AL 083	Serum, Dietary, and Urinary Potassium and Their Associations with Diabetes Risk in a Multi-ethnic Population: the Multi-ethnic Study of Atherosclerosis (MESA)	Chatterjee, Ranee	05/11/2012
AL 084	Associations of neighborhood segregation with BMI and obesity in the Multi-ethnic Study of Atherosclerosis (MESA)	Do, D. Phuong	05/18/2012
AE 070	Multimarker Approach to Evaluate the Risk of Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis	Balfour, Pelbreton C	05/25/2012

	The association between transition metal components of PM2.5		
AC 389	and lung function and density: The Multi-Ethnic Study of Atherosclerosis.	Sullivan, Mark D	05/30/2012
AC 386	Evaluation of myocardial fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA) by modified Selvester QRS score: relationship with myocardial scar and interstitial fibrosis	Inoue, Yuko	05/30/2012
AC 387	Strain Relaxation Index and Diastolic Function from Echocardiography: The Multi-Ethnic Study of Atherosclerosis	Ambale-Venkatesh, Bharath	05/30/2012
AL 085	Long-term Exposure to Ambient Particulate Matter and Other Air Pollutants and Progression of Subclinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air)	Kaufman, Joel	05/30/2012
AE 073	Multisite Atherosclerosis and Cardiovascular Event Risk: The Multiethnic Study of Atherosclerosis	Wong, Nathan	05/30/2012
AE 074	Rheumatoid Factors Are Associated with Subclinical and Clinical Atherosclerosis in a Community Based Population Cohort: The Multi-Ethnic Study of Atherosclerosis (MESA)	Majka, Darcy S.	06/19/2012
AE 075	Identifying the Interaction between Left Ventricular Mass and Thoracic Aortic Distensibility in Predicting Cardiovascular Outcomes: The Multi-Ethnic Study of Atherosclerosis	Chacko, Billy G.	06/21/2012
AL 087	Serum Phosphate, FGF-23 and Carotid Atherosclerosis among Adults with Normal Kidney Function and Chronic Kidney Disease: The Multi-Ethnic Study of Atherosclerosis	Rosas, Sylvia E.	06/22/2012
AE 077	All-Cause Mortality in Hypertensive Normal Weight Adults	Arguelles, Lester Molina	06/27/2012
AC 395	Occupational risk factors for percent emphysema and airway wall thickness on computed tomography in the Multi-Ethnic Study of Atherosclerosis Lung Study	Doney, Brent	07/06/2012
AL 088	Determinants of temporal change in regional myocardial function: The MESA study	Donekal, Sirisha	07/13/2012
AC 394	Carotid IMT comparisons between South Asians and MESA ethnic groups: MASALA and MESA studies	Kanaya, Alka M.	07/13/2012
AL 090	Long-term exposure to ambient fine particulate matter and decline in lung function, progression of emphysema and incident COPD. The MESA Lung and MESA Air Studies.	Madrigano, Jaime	07/26/2012
AL 089	Associations of Serum Fetuin-A with Aortic Valve and Mitral Annular Calcification in the Multi-Ethnic Study of Atherosclerosis	Linefsky, Jason	07/26/2012
AC 396	Reference Limits for Renal Duplex Sonographic Parameters: The Multi-Ethnic Study of Atherosclerosis	Craven, Timothy	07/26/2012
AC 397	Prevalence of Renovascular Disease in Late Middle-aged Adults: The Multi-Ethnic Study of Atherosclerosis	Hansen , Kimberley J	07/26/2012
AL 092	Neighborhood characteristics and changes in systolic blood pressure over time: the Multi-Ethnic Study of Atherosclerosis	Kaiser, Paulina MB	08/09/2012
AC 399	Relationship between total arterial compliance (stroke volume to pulse pressure ratio) and aortic stiffness: The Multi-Ethnic Study of Atherosclerosis	Tanami, Yutaka	08/24/2012

AC 400	Association of Mineral Metabolism Biomarkers with Renal Artery Calcium: The Multi-Ethnic Study of Atherosclerosis	Kremsdorf, Robin A	08/24/2012
AL 095	Evolution of aortic wall thickness and stiffness with atherosclerosis: long-term follow up from the Multi-Ethnic Study of Atherosclerosis (MESA)	Liu, Chia-Ying	08/31/2012
AC 402	Chronic stress, neighborhood-level resources, and visceral adiposity: The Multi-Ethnic Study of Atherosclerosis	Kershaw, Kiarri N.	08/31/2012
AC 403	The association between perceived discrimination and the diurnal cortisol rhythm: Evidence from the Multi-Ethnic Study of Atherosclerosis	Hajat, Anjum	09/18/2012
AC 404	Circulating Levels of Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) and Matrix Metalloproteinase-2 (MMP-2) in Relation to Cardiovascular Risk Factors and Subclinical and Clinical Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA) Study	Bielinski, Suzette J.	09/18/2012
AC 405	Anthropometric Measures of Obesity and Renal Artery Calcification: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Ricalde, Aldrich A	09/18/2012
AC 406	Diastolic Function from Tagged MRI and Myocardial Fibrosis: The Multi-Ethnic Study of Atherosclerosis	Ambale-Venkatesh, Bharath	09/18/2012
AC 409	Rheumatoid arthritis-related autoimmunity and lung abnormalities: a population based study	Weisman, Michael H.	10/02/2012
AC 412	Pulmonary artery cross-sectional area in COPD: the MESA- COPD study	Poor, Hooman Dadkhahi	10/26/2012
AL 097	Do sex hormones or HRT modify the relation of n-3 fatty acids with incident depressive symptoms in postmenopausal women? The MESA Study.	Colangelo, Laura	10/26/2012
AL 099	Left Ventricular Size and Incident Left Intraventriuclar Conduction Delay in the Multi Ethnic Study of Atherosclerosis. (MESA)	Rezaeian, Panteha	11/02/2012
AC 416	Comparison of Peripheral and Coronary Imaging Markers of Subclinical Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis	Murthy, Venkatesh L.	11/08/2012
AC 339	The association of subclinical cardiovascular abnormalities and subclinical kidney injury as measured by novel urinary biomarkers: The Multi-Ethnic Study of Atherosclerosis	Park, Meyeon	11/28/2012
AL 101	Reported and Perceived Crime and Changes in Body Mass Index and Waist Circumference Over Time: Multi-Ethnic Study of Atherosclerosis (MESA)	Powell-Wiley, Tiffany M	11/30/2012
AM 040	A Simple Approach for Estimating Windkessel Model Parameters from the Radial Artery Pressure Waveform: The Multi-Ethnic Study of Atherosclerosis	Brumback, Lyndia	11/30/2012
AE 084	Sex Differences in the Association of Diabetes with Mortality: A Pooled Cohort Analysis	Carson, April P	12/12/2012
AL 102	Change in neighborhood characteristics and change in subclinical indicators of coronary heart disease: A longitudinal investigation in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort	Tomey, Kristin	12/28/2012

AE 088	High-density lipoprotein cholesterol, decline in lung function, and chronic lower respiratory disease events in seven population-	Oelsner, Elizabeth C	01/23/2013
AC 421	based cohorts. Cellular Aging (Leukocyte Telomere Length) and Carotid Artery	Vaidya, Dhananjay	01/24/2013
AL 104	Distensibility: Multi-Ethnic Study of AtherosclerosisVariation in the association between race/ethnicity and progression of subclinical cardiovascular disease: implications for understanding the Hispanic paradox, the Multi-ethnic Study of Atherosclerosis	Albrecht, Sandra S.	01/24/2013
AE 089	Edge detected common carotid artery IMT and incident peripheral arterial disease events in the Multi-Ethnic Study of Atherosclerosis.	Polak, Joseph F.	02/08/2013
AL 105	Anti-human Heat Shock Protein 60 Antibodies and Longitudinal Change in Lung Function and Percent Emphysema: The MESA Lung Study	Aaron, Carrie P	02/08/2013
AL 106	Vitamin D Metabolites and Longitudinal Change in Coronary Artery Calcium: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Sachs, Michael C	03/22/2013
AL 107	Phosphate Metabolism and Longitudinal Change in Coronary Artery Calcium: Results from the Multi-Ethnic Study of Atherosclerosis (MESA)	Sachs, Michael C	03/22/2013
AL 108	Gamma-glutamyltransferase (GGT) Activity and Risk of Type 2 Diabetes: The Multi-Ethnic Study of Atherosclerosis	Bradley, Ryan	03/22/2013
AE 091	Gamma-glutamyltransferase (GGT) Activity and Risk of Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis	Bradley, Ryan	03/22/2013
AL 109	The association between neighborhood racial/ethnic segregation and allostatic load: The Multi-Ethnic Study of Atherosclerosis	Hicken, Margaret T	04/12/2013
AL 110	Relationship of Antihypertensive Therapy on the Progression of Arterial Stiffness Over Ten Years: The Multi-Ethnic Study of Atherosclerosis (MESA)	Gepner, Adam D	04/17/2013
AC 432	Serum 25-hydroxyvitamin D and hemostatic / inflammatory biomarkers in the Multi-Ethnic Study of Atherosclerosis.	Blondon, Marc	04/17/2013
AL 112	Long-term residential coarse particulate matter exposure and indicators of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis and Coarse Particles (MESA Coarse)	Adar, Sara D.	05/17/2013
AC 433	Association between Sleep Duration and Quality and Alteration of the Hypothalamic-Pituitary Adrenocortical (HPA) Axis in the Multi-Ethnic Study of Atherosclerosis (MESA)	Castro-Diehl, Cecilia	05/17/2013
AC 434	Association of plasma renin with subclinical cardiovascular disease in a community-based cohort: The Multi-Ethnic Study of Atherosclerosis	Rifkin, Dena	05/17/2013
AC 435	Testosterone Deficiency in Pulmonary Arterial Hypertension: A Case-Control Study from the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study	Ventetuolo, Corey E.	05/17/2013
AC 436	Association of ECG R-wave to Arterial Pulse Delay with Subclinical Cardiovascular Disease and Risk Factors: The Multi- Ethnic Study of Atherosclerosis (MESA)	Whelton, Seamus	05/17/2013

AC 437	Influence of circadian rhythm on cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis	Lu, Brandon S.	06/20/2013
AC 438	Association between Sleep Duration and Quality and Sympathetic Nervous System Activation: The Multi-Ethnic Study of Atherosclerosis	Castro-Diehl, Cecilia	06/20/2013
AL 117	Associations between indices of subclinical vascular disease and cognitive function: Multi-Ethnic Study of Atherosclerosis (MESA)	Tomey, Kristin	07/02/2013
AC 440	Workforce participation, job strain, and differences in daily salivary cortisol profiles: the Multi-Ethnic Study of Atherosclerosis	Rudolph, Kara E	07/02/2013
AL 122	Long-term air pollution exposure and measures of MR cardiac structure and function: the Multi-Ethnic Study of Atherosclerosis and Air Pollution	Ross, Michelle E	07/09/2013
AC 442	Exposure to Ambient Air Pollution as a Potential Explanation of Ethnic Disparities in Subclinical Atherosclerosis: Evidence from the Multi-Ethnic Study of Atherosclerosis (MESA)	Jones, Miranda Renee	07/26/2013
AE 095	Exposure to Ambient Air Pollution as a Potential Explanation of Ethnic Disparities in Cardiovascular Disease: Evidence from the Multi-Ethnic Study of Atherosclerosis (MESA)	Jones, Miranda Renee	07/26/2013
AL 119	The interaction between long-term exposure to air pollutants and psychosocial stress on markers of inflammation, coagulation and endothelial activation: The Multi-Ethnic Study of Atherosclerosis (MESA)	Hajat, Anjum	07/26/2013
AL 118	Measurement of Tobacco Exposure in the Multi-Ethnic Study of Atherosclerosis (MESA): Comparison of Self-Report with Urinary and Plasma Biomarkers	Hinckley Stukovsky, Karen	07/26/2013
AC 443	Endothelial progenitor cells (EPC) and circulating endothelial cells (CEC) in chronic obstructive pulmonary disease (COPD): the MESA COPD Study.	Doyle, Margaret	07/26/2013
AE 096	Distribution of Systemic Atherosclerosis in Persons with Metabolic Syndrome and Diabetes and Prediction of CVD Events	Evans, Marcella	07/26/2013
AC 444	Ultrasound Assessment of Carotid Arterial Stiffness with Speckle Tracking: A New Use of a Novel Imaging Technique for Evaluating Arterial Stiffness in the Multi-Ethnic Study of Atherosclerosis (MESA)	Gepner, Adam D	07/26/2013
AC 445	Aortic stiffness in obstructive sleep apnea - MESA study	Kwon, Younghoon	07/26/2013
AC 446	Ethnic differences in the associations between sleep-disordered breathing, sleep disruption, and glycemic control: The Multi-Ethnic Study of Atherosclerosis.	Bakker, Jessie P	07/31/2013
AM 047	Discovering Biomarkers for Cardiovascular Disease Using Rule Learning	Menon, Prahlad G	08/09/2013
AL 126	Examining the association between stress and depression, and HbA1c as a potential mediator, in individuals with low socioeconomic standing	Voege, Patricia	08/12/2013

End table.

3.7.5 Table: Time from Manuscript Approval – Genetics Papers Pending

Genetics Papers Proposals Over 12 Months with no Pen Draft Submission

#	Title	Author	Approval Date
G 003	Association between age-related macular degeneration and genetic variants of C-reactive protein, MTHFR, interleukin 6 and fibrinogen- beta genes	Ching-Yu Cheng MD, MPH	3/14/2007
G 004	Associations between genetic variants in the LDLR, LPA, LRP and OLR1 genes and lipids, CAC and carotid IMT in the Multi-Ethnic Study of Atherosclerosis (MESA)	Laura A. Raynor MS	11/5/2009
G 005	Associations Between Aldosterone Synthase (CYP11B2) Polymorphisms and Hypertension and Left Ventricular Hypertrophy	Kurt R. Daniel D.O.	3/15/2010
G 006	Associations between ABCA1 and CETP polymorphisms and lipoproteins, inflammatory markers, and subclinical atherosclerosis in the Multi-Ethnic Study of Atherosclerosis	Kurt R. Daniel D.O.	3/14/2007
G 007	Association of LPL genetic variants with phenotypes related to diabetes, structural atherosclerosis, lipids, hypertension, vessel function, and inflammation in the Multi-Ethnic Study of Atherosclerosis	Mark O Goodarzi MD, PhD	4/13/2007
G 008	Associations between genetic variants in the diabetes genes GCK, CAPN10, AMPD1, AMPD2, PRKAA2, and SORCS1 and diabetes- related traits and measures of structural atherosclerosis in the Multi- Ethnic Study of Atherosclerosis	Mark O Goodarzi MD, PhD	4/13/2007
G 009	Association between ACE pathway genes and subclinical atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)	Xiaohui Li MD, MS	4/13/2007
G 010	Relationship of lipoxygenase pathway gene variants, lipid levels, and obesity in the Multi-Ethnic Study of Atherosclerosis (MESA)	Kiran Musunuru MD, PhD	5/14/2007
G 012	Gene/Environment Interactions and the Effect of Short and Long-term Exposure to PM2.5 and Traffic-related Air Pollution on Functional Measures of Arterial Health: The Multi-Ethnic Study of Atherosclerosis	Erin O'Brien Semmens	5/14/2007
G 015	Association between genetic variants in the PPARG gene and subclinical atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)	Yi-Chun Chen MD	6/8/2007
G 016	Association between polymorphisms of the C-reactive protein (CRP) gene and plasma CRP levels in The Multi-Ethnic Study of Atherosclerosis	Ching-Yu Cheng MD, MPH	7/13/2007
G 017	Associations between polymorphisms of genes in the homocysteine metabolic pathway and homocysteine: The Multi-Ethnic Study of Atherosclerosis (MESA)	Dr. Michele M. Sale PhD	7/13/2007
G 019	Associations between genetic variants in the FGA, FGB, and FGG genes and fibrinogen and subclinical atherosclerosis in the Multi- Ethnic Study of Atherosclerosis	Sudip Saha	8/1/2007
G 022	Machine Learning to Identify Complex Interactions in Candidate Genes: The Multi-Ethnic Study of Atherosclerosis	Yongmei Liu PhD	8/1/2007
G 023	EDG1, EDG5 SNPs and Subclinical Atherosclerosis in the Multi- Ethnic Study of Atherosclerosis (MESA)	Catherine C. Hedrick PhD	8/23/2007
G	Associations between genetic variants in the blood pressure genes AGT, NOS3, ARDB2, SCNN1A, AGTR and diabetes/metabolic syndrome related traits in the Multi-Ethnic Study of Atherosclerosis		
025 G 027	(MESA) The MESA Family Study: A sibship approach to identify genes contributing to the onset of atherosclerosis	Dr. Xiuqing Guo PhD James Pankow PhD, MPH	8/31/2007 8/31/2007

	Association of Polymorphisms in Genes Related to Renin-		
	Angiotensin-Aldosterone and Adrenergic Systems with Left	Hossein Bahrami	
G	Ventricular Structure and Function and Incident Heart Failure; The	MD, MPH, Belle	2/11/2000
028	Multi-Ethnic Study of Atherosclerosis	Fang, Xiuqing Guo	2/11/2008
G	Associations of Serum Amyloid P Phenotype and Genotypes with	Nancy Swords Jenny,	10/16/2007
029	Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis Phosphodiesterase 4D gene polymorphisms and lung function/lung	PhD	10/16/2007
G	density in a multiethnic population. The Multi Ethnic Study of	Elizabeth M Kiefer	
030	Atherosclerosis (MESA)-Lung Study	MD	10/16/2007
020	Relationship between fibulin polymorphisms and subclinical		10/10/2007
G	atherosclerosis, blood pressure and arterial stiffness: The Multi-Ethnic	Jose Vargas MD,	
032	Study of Atherosclerosis (MESA)	PhD	11/9/2007
	Ancestry informative markers and spirometry in a multiethnic		
G	population: The Multi-Ethnic Study of Atherosclerosis (MESA) Lung	Dr. Michele M. Sale	
034	Study	PhD	11/9/2007
G	MCP-1 polymorphisms, inflammation mediators, subclinical atherosclerosis, and incident coronary heart disease: The Multi-Ethnic	Suzette J. Bielinski	
035	Study of Atherosclerosis (MESA)	PhD	12/21/2007
035	Association study between genetic variants in the membrane metallo-		12/21/2007
G	endopeptidase (MME) gene and subclinical atherosclerosis in the		
036	Multi-Ethnic Study of Atherosclerosis (MESA)	Yi-Chun Chen MD	5/6/2008
	A Candidate Gene Association Study of Vascular Endothelial Growth		
	Factor (VEGF), Endothelial Nitric Oxide Synthase (eNOS) and		
	Endothelial Differentiation-Sphingolipid G-protein-coupled receptors		
C	1 and 5 (EDG1 and EDG5) Polymorphisms with Lung Function and	Kaistin Manis Deales at	
G 038	CT Lung Density in a Multi-Ethnic Population. The MESA Lung Study.	Kristin Marie Burkart MD, MSc	1/23/2008
	•	MD, MSC	1/25/2008
G 039	ABCG1 SNPs and Subclinical Atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)	Stephen Rich PhD	2/12/2008
G	•		2/12/2008
040	GPR132 SNPs and variation in lipid metabolism in the Multi-Ethnic Study of Atherosclerosis (MESA)	Stephen Rich PhD	2/12/2008
040	Associations between renin-angiotensin system genes and aortic and		2/12/2000
G	carotid artery stiffness and diameter in The Multi-Ethnic Study of	Jose Vargas MD,	
041	Atherosclerosis (MESA)	PhD	2/12/2008
	Associations between genetic variants in the ACE, AGT, AGTR1, and		
G	AGTR2 genes and hypertension in the Multi-Ethnic Study of	J. Hunter Young MD,	
042	Atherosclerosis	MHS	4/16/2008
C	Genetic variation in TLR2 and TLR4, endothelial function and	C · D I	
G	subclinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis	Craig R. Lee PharmD, PhD	2/4/2008
044	(MESA) study	PharmD, PhD	3/4/2008
G	Dietary polyunsaturated fatty acids, lipoxygenase genotypes and	Michael Taei DhD	5/6/2008
046	atherosclerosis: the Multi-Ethnic Study of Atherosclerosis Investigation of candidate genes in the syntenic region of a murine	Michael Tsai PhD	5/6/2008
G	locus for fasting blood glucose levels, Bglu3, in The Multi-Ethnic		
048	Study of Atherosclerosis (MESA)	Weibin Shi MD, PhD	6/12/2008
_	Genetic variation in estrogen receptors 1 and 2 and endogenous	,	
G	estradiol levels in relation to left ventricular mass in women: the Multi-	Susan Heckbert MD,	
049	Ethnic Study of Atherosclerosis	PhD	7/10/2008
G	Associations of a Candidate Gene Panel with Circulating D-dimer		
050	Concentration: The Multi-Ethnic Study of Atherosclerosis (MESA)	Mary Cushman MD	8/7/2008
	Genetic variation in paraoxonase in relation to subclinical		
G 051	atherosclerosis and cardiovascular events: the Multi-Ethnic Study of	Karol E. Watson MD,	5/4/2000
051	Atherosclerosis	PhD	5/4/2009

G 052	Novel Type 2 Diabetes Candidate Genes, Subclinical Atherosclerosis and Intermediate Traits in the Multi-Ethnic Study of Atherosclerosis	Nehal N Mehta MD	10/7/2008
G 053	Investigation of association between TCF7L2 and kidney function in The Multi-Ethnic Study of Atherosclerosis (MESA)	Jamison Chang MD	10/7/2008
G 056	Genetic Determinants of Right Ventricular Morphology and Function: MESA-RV CARe	Steven M. Kawut MD, MS	2/13/2009
G 057	Association between polymorphisms in the C-reactive protein (CRP) gene with blood pressure levels and hypertension in the Multi-Ethnic Study of Atherosclerosis	Dr. Walter Palmas MD	3/20/2009
G 058	A Candidate-wide Gene Association Study of Right Ventricular Morphology and Function: MESA-D-RV CARe	Steven M. Kawut MD, MS	5/5/2009
G 060	Association between OLR1 Gene Polymorphisms and Endothelial Function in the Multi-Ethnic Study of Atherosclerosis	Tina E Brinkley PhD	5/5/2009
G 061	Genetic variation in KLOTHO and calcium-phosphorous metabolism: The Multi-Ethnic Study of Atherosclerosis	Bryan Kestenbaum MD, MS	9/5/2009
G 063	Association between KLOTHO polymorphisms and subclinical atherosclerosis in The Multi-Ethnic Study of Atherosclerosis (MESA)	Dan Arking PhD	9/5/2009
G 064	Candidate-wide gene-air pollution interactions and cardiac structure & function in The Multi-Ethnic Study of Atherosclerosis (MESA)	Victor C. Van Hee MD	9/18/2009
G 065	Associations of a Candidate Gene Panel with blood pressure levels and hypertension in the Multi-Ethnic Study of Atherosclerosis	Dr. Walter Palmas MD	3/11/2010
G 066	Finding better predictors of Left Ventricular Mass among Hispanic Subgroups involving ancestry informative markers: The Multi-Ethnic Study of Atherosclerosis (MESA).	Carlos Jose Rodriguez MD, MPH, FACC	5/6/2010
G 068	GWAS of LV Structure	Sanjiv Shah	5/19/2010
G 072	CHARGE collaboration - GWAS of BMI genotype interaction	Walter Palmas	6/10/2010
G 074	Meta-analysis of GWAS data for PR interval duration	Nona Sotoodehnia	6/24/2010
G 077	Alochol GWAS: CHARGE meta-analysis	Jennifer Nettleton	6/24/2010
G 080	GWAS of sex-specific genotypic association with BP levels	Walter Palmas	7/14/2010
G 081	GWAS of BP Levels and Hypertension in MESA	Walter Palmas	7/14/2010
G 082	GWAS for Retinal Venular Caliber	Kamran Ikram	7/14/2010
G 083	GWAS of abdominal aortic diameter measurements	Christina Wassel	7/14/2010
G 084	Validation of ECG-association genetic variants in MESA	Dan Arking	7/14/2010
G 086	GWAS of Caffeine Intake	Jennifer Nettleton	7/28/2010
G 088	GWAS for development of Heart Failure and Precursors	Harjit Chahal	7/28/2010
G 089	TCF7L2 and Kidney Function	Jamison Chang	7/28/2010
G 092	Genetics of atrial fibrillation in multiple race/ethnic groups	Dan Arking	8/26/2010

	Predictive Model of Coronary Artery Calcification in Atherosclerosis		
G 093	in a Chinese American Cohort: The Multi-Ethnic Study of Atherosclerosis (MESA)	Michael McGeachie PhD	8/26/2010
G 096	Systems Constists of Dyslinidamic and Hymorphysemia	Ani Manichaikul	9/22/2010
090 G	Systems Genetics of Dyslipidemia and Hyperglycemia		9/22/2010
097	GWAS of coronary artery disease in MESA	Matthew Sellers	9/22/2010
G 099	GWAS of lung function in Hispanics and Asians (MESA Lung)	Rhea Powell	10/8/2010
G 100	Meta-analysis of GWAS data for QRS voltage-duration product	Kathleen Kerr	10/21/2010
G 111	Admixture Mapping Study of Atrial Fibrillation in AA	Gregory Marcus	1/6/2011
G 112	SNP Age interaction in Atrial Fibrillation	Lin Yee Chen	1/21/2011
G 113	GWAS meta-analysis of incident CKD & rapid decline in GFR	Holly Kramer	2/3/2011
G 115	Hemostatic factors in European-Americans	Dhananjay Vaidya	2/22/2011
G 116	GIANT meta analysis physical activity x GWAS for adiposity	Laura Rasmussen- Torvik	3/17/2011
G 117	GWAS - age at natural menaopause	Leslie Raffel	3/17/2011
G 120	Genetic Variation and the Risk of Cardiovascular Disease Associated with Exposure to Chemical Components of Particulate Matter: The Multi-Ethnic Study of Atherosclerosis and Air Pollution	Shizhen Wang Ph.D.	4/13/2011
G 122	Meta-analysis of GWAS for intake of fish & dietary EPA-DHA	Dariush Mozaffarian	4/7/2011
G 123	GWAS meta-analysis of salivary cortisol concentrations	Erin Payne	4/7/2011
G 124	CHARGE Meta GWAs in CRP	Sylvia Rosas	4/7/2011
G 126	Replication of GWAS for Diabetic Retinopathy - Scotland	Jane Kuo	4/21/2011
G 128	Population diversity and association with glucose homeostasis	Michelle Jones	4/21/2011
G 130	Plasma fatty acid composition, 5-lipoxygenase activating protein (ALOX5AP) polymorphisms and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)	Shuang Liang PhD	4/29/2011
G 131	GWAS of BP Levels and Hypertension in Hispanics	Walter Palmas	4/21/2011
G 133	Sex interaction GWAS of plasma phospholipid fatty acids	Millennia Foy	5/5/2011
G 136	Candidate gene and Genome Wide Association Study (GWAS) of aortic dimensions and biomechanics: The Multi-Ethnic Study of Atherosclerosis	Gisela Teixido-Tura	5/5/2011
G	CWAS of heart rate variability	Sugar Hashbart	5/5/2011
137 G 139	GWAS of heart rate variability Genetic associations of diabetic retinopathy (DR) candidate genes in the Multi-Ethnic Study of Atherosclerosis (MESA) study DR and retinal vascular caliber	Susan Heckbert Jane Z Kuo MD	5/5/2011 6/2/2011

G	RYR3 Gene Variants in Carotid Atherosclerosis in the Multi-Ethnic		
141	Study of Atherosclerosis	Sadeep Shrestha PhD	6/13/2011
G 142	Interaction between a multi-facotiral diet score for BMI and WHR	Jennifer Nettleton	6/3/2011
G 143	NFE2L2 SNPs and variation in atherosclerosis and inflammatory markers in the Multi-Ethnic Study of Atherosclerosis	Norbert Leitinger PhD	7/19/2011
G 145	GWAS of plasma phospholipid long-chain saturated fatty acids	Rozenn lemaitre	7/21/2011
G 146	Replication of 2 novel SNPs related to early menopause	Melissa Wellons	7/21/2011
G 148	P-selectin polymorphisms, subclinical and clinical atherosclerosis, and circulating levels of serum P-selectin: The Multi-Ethnic Study of Atherosclerosis (MESA)	Suzette J. Bielinski PhD	8/18/2011
G 149	Genetic contributors to NMR-based lipoprotein subclasses in Afr.Am.	Michele Sale	8/18/2011
G 150	GWAS of Serum Natriuretic Peptide Levels	Walter Palmas	9/8/2011
G 152	Association of Coronary Artery Calcified Plaque with DNA Polymorphisms in the Selenoprotein S Gene: The Multi-Ethnic Study of Atherosclerosis and Diabetes Heart Study	Amanda Cox Postdoctoral Fellow	9/14/2011
G	Genome-Wide Association Study of n-3 and n-6 polyunsaturated fatty acids (PUFAs) in African American, Hispanic and Chinese cohorts through the CHARGE Consortium – Participation of the Multi Ethnic		
G 153	Study of Atherosclerosis in a CHARGE Plasma Fatty Acids Working Group Meta-analysis	Ani Manichaikul	9/22/2011
G 155	Proglucagon Gene Loci and Type 2 Diabetes Risk, Prevalence and Incidence: the Multi-Ethnic Study of Atherosclerosis	Carla Isabel Mercado	10/1/2011
G 156	Genome Wide Association Study of T Helper Cell Bias in the Multi- Ethnic Study of Atherosclerosis	John Peter Durda	10/1/2011
G 157	Genome-wide association study of odd-numbered chain saturated fatty acids in plasma phospholipids: CHARGE Fatty Acid Consortium	Qi Sun	10/19/2011
G 161	MESA participation in population structure analysis in African Americans	Huang	12/7/2011
G 162	Genome-wide association scan (GWAS) for SNPs associated with small artery elasticity (SAE) and large artery elasticity (LAE) in the Multi-Ethnic Study of Atherosclerosis (MESA)	Jennifer Hall	12/7/2011
G 163	Variation in Subclinical Emphysema among Lung Zones, Families, and Neighborhoods. The MESA Lung Study.	Gina Lovasi	12/22/2011
G 165	GWAS meta-analysis of leptin	Laura J. Rasmussen- Torvik	12/22/2011
G 166	Replication of common genetic polymorphisms associated with circulating 25-hydroxyvitamin D concentration among Europeans	Ian de Boer	1/4/2012
G 167	A GWAS Linkage Study of Subclinical Interstitial Lung Disease on CT scan: The Multi-Ethnic Study of Atherosclerosis Lung Fibrosis Study	Ani Manichaikul	1/4/2012
G	Comemo wide acceptation analyzia of fatuin A lowels	Majken Karoline	2/1/2012
171 G 172	Genome-wide association analysis of fetuin-A levels Candidate gene study of common genetic polymorphisms associated with circulating 25-hydroxyvitamin D concentration among persons of African ancestry	Jensen Ian de Boer	2/1/2012
1/2	ran tan antosu y		21912012

G 173	Genomewide Associations Study of Serum Estradiol in European- Origin men – CHARGE consortium - The Multi-Ethnic Study of Atherosclerosis (MESA) joining as discovery cohort	Dhananjay Vaidya	3/7/2012
G 174	Genome-wide interaction with dietary factors with respect to fasting plasma LDL, HDL, and triglyceride concentrations	Nettleton	4/4/2012
G 176	Interactions between the social environment and genetic factors in the prediction of depressive symptoms in the Multi-Ethnic Study of Atherosclerosis (MESA).	Bakshis	4/4/2012
G 178	SNPs associated with coronary artery disease and type 2 diabetes as determinants for age at natural menopause GENOME-WIDE SNP x DIET INTERACTION STUDIES: whole	Kerr	4/4/2012
G 179	grains, magnesium, and zinc FOR FASTING GLUCOSE and INSULIN	Nettleton	4/18/2012
G 181	GIANT Meta-analysis of Interactions between Smoking and Genome- Wide SNP data for Anthropometric Traits	Manichaikul	4/18/2012
G 184	Participation of MESA in a TAGC Genome-Wide Association Study of Asthma	Katie Donohue	5/15/2012
G 185	n-3 fatty acids and insulin traits in the context of genetic variation	Ani Manichaikul	5/16/2012
G 187	Common Genetic Variants and Circulating Parathyroid Hormone Concentrations: The Multi-Ethnic Study of Atherosclerosis (MESA)	Cassianne Robinson- Cohen	5/16/2012
G 188	Association of Phosphorous Metabolism Gene Polymorphisms wth Subclinical and Clinical Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA)	Cassianne Robinson- Cohen	5/30/2012
G 189	Common Genetic Variants and Circulating Fibroblast Growth Factor- 23 Concentrations: The Multi-Ethnic Study of Atherosclerosis (MESA)	Cassianne Robinson- Cohen	5/30/2012
G 190	Meta- analyses of Toatl and Free Testosterone in Women CHARGE constorium -The Multi-Ethnic Study of Atherosclerosis (MESA) joining as discovery cohort	Leslie Raffel	6/13/2012
G 191	GWAS meta-anslyses of Estradiol and Estrone in Post-menopausal Women - CHARGE consortium - The Multi-Ethnic Study of Atherosclerosis (MESA) joining as a discovery cohort	Leslie Raffel	6/13/2012
G 192	GWAS of Fertility Behavior - CHARGE consoritum - The Multi- Ethnic Study of Atherosclerosis (MESA) joining as a discovery cohort	Leslie Raffel	6/13/2012
G 195	Genome-wide Association Study of Spine Volumetric Bone Measures from Computed Tomography	Christina Wassel	6/13/2012
G 196	Interactions between psychosocial factors and genes in shaping blood pressure distribution: the Atherosclerosis Risk in Communities Study (ARIC) and the Multi-Ethnic Study of Atheroslerosis (MESA)	Jennifer Smith	6/27/2012
G 197	Novel locus including FGF21 as a predictor of dietary macronutrient intake	Audrey Chu	7/24/2012
G 198	Genome-wide association study of electrocardiographic P wave indices	Susan Heckbert	7/18/2012
G 199	Interactions between cortisol levels and candidate gene polymorphisms in predicting anthropometric and metabolic characteristics in the Multi-Ethnic Study of Atherosclerosis	Erin Payne	7/18/2012
G 200	Genetic Associations with Lipoprotein Subfraction Measures Differ by Ethnicity in the Multi-Ethnic Study of Atherosclerosis	Alexis C. Wood	7/18/2012
G 202	Fasting glucose and insulin and thiazide diuretic gene interactions: a CHARGE meta-analysis	Mark Goodarzi	8/1/2012

G	Fasting glucose and insulin and statin gene interactions: a CHARGE		
203	meta-analysis	Mark Goodarzi	8/1/2012
G			
204	A GWAS Meta Analysis of African American Diabetic Nephropathy	Maggie Ng	8/1/2012
	Meta-Analysis of Genetic Associations with Blood Pressure		
C	Phenotypes in the International Consortium of Blood Pressure Genome		
G 205	Wide Association Studies (ICBP-GWAS) Using 1000Genomes Imputed Data	Walter Palmas	8/8/2012
<u>205</u> G	Common and Exonic Variants Associated with Biomarkers of	watter Faimas	0/0/2012
207	Inflammation	Alex Reiner	8/28/2012
	Genetic contributors to NMR-based lipoprotein subclasses in African		
	Americans from the Sea Islands Genetic Network (SIGNET), the		
G	Multi-Ethnic Study of Atherosclerosis (MESA), and the	x7' ' TT	0/5/2012
208	Cardiovascular Health Study (CHS) GWAS of moderate/vigorous leisure physical activity and sedentary	Yiqi Huang	9/5/2012
G	behavior:		
209	The Multi-Ethnic Study of Atherosclerosis	Katie Kerr	9/19/2012
G	Genome-Wide Association Study of Right Ventricular Structure and	Steven M. Kawut	
211	Function: The MESA-Right Ventricle Study	MD, MS	10/17/2012
	Genome-wide association study of monounsaturated fatty acids in		
G	Chinese and Caucasian cohorts – Participation of MESA in a	Linear Thu	11/15/2012
213	CHARGE Plasma Fatty Acids Working Group Meta-analysis	Jingwen Zhu	11/15/2012
G 215	A GWAS Study of Airways on CT scan	Kathleen Donoahue	10/17/2012
G	Peripheral Blood Mononuclear Cell (PBMC) Gene Expression and		10/17/2012
216	Pulmonary Parenchymal Perfusion	Tess Pottinger	11/5/2012
	Genome-Wide Association Study of n-3 and n-6 Polyunsaturated Fatty	_	
G	Acids (PUFAs) in Chinese – Participation of MESA in a CHARGE	T. T	11/15/2012
217	Plasma Fatty Acids Working Group Meta-analysis	Ling Lu	11/15/2012
G 220	CHARGE Consortium Meta-Analysis for Anthropometric Traits: The Multi-Ethnic Study of Atherosclerosis	Talin Haritunians	12/15/2012
220	Association of Rare and Low Frequency Variants with Subclinical		12/13/2012
G	Atherosclerosis in the CHARGE Consortium: An Exome Chip		
221	Analysis	Christina Wassel	12/15/2012
C	CardioMetabochip Collaborative Study of Blood Pressure and		
G 222	Hypertension: Participation of the Multi-Ethnic Study of Atherosclerosis (MESA)	Walter Palmas	12/20/2012
222	The role of inflammatory biomarkers in the association of SCARB1	watter Faimas	12/20/2012
G	variant, rs10846744, with subclinical atherosclerosis and incident		
223	cardiovascular disease.	Ani Manichaikul	12/20/2012
	Analysis of Adiponectin (ADIPOQ) Low Frequency Variants		
G 227	including Coding variants from the Exome Chip in the Multi-Ethnic Study of Atherosclerosis SHARe	Nicholette D Allred PhD	2/23/2013
221	Does the apolipoprotein E (APOE) epsilon-4 allele modify	riiD	2/23/2013
	associations between social factors and cognitive functioning? A cross-		
G	sectional investigation in the Multi-Ethnic Study of Atherosclerosis		
228	(MESA) cohort	Kristin Tomey PhD	1/4/2013
G		Laura J. Rasmussen-	1/1/2010
230	1000G Meta-Analysis for BMI in African Americans	Torvik PhD, MPH	1/16/2013
G 231	Paraoxonase and Subclinical Atherosclerotic Burden: The Multi- ethnic Study of Atherosclerocis	Vibha Bhatnagar MD MPH	1/25/2012
G	ethnic Study of Atherosclerosis		1/25/2013
G 232	Peripheral blood gene expression and airway morphology on CT scan: The MESA COPD Study	Kathleen Donoahue	5/3/2013
232		isumeen Donoanue	5, 5, 2015

G 233	Interactions between Inflammation and Genes on Cognition: The Multi-Ethnic Study of Atherosclerosis (MESA)	Annette Fitzpatrick PhD	2/6/2013
G 234	GWAS Meta-analysis of C-reactive protein (CRP) in Asian populations	Dr. Xiuqing Guo PhD	2/6/2013
G 235	DNA Methylation related SNPs Interact with Fatty Acids for HDL: Participation of MESA in a CHARGE Plasma Fatty Acids Working Group Meta-analysis	Ani Manichaikul	2/14/2013
G 237	Common Genetic Variants and Circulating 24,25(OH)2D Concentrations: The Multi-Ethnic Study of Atherosclerosis (MESA)	Cassianne Robinson- Cohen MS	2/6/2013
G 238	Developing New Methodologies for Network-Based Methods for Integrative Analysis of Biological Pathways in Cardiovascular Diseases	Ali Shojaie PhD	2/14/2013
G 239	Admixture Mapping of Loci for Arterial Distensibility in African Americans using Ancestry Informative Panels from Genomewide Arrays	Dr. Dhananjay Vaidya PhD, MPH	2/7/2013
G 240	Genetic analyses of obstructive sleep apnea and related traits in The Multi-Ethnic Study of Atherosclerosis (MESA)	Brian Edmand Cade PhD	2/21/2013
G 243	Association of KCNK3 and KCNK9 SNPs with hypertension, aldosterone and renin in The Multi-Ethnic Study of Atherosclerosis (MESA)	Ani Manichaikul PhD	2/20/2013
G 245	DNA Methylation and Gene Expression of P2Y12 ADP Receptor: The Multi-Ethnic Study of Atherosclerosis.	Michael Cammarata	3/5/2013
G 247	Common Genetic Variants and Subclinical Atherosclerosis: The Multi- Ethnic Study of Atherosclerosis (MESA)	Jose Vargas MD, PhD	10/25/2013
G 248	Join the CHARGE Consortium for GENOME-WIDE SNP x DIET INTERACTION STUDIES	Xiuqing Guo	3/20/2013
G 250	Gene-environment interactions and effect of short-term and long-term PM2.5 and NOx air pollution on arterial stiffness: The Multi-Ethnic Study of Atherosclerosis	Elizabeth Hom	3/20/2013
G	Analysis of gene-environment (G x E) interaction using a novel additive main effects and multiplicative interactions model and an empirical Bayes estimator for longitudinal data in the Multi-Ethnic		
251 G	Study of Atherosclerosis Cohort MESA SHARe Exome Project: ESP-GO Renal Working Group Manuscript	Ko, Yi-An, MS	3/20/2013
252 G	Proposal Exome Chip and Blood Pressure Phenotypes: Participation of MESA	Holly Kramer	3/20/2013
253	in a CHARGE Consortium Meta-Analysis	Walter Palmas	3/20/2013
G 256	Air Pollution, DNA Methylation, and Transcription: Results from the Multi-ethnic Study of Atherosclerosis and Air Pollution (MESA Air)	Gloria Chi	5/19/2013
G 257	Exposure to Ambient Particulate Matter and Other Air Pollutants, and Variation of Transcription and Epigenetic Methylation: The Multi- Ethnic Study of Atherosclerosis and Air Pollution (MESA Air)	Mark Hensley	10/4/2013
G 259	Common genes underlying asthma and chronic obstructive pulmonary disease. A genome-wide association study on the Dutch hypothesis	Kathleen Donohue	4/17/2013
G	Proposal for an extended analysis under approved CARe manuscript proposal CMP00119 (Meta Analysis of Genome Wide Association Data for Type 2 Diabetes Quantitative Traits in African Americans		
261 G	including the Candidate Gene Association Resource [CARe] Project) Airway dimensions at CT scan and gene expression in peripheral blood	Guo	5/1/2013
262	monocytes: The MESA Epigenetics Study	Donohue	5/1/2013

G 263	Genome-wide Association Study of Nonalcoholic Fatty Liver Disease in a Multiethnic Meta-analysis	Nicholette Allred	7/3/2013
G 264	Meta-analysis of Exome Chip Data in a Multiethnic Sample to Identify Variants Associated with Nonalcoholic Fatty Liver Disease	Nicholette Allred	7/3/2013
G 265	CHARGE Consortium Hemostasis Working Group Exome project manuscript proposal	Xiuqing Guo	5/16/2013
G 266	Gene expression analyses of blood pressure measures in GHS and MESA	Xiuqing Guo	6/4/2014
G 267	Blood Pressure and global DNA methylation in the Multi-Ethnic Study of Atherosclerosis (MESA)	Xiuqing Guo	5/15/2013
G 268	The Exome Chip Analysis of Pulmonary Function- the CHARGE Consortium	Tess Diandra Pottinger	5/16/2013
G 269	Longitudinal GWAS Analysis of Interaction between QT interval and Drug Use: the Meta-Analysis by CHARGE consortium (AGES, ARIC, CHS, FHS, RS, PROSPER, HABC, ERF, Health 2000 and MESA)	Xiaohui Li MD, MS	6/6/2013
G 270	Multi-ethnic GWAS of diabetic retinopathy: enhanced power using new methods	Sobrin	6/5/2013
G 271	MESA-SHARE Participation in the AAGILE Consortium: Meta Analysis of Genome Wide Association Data for Fasting Glucose and Insulin in ~25,000 nondiabetic	Xiuqing Guo PhD	6/19/2013
G 272	Transethnic analysis: Age at Menarche, Age at Natural Menopause - The Multi-Ethnic Study of Atherosclerosis (MESA) and MESA Family joining as discovery cohort in ReproGen	Leslie Raffel	7/17/2013
G 275	Analysis of gene-gene interaction and gene-environment interaction using a novel additive main effects and multiplicative interactions model for longitudinal data in the Multi-Ethnic Study of Atherosclerosis Cohort	Ko, Yi-An, MS	8/8/2013
G 276	Genetic association of kidney traits in African American and Hispanic individuals using the MetaboChip array: Discovery and Fine Mapping in the Population Architecture Using Genomics in Epidemiology (PAGE) Consortium	Christina Wassel	8/8/2013
G 277	Generalization and fine mapping of previously identified QT loci to multi-ethnic populations	Christina Wassel	8/8/2013
G 278	Rare variants and stroke risk: MESA contribution to the CHARGE Neurology Working Group ExomeChip Analysis	Ani Manichaikul	8/8/2013
G 279	Generalization and fine mapping of previously identified PR loci to multi-ethnic populations	Christina Wassel	8/8/2013

3.8. MESA Manuscripts and Papers

The MESA P&P status table and published papers lists can be viewed at the internal P&P Web page: <u>http://mesa-nhlbi.org/MesaInternal/Publications.aspx</u>

Go to: Paper Status Information

Table of Status and Authorship Information

Published Papers Lists

- Alphabetical List in Order by First Author
- Chronological List in Order by Date Published
- Data Repository and Consortium Published Papers

3.9 CARe Manuscript Proposals

A list of CARe manuscript proposals is posted on the MESA P&P webpage under "Search (Paper Proposals) - <u>http://mesa-nhlbi.org/MesaInternal/Publications.aspx</u>

BLANK

Section 4: Laboratory Repository Inventory

Intr	oductio	on		69
4.1	MES	A Lab Va	riables and Current Completion Status as of 8.28.2014	69
	4.1.1	Table: 1	Baseline Visit Assays	69
	4.1.2	Table: V	visit 2 Assays	71
	4.1.3	Table: V	visit 3 Assays	71
	4.1.4	Table: V	visit 4 Assays	71
	4.1.5	Table: V	visit 5 Assays	72
	4.1.6	Table: A	ncillary Study Assays, Funded	73
4.2	MES.	A Reposi	tory Summary as of August, 2014	77
	4.2.1	Baseline		77
	4.2.2	Exam 2		
	4.2.3	Exam 3		
	4.2.4	Exam 4		85
	4.2.5	Exam 5		
4.3	MES.	A Reposi	tory Report, as of August, 2014	89
	4.3.1	MESA I	Repository Availability, by Category	89
		4.3.1.1	Table: Baseline	89
		4.3.1.2	Table: Exam 2	91
		4.3.1.3	Table: Exam 3	93
		4.3.1.4	Table: Exam 4	95
		4.3.1.5	Table: Exam 5	97
	4.3.2	MESA I	DNA Repository Availability, by Category	99
		4.3.2.1	Table: Distribution of quantities of DNA remaining in MESA Repository	99
		4.3.2.2	Table: MESA DNA Released	99

BLANK

Introduction

This section was produced by the Central Laboratory in Vermont. Section 4.1 is the status of MESA Laboratory Variables as of August, 2014. Section 4.2 provides a complete inventory of samples in the repository as of August, 2014 and includes additional information about how much of each type of sample was received, how each type of sample has been used, and other activities related to samples. Tables showing the status of samples from Exam 2, Exam 3, Exam 4 and Exam 5 are also provided.

Section 4.3 is a report of availability of samples in the repository for the MESA cohort.

4.1 MESA Lab Variables and Current Completion Status as of 8.28.2014

Details of the rationale for each assay, including those we are performing and those we considered but are not performing, are posted on the MESA website, MESA Lab Master List 9-03.doc. Ancillary study investigators should send updates on the status of their studies and assays to Mary Cushman@uvm.edu) and Sandi Shrager (sandis@u.washington.edu).

4.1.1 Table: Baseline Visit Assays

Analyte	Group #	Lab	Completion Status	Estimated Completion Date
Lipid profile	1	MN	Done	Done
Glucose	1	MN	Done	Done
Creatinine	1	MN	Done	Done
Urine albumin and creatinine	2	VT	Done	Done
Interleukin-6	2	VT	Done	Done
C-reactive protein	2	VT	Done	Done
Chlamydia pneumoniae IgG antibody	2	MN	Done	Done
Homocysteine	2	MN	Done	Done
Insulin	2	MN	Done	Done
Fibrinogen antigen	2	VT	Done	Done
Factor VIIIc	2	VT	Done	Done
D-dimer	2	VT	Done	Done
Plasmin-antiplasmin complex	2	VT	Done	Done
NMR Lipids	2	Liposcience	Done	Done
Soluble ICAM-1	3	VT	Done	Done
von Willebrand factor	3	VT	Done	Done
Plasminogen activator inhibitor-1	3	VT	Done	Done
HDL electrophoresis	3	MN	Done	Done
CETP ag, activity, 4 genotypes	3	MN	Done	Done
ABC genotypes	3	MN	Done	Done

MESA STEERING COMMITTEE MEETING

Chylomicron remnants	3	MN	Done	Done
Plasma fatty acids	3	MN	Done	Done
Cytomegalovirus antibodies	3	MN	Done	Done
Herpes Simplex Virus antibodies	3	MN	Done	Done
Chlamydia heat shock protein-60	3	MN	Done	Done
Hepatitis A Virus antibodies	3	MN	Done	Done
Helicobacter pylori antibodies	3	MN	Done	Done
Interleukin-2 receptor	4	VT	Done	Done
TNF alpha receptor-1	4	VT	Done	Done
Soluble thrombomodulin	3	VT	Done	Done
Tissue factor pathway inhibitor	3	VT	Done	Done
Thrombin activatable fibrinolysis inhibitor	3	VT	Done	Done
Soluble Tissue Factor	3	VT	Done	Done
E-selectin	3	VT	Done	Done
Matrix metalloproteinase-9	3	VT	Done	Done
Matrix metalloproteinase-3 (Stromelysin)	3	VT	Done	Done

Analyte	Group#	Lab	Completion Status	Estimated Completion Date
CD40 ligand	3	VT	Done	Done
Oxidized LDL / malenaldehyde modified LDL	3	Leuven	Done	Done
HDL RNA Expression Pilot	3	Minn	Pending	
F2 Isoprostanes	436	MN	Done	Done
Abell-Kendall cholesterol	25	NW Lipid Labs	Done	Done
Interleukin-10	4	VT	Done	Done

Group indicates which participants are having each measure:

Group 1. Run on all participants and results reported to participants

Group 2. Run on all participants

Group 3. Run on a random sample of 1000 participants

Group 4. 2880 participants with candidate gene assays (includes Group 3).

4.1.2 Table: Visit 2 Assays

Analyte	Group#	Lab	Completion Status
Lipid profile	1	MN	Done
Glucose	1	MN	Done
Hemoglobin A1c	2	MN	Done
Urine albumin and creatinine	2	VT	Done

4.1.3 Table: Visit 3 Assays

Analyte	Group#	Lab	Completion Status
Lipid profile	1	MN	Done
Glucose	1	MN	Done
Creatinine	1	MN	Done
Urine albumin and creatinine	2	VT	Done

4.1.4 Table: Visit 4 Assays

Analyte	Group#	Lab	Completion Status
Lipid profile	1	MN	Done
Glucose	1	MN	Done

Creatinine 1 MN Done

4.1.5 Table: Visit 5 Assays

Analyte	Group#	Lab	Completion Status
Lipid profile	1	MN	Done
Glucose	1	MN	Done
Creatinine	1	MN	Done
HgA1c	1	MN	Done
Insulin	1	MN	Done
Urinary Albumin and creatinine	1	MN	Done

4.1.6 Table: Ancillary Study Assays, Funded

Lotal and free Testosterone, DHEA, E2, and SHBG Gapstur/ Ouvyang ~6100 (no premenoip females) Longcope 1 Complete Serum anyloid P, pentraxin-3 Jenny 2880 (DNA Group) Vermonti I Complete MESA Family Rotter Genotyping, various analytes on MESA probands Vermonti UCLAWFU 1 In progress MESA Family - CRP, IL-6, Insulin, D-dimer, PAI-1, adponectin, resistin, TNF-alpha, MCP-1 Diez-Roux 1000 Vermont 3.4 Complete Stress Diez-Roux 1000 Vermont 3.4 Complete CORINSNPS Rame 6800 who consented to DNA UTSW 1 Complete Unary Cotinie, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 1 In progress Viriary cotinie, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 In progress Viriary cotinie, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Shin 6800 Arking 6800 Arking Complete Osteoprotegerin Shin 6800 Out new recruits Vermont 3-4 In progress Voystatin C <th>Analyte</th> <th>PI</th> <th>Ν</th> <th>Lab</th> <th>Visit</th> <th>Lab Status</th>	Analyte	PI	Ν	Lab	Visit	Lab Status
Ouvgang Ouvername Ouvername Ouvername Serum amyloid P, pentraxin-3 Jenny 2880 (DNA Group) Vermont 1 Complete MESA Family Rotter Genotyping, various analytes on MESA probands Vermont/UCLAWFU 1 In progress MESA Family - CRP, IL-6, Insulin, D-dimer, PAI-1, adiponectin, resistin, TNF-alpha, MCP-1 Rotter New recruits (~1650) + MESA Classic in MESA Family (n=420) Vermont 1 Complete Stress Diez-Roux 1000 Vermont 3.4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Diract PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est CFR, 800 (or 300) Vermont 1 In progress Unary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 irAM-1 250 irAM-1 In progress CRP, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 In progress Veryl inflammation Tracy 1000, separate blood draw Vermont 3-4 In progress <tr< td=""><td>Sphingomyelin</td><td>Tall</td><td></td><td>Tall</td><td>1</td><td>Complete</td></tr<>	Sphingomyelin	Tall		Tall	1	Complete
Serum amyloid P, pentraxin-3 Jenny 2880 (DNA Group) Vermont 1 Complete MESA Family Rotter Genotyping, various analytes on MESA probands Vermont/UCLAWFU 1 In progress MESA Family - CRP, IL-6, Insulin, D-dimer, PAI-1, adjonnectin, resistin, TNF-alpha, MCP-1 Rotter New recruits (r-1650) + MESA Vermont 1 Complete Stress Diez-Roux 1000 Vermont 3.4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Diract PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est GFR, 800 (or 300) Vermont 1 In progress Urinary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 Urines Vermont 1 In progress Newel Inflammation Tracy 1000 + new recruits Vermont 3-4 In progress Steoprotegerin Shin 400 Arking Complete Osteoprotegerin Shin 400 Arking Complete Osteoprotegerin Shin 800 VT<	total and free Testosterone, DHEA, E2, and SHBG	Gapstur/	~6100 (no premenop females)	Longcope	1	Complete
MESA Family Rotter Genotyping, various analytes on MESA probands Vermont/UCLAWFU 1 In progress MESA Family – CRP, IL-6, Insulin, D-dimer, PAI-1, adiponectin, resistin, TNF-alpha, MCP-1 Rotter New recruits (~1650) + MESA Classic in MESA Family (n=420) Vermont 1 Complete Stress Diez-Roux 1000 Vermont 3,4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete intact PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est GFR, 800 (or 300) Vermont 1 Complete Unary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 urines Vermont 3.4 In progress Novel inflammation 250 ICAM-1 CAM-1 Complete Arking 6600 Arking 1 Complete Vertrand Tracy 1000, separate blood draw Vermont 3.4 In progress Volatin G Shin 400 Arking 1 Complete Vertand Shin 800 VT 2 Complete		Ouyang				
MESA Family – CRP, IL-6, Insulin, D-dimer, PAI-1, adiponectin, resistin, TNF-alpha, MCP-1 Rotter New recruits (~1650) + MESA, Vermont 1 Complete Stress Diez-Roux 1000 Vermont 3,4 Complete Stress Diez-Roux 1000 Vermont 3,4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete D, FGF-23 Rame 6800 who consented to DNA UTSW 1 Complete Unary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 urines Vermont 1 In progress Novel inflammation Tracy 1000 + new recruits Vermont 3-4 In progress Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete Osteoprotegerin Shin 400 Arking Complete Complete Osteoprotegerin Shin 8000 for ulpreviously thaved serum VT 1 Complete Osteoprotegerin Shin 600 Arking 1 Complete </td <td></td> <td>/</td> <td></td> <td></td> <td></td> <td></td>		/				
adiponectin, resistin, TNF-alpha, MCP-1 Classic in MESA Family (n=420) Stress Diez-Roux 1000 Vermont 3,4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Intact PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est GFR, 800 (or 300) Vermont 1 Complete D, FGF-23 Urinary cotinine, ICAM Eselectin, 20 SNPs (300 Bar 3250 urines Vermont 1 In progress meg) 1125 E-selectin 250 ICAM-1 C Complete Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Arking 1 Complete Complete Osteoprotegerin Shin 400 Arking 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Pilot study to measure endothelial progenitor cells Folsom Sol CAM-1 C Complete Vermont Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Disteoprotegerin Shin 600	MESA Family	Rotter		Vermont/UCLA/WFU	1	In progress
Stress Diez-Roux 1000 Vermont 3,4 Complete CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Intact PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est GFR, 800 (or 300) Vermont 1 Complete Urinary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 urines Vermont 1 In progress 0. FGF-23 1125 E-selectin 201 ICAM-1 201 ICAM-1 Complete 1125 E-selectin 1 In progress 0. Wovel inflammation Tracy 1000 + new recruits Vermont 3-4 In progress Vovel inflammation Tracy 1000 + new recruits Vermont 3-4 Complete KLO7HO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Arking 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Pilob Rtand abublin dis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease	MESA Family – CRP, IL-6, Insulin, D-dimer, PAI-1,	Rotter		Vermont	1	Complete
new blood draw new blood draw CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Intact PTH, calcium, phosphate. 25 and 1,25 vitamin D, FGF-23 Statumin Statumin Userum Userum <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
CORIN SNPs Rame 6800 who consented to DNA UTSW 1 Complete Intact PTH, calcium, phosphate. 25 and 1,25 vitamin Kestenbaum 535 with low est GFR, 800 (or 300) Vermont 1 Complete Urinary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 urines Vermont 1 In progress 0 125 E-selectin 250 ICAM-1 250 ICAM-1 Complete Arking 1000 + new recruits Vermont 3-4 In progress Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 In progress KLOTHO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Angen 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin Borops of EDTA whole blood for hgb NA	Stress	Diez-Roux		Vermont	3,4	Complete
intact PTH, calcium, phosphate. 25 and 1,25 vitamin D, FGF-23 Unary cotinine, ICAM Eselectin, 20 SNPs (300 mcg) 20 CAM-1, 0x-LDL, F2 isoprostanes, P selectin XL07H/0 gene CRP, ICAM-1, 0x-LDL, F2 isoprostanes, P selectin Tracy Novel inflammation Novel inflammat						
Urinary cotinine, ICAM Eselectin, 20 SNPs (300 Barr 3250 urines Vermont 1 In progress meg) 1125 E-selectin 250 ICAM-1 S26 ICAM-1 S26 ICAM-1 S27 ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 Complete Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete KLOTHO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Amgen 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Big MR1 and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done mRNA expression Huang ~30 ppts each site-collecting 5 ml Huang After Done, Additional assay requested LipPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 Gotoprotegerin Shina 2000 aortic Ca study VT 2-3 Done Cushman/Jenny Baseline full cohort 100ul for 2 assay requested Complete 1,3 Done MRNA expression Huang ~30 ppts each site-collecting 5 ml Huang After Done, Additional assay requested Complete 2,3,4 Complete Cushman/Jenny Baseline full cohort 100ul for 2 assay requested Complete 2,3,4 Complete Cystatin C Shilpak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete Peralta space GGT Bradley Full cohort VT 1 Complete						
1125 E-selectin 250 ICAM-1 CRP, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 In progress Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete Soteoprotegerin Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Amgen 1 Complete Osteoprotegerin Shin 6800 50 ul previously thawed serum VT 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Pigb MRI and subclin dis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3.100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN psts, collecting own samples MN 4 Withdrawn RNA expression Huang ~30 pts each site-collecting 5 ml Huang After Done, Additional assay requested LpPLA2 activity and mass Cushmani.Jenny </td <td>D, FGF-23</td> <td>Kestenbaum</td> <td></td> <td>Vermont</td> <td>1</td> <td>Complete</td>	D, FGF-23	Kestenbaum		Vermont	1	Complete
250 250 ICAM-1 CRP, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 In progress Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete KLOTHO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Angen 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Pilo MRI and subclindis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1,3 Done NT-pro BNP Daniels/Bahrami/Lima Fuli cohort UCSD Maisel	Urinary cotinine, ICAM Eselectin, 20 SNPs (300	Barr	3250 urines	Vermont	1	In progress
CRP, ICAM-1, ox-LDL, F2 isoprostanes, P selectin Kaufman 1000 + new recruits Vermont 3-4 In progress Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete Novel inflammation Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Angen 1 Complete Osteoprotegerin Shin 6800 VT 2 Complete Qsteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Hgb MRI and subclin dis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN pts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done LpPLA2 activity and mass Cushman/Jenny <	mcg)					
Novel inflammation Tracy 1000, separate blood draw Vermont 3-4 Complete KLOTHO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Amgen 1 Complete Osteoprotegerin Shin 6800 50 ul previously thawed serum VT 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Hgb MRI and subclindis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pliot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done RPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2						
KLOTHO gene Arking 6800 Arking 1 Complete Osteoprotegerin Shin 400 Amgen 1 Complete Osteoprotegerin Shin 6800 50 ul previously thawed serum VT 1 Complete Osteoprotegerin Shin 800 VT 2 Complete Osteoprotegerin Shin 800 VT 2 Complete Hgb MRI and subclin dis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done mRNA expression Huang ~30 ppts each site-collecting 5 ml Huang After Done, Additional assay requested LpPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 DiaDexus 1 Done FGN 2000 a		Kaufman	1000 + new recruits	Vermont	-	In progress
OsteoprotegerinShin400Amgen1CompleteCystatin CShlipak6800 50 ul previously thawed serumVT1CompleteOsteoprotegerinShin800VT2CompleteHgb MRI and subclin disAstorDrops of EDTA whole blood for hgbNA4WithdrawnTelomere length, stress, and subclinical diseaseDiez-RouxGroup 3. 100 ng DNA for telomeresOutside1CompletePilot study to measure endothelial progenitor cellsFolsom50-100 MN ppts, collecting own samplesMN4WithdrawnNT-pro BNPDaniels/Bahrami/LimaFull cohortUCSD Maisel1,3DonemRNA expressionHuang~30 ppts each site-collecting 5 ml sampleHuangAfterDone, Additional assaysLpPLA2 activity and massCushman/JennyBaseline full cohort 100ul for 2 biaDexus1DoneFGNPDAY validationHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/50 ul EDTA or serum (250 ul deadVT2,3,4CompleteGGTBradleyFull cohortVT1Complete		, ,			3-4	Complete
Cystatin CShlipak6800 50 ul previously thawed serumVT1CompleteOsteoprotegerinShin800VT2CompleteHgb MRI and subclin disAstorDrops of EDTA whole blood for hgbNA4WithdrawnTelomere length, stress, and subclinical diseaseDiez-RouxGroup 3. 100 ng DNA for telomeresOutside1CompletePilot study to measure endothelial progenitor cellsFolsom50-100 MN ppts, collecting own samplesMN4WithdrawnNT-pro BNPDaniels/Bahrami/LimaFull cohortUCSD Maisel1,3DonemRNA expressionHuang~30 ppts each site-collecting 5 mlHuangAfterDone, Additional assaysLpPLA2 activity and massCushman/JennyBaseline full cohort 100ul for 2 assaysDiaDexus1DoneFGNHerrington6500* 10 ug DNA1CompletePDAY validationHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/50 ul EDTA or serum (250 ul dead VT2,3,4CompleteGGTBradleyFull cohortVT1Complete	KLOTHO gene	<u> </u>		ě	1	
Osteoprotegerin Shin 800 VT 2 Complete Hgb MRI and subclin dis Astor Drops of EDTA whole blood for hgb NA 4 Withdrawn Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done mRNA expression Huang ~30 ppts each site-collecting 5 ml Huang After Done, Additional sample LpPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 assays DiaDexus 1 Done FGN Complete Station 2000 aortic Ca study VT 2.3 Done FGN Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete GGT Bradley Full cohort VT 1 Complete	Osteoprotegerin				1	
Hgb MRI and subclin disAstorDrops of EDTA whole blood for hgbNA4WithdrawnTelomere length, stress, and subclinical diseaseDiez-RouxGroup 3. 100 ng DNA for telomeresOutside1CompletePilot study to measure endothelial progenitor cellsFolsom50-100 MN ppts, collecting own samplesMN4WithdrawnNT-pro BNPDaniels/Bahrami/LimaFull cohortUCSD Maisel1,3DonemRNA expressionHuang~30 ppts each site-collecting 5 ml sampleHuangAfter assay requestedDone, Additional assaysLpPLA2 activity and massCushman/JennyBaseline full cohort 100ul for 2 assaysDiaDexus1DonePGNHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/ Peralta50 ul EDTA or serum (250 ul dead spaceVT2,3,4CompleteGGTBradleyFull cohortVT1Complete	Cystatin C	1	6800 50 ul previously thawed serum		1	Complete
Telomere length, stress, and subclinical disease Diez-Roux Group 3. 100 ng DNA for telomeres Outside 1 Complete Pilot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done mRNA expression Huang ~30 ppts each site-collecting 5 ml sample Huang After Done, Additional assay requested LpPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 sasays DiaDexus 1 Done Adiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGN Allison 2000 aortic C a study VT 2-3 Done PDAY validation Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete GGT Bradley Full cohort VI 1 Complete	Osteoprotegerin	Shin	800		2	Complete
Pilot study to measure endothelial progenitor cells Folsom 50-100 MN ppts, collecting own samples MN 4 Withdrawn NT-pro BNP Daniels/Bahrami/Lima Full cohort UCSD Maisel 1,3 Done mRNA expression Huang ~30 ppts each site-collecting 5 ml Huang After Done, Additional asample LpPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 assays DiaDexus 1 Done Adiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGN Allison 2000 aortic Ca study VT 2-3 Done PDAY validation Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete GGT Bradley Full cohort VT 1 Complete	Hgb MRI and subclin dis	Astor		NA	4	Withdrawn
NT-pro BNPDaniels/Bahrami/LimaFull cohortUCSD Maisel1,3DonemRNA expressionHuang~30 ppts each site-collecting 5 mlHuangAfterDone, Additional assay requestedLpPLA2 activity and massCushman/JennyBaseline full cohort 100ul for 2 assaysDiaDexus1DoneAdiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGNAllison2000 aortic Ca studyVT2-3DonePDAY validationHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/ Peralta50 ul EDTA or serum (250 ul dead spaceVT2,3,4CompleteGGTBradleyFull cohortVT1Complete	Telomere length, stress, and subclinical disease	Diez-Roux	Group 3. 100 ng DNA for telomeres	Outside	1	Complete
MRNA expressionHuang assay~30 ppts each site-collecting 5 ml sampleHuang HuangAfter Assay requestedDone, Additional assay requestedLpPLA2 activity and massCushman/Jenny Baseline full cohort 100ul for 2 assaysDiaDexus1DoneAdiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGNAllison2000 aortic Ca studyVT2-3DonePDAY validationHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/ Peralta50 ul EDTA or serum (250 ul dead spaceVT2,3,4CompleteGGTBradleyFull cohortVT1Complete	Pilot study to measure endothelial progenitor cells	Folsom		MN	4	Withdrawn
LpPLA2 activity and massCushman/JennyBaseline full cohort 100ul for 2 assaysDiaDexus1DoneAdiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGNAllison2000 aortic Ca studyVT2-3DonePDAY validationHerrington6500* 10 ug DNA1CompleteCystatin CShlipak/ Peralta50 ul EDTA or serum (250 ul dead spaceVT2,3,4CompleteGGTBradleyFull cohortVT1Complete	NT-pro BNP	Daniels/Bahrami/Lima	Full cohort	UCSD Maisel	1,3	Done
LpPLA2 activity and mass Cushman/Jenny Baseline full cohort 100ul for 2 assays DiaDexus 1 Done Adiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, Allison 2000 aortic Ca study VT 2-3 Done FGN PDAY validation Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead space VT 2,3,4 Complete GGT Bradley Full cohort VT 1 Complete	mRNA expression	Huang		Huang		,
Adiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, Allison 2000 aortic Ca study VT 2-3 Done FGN PDAY validation Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete Peralta space Space 2000 aortic Ca study VT 1 Complete	LpPLA2 activity and mass	Cushman/Jenny	Baseline full cohort 100ul for 2	DiaDexus		
PDAY validation Herrington 6500* 10 ug DNA 1 Complete Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete Peralta space Space VT 1 Complete GGT Bradley Full cohort VT 1 Complete	Adiponectin, leptin, TNF-alpha, insulin, CRP, IL-6, FGN	Allison	,,	VT	2-3	Done
Cystatin C Shlipak/ 50 ul EDTA or serum (250 ul dead VT 2,3,4 Complete Peralta space Space 1 Complete GGT Bradley Full cohort VT 1 Complete	PDAY validation	Herrington	6500* 10 ug DNA		1	Complete
	Cystatin C	Shlipak/	50 ul EDTA or serum (250 ul dead	VT	2,3,4	Complete
Urine phosphorous calciumpilot Kestenbaum 200 ul Urine on 440 with CKD Seattle 1 Complete	GGT	Bradley	Full cohort	VT	1	Complete
	Urine phosphorous calciumpilot	Kestenbaum	200 ul Urine on 440 with CKD	Seattle	1	Complete

Analyte	PI	Ν	Lab	Visit #	Lab Status
Autoantibody panel	Majka	6800 (all) 100 ul serum	TheraTest Labs	1	Complete
Nitrotyrosine, 25 µl EDTA; 25-hydroxy vit D, 120 µl EDTA	Jiang	145 ul. Random 2000 MESA Lung ppts prior thaw ok	VT	1	Complete
Predictors of RV Function	Barr	1550 non-group 3. vWF, TM	VT	1	Complete
Vitamin D associations with urine albumin excretion, inflammation, and coronary artery calcification	deBoer	1000-person sample (not Group 3;overlaps with lx sample) 25-hydroxy vitamin D; 400 ul serum; PO4	VT	1	Complete
Apo B and Apo A1	Tsai Paramsothy	Baseline minus ppts on lipid lowering or in Group 3	Tsai	1	Complete
BK Viruria and CKD	Johnson	250 CKD cases, 250 controls	Seattle – Corey	1	Complete
MESA COPD: endoth cells and MPs, sphingosine- 1phosphate, mRNA expression	Barr	Collect own samples	Vermont	5	Complete
Gene-environment interactions of traffic related pollution and CVD	Vedal	750 random sample from candidate gene gp and MESA Air IL-6, ICAM-1, HSP-60, oxidized LDL and E-selectin	Vermont	2, 3, 4	Pending
Vitamin K	Shea	300 cases of CAC prog, 759 controls. 300 ul serum for VK. NOT group 3 without justification	Tufts Vit K Lab	1	Complete
Renal Artery Calcium, renin, aldosterone creatinine cysC	Allison	700 ul EDTA V2 or 3, 75 ul serum V2, 700 EDTA 40 serum V3 on Aortic Ca subset	VT	2-3	Complete
Fetuin A, Ca, PO4, CVD and DM	lx	3196 baseline serum, 150 ul	U Md	1	Complete
CRP, ferritin, insulin, adiponectin, IL2Ra, lipid markers: CE 16:1, 20:3, 18:2, 16:0, 18:1, 18:2, 18:1	Bertoni	5245 V2 full cohort, 400 ul serum	Tethys	2	Samples sent
PALM. 45 proteins* Aviir	McCluskey	150 ul V1 serum 232 incident CHD, 603 cohort rndm sample	VT	1	Complete
Autoimmunity and Athero 1	Majka	40 ul serum FC minus 860. RF, anti-CCP Ab	TheraTest	1	Samples sent
Stress II Stress and epigenetic changes IL-6, IL-10, TNF-a, D-dimer, FVIII	Diez Roux	275 ul EDTA, 200 ul citrate on 1300 Stress participants	VT	5	Complete

SEPTEMBER 17-18, 2014

Analyte	PI	Ν	Lab	Visit #	Lab Status
Phosphorous/ Vitamin D and CVD	Kestenbaum/ deBoer	Full cohort minus those with measures already done. 450 ul serum, 200 ul urine. Ca, PO4, 25OHvitD, 24,25OHvitD, FGF- 23, PTH. lytes, Urine: Ca, PO4, lytes, uric acid	Seattle, U Washington	1	Samples sent
Athero and adhesion	Bielinski	Group 4 2880. 6Ckine, ecadherin, MCP-1, IL-1F2, MMP1, MMP2, RANTES, SDF-1a, VCAM-1	UMinn	2	Samples sent
Lung II	Barr	V5. PAI-1, plasma viscosity, urinary cotinine on Lung 1 ppts	VT	5	In progress
Urinary biomarkers & Kidney decline	Shlipak/ Peralta	500 Incident CKD 500 controls 680 BL CKD. 2 ml urine NGAL, KIM 1, IL-18, uromodulin, TGF-β	VT	1,5	Samples sent
Estrogen metabolism and RV fxn	Venetuolo	0.15 ml urine in 1738 MESA RV women`	VT	1	Funded July 2011
Lung Fibrosis	Lederer	300 ul Exam 1 serum for 2,047 non- group 3 ppts; 500 ul exam 5 urine from all ppts with available sample.	VT	1,5	In progress
Neurocognitive effects of dietary exposure to organophosphorous pesticides	Curl	2 mL urine in 800 ppts (400 random ppts from Exam 1 (Group 3 excluded) + 400 ppts at Exam 5).	UW Environmental Health Laboratory and Trace Organic Analytical Center (Dills)	1,5	Funded

MESA STEERING COMMITTEE MEETING		Septem	BER 17-18, 2014		
Plasma fatty acid composition, polymorphisms in the 5-Lipoxygenase pathway and atherosclerosis.	Tsai	250 ul previously thawed samples EDTA plasma + 100ng DNA, Baseline (visit 1) ppts excluding 2880 MESA Candidate Gene ppts.	UMinn	1	Active, funded
Leukotrienes, allergy, and the risk of cardiovascular disease	Savage	200 ul serum from exam corresponding to 2nd CAC esam, 250 ul serum and 200 ul urine from any later exam	Robert Wood Laboratory, Dermatology, Allergy and Clinical Immunology Iaboratory at Johns Hopkins Bayview	2-4	Active, funded
Vitamin K dependent proteins	Danziger	0 ul EDTA plasma from 1119 ppts at baseline (681 (subcohort) + 438 (cases)):	VT	1	Active, funded
Perfluoroalkyl chemicals and the risk of developing cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis	Gurka	250 ul baseline serum, 250ul Exam 3 serum, 500ul Exams 2,3,4&5 urine. Note: 50% Group 3 for all. 1800 (1000 cohort random sample + 800 cases of incident CVD/CKD)		1-5	Funded
Plasma free fatty acids	Tsai	20 ul baseline serum on all participants	UMN	1	Active, funded
Combi-Biomarkers	Elliott	0.4 ml serum (.8ml total) in 4000 MESA ppts in V1 and V2.	Metabometrix, Ltd	1-2	Active, funded
HDL subclasses defined by apolipoprotein C-III	Jensen	250 ul baseline EDTA plasma in N=5814 (no group 3)	Harvard School of Public Health (Sacks)	1	Active, funded

* excluding 300 participants with < 100 ug of DNA available.

HILTON CRYSTAL CITY HOTEL, ARLINGTON, VA

4.2 MESA Repository Summary as of August, 2014

4.2.1 Baseline

(Table continues on the following two pages)

		#	#	Percent	#	# Fresh	#		#2x	#3x	#4x #5x #6x #7x		
Туре	Cryo	Received	Available	Available	Reserved	Frozen	Thawed	#1x Used	Used	Used	Used UsedUsed Used	d Sample Selections	Sample Selection/Comments
EDTA	01	6799	1	0%	0	0	1	6799	0	0	0	Uminn Group 1 Lipids (n=6799) Uminn Group 2 (n=6797), N. Jenny 1 (n=5),	Uminn Group 1 - complete. Uminn Group 2, N. Jenny 1 and 2, Candidate Case Cramond M. Jassen
EDTA	02	6798	6724	99%	0	1	6723	6797	212	28	3	N.Jenny 2 (n=28), CandidateGene Grp (n=31), and M. Jensen (n=179)	Candidate Gene Grp, and M. Jensen - complete.
EDTA	03	6795	6595	97%	200	6595	0	0	0	0	0	Drift selection reserved (n=200)	Drift selection - reserved.
EDTA	04	6798	5768	85%	0	5768	0	1030	0	0	0	Uminn Group 3 (n=1030) Liposcience/NMR (n=6797), N. Jenny 1 (n=5).	Uminn Group 3 - complete. Liposcience/NMR, N. Jenny 1, M. Tsai
EDTA	05	6797	6751	99%	0	0	6751	6797	405	0	0	M. Tsai 3 (n=68), and M. Jensen (n=332) Liposcience/NMR (n=1), and Drift selection	3, and M. Jensen - complete. Liposcience/NMR - complete. Drift
EDTA	06	6794	6594	97%	200	6593	1	1	0	0	0	reserved (n=200)	selection - reserved.
EDTA	07	6793	6793	100%	0	6793	0	0	0	0	0		
EDTA	08	6779	6779	100%	0	6779	0	0	0	0	0		
EDTA	09	6763	6760	100%	0	6760	0	3	0	0	0	D. Jacobs (n=3) P. Holvoet (n=2), B. Kestenbaum 2 (n=3), Cushman/Jenny (n=5), Candidate Gene Grp (n=34), M. Tsai 3 (n=4), M. Jensen (n=5), and	D. Jacobs - complete. P. Holvert, B. Kestenbaum 2, Cushman/Jenny, Candidate Gene Grp, M. Tsai 3. M. Jensen, and D. Jacobs -
EDTA	10	6743	6731	100%	0	6693	38	49	12	0	0	D. Jacobs (n=8) P. Holvoet (n=997), B. Kestenbaum 2 (n=4), M. Tsai 1 (n=1862) and 2 (n=23) and 3 (n=17) Cushman/Jenny (n=17), M. Jensen (n=3), and	complete. ,P. Holvert, B. Kestenbaum 2, M. Tsai 1,
EDTA	11	6734	3845	57%	0	3826	19	2908	20	0	0	D. Jacobs (n=5)	and D. Jacobs - complete.

Turne	C	# Received	# Availabla	Percent	# Decominant	# Fresh	# Thousa	#1.	#2x	#3x		#5x #6		d Sample Selections	Sample Selection/Commonte
Туре	Cryo	Received	Available	Available	Reserved	Frozen	Thawed	#1x Used	Used	Used	Usea	Useau	sea Use	A.Tall (n=20), M.Gross (n=25), B.Kestenbaum	Sample Selection/Comments
EDTA	12	6723	6502	97%	0	5811	691	909	62	5	1			1 (n=212) and 2 (n=6) N.Jenny 1 (n=3), and 2 (n=5), Cushman/Jenny (n=35), Candidate Gene Grp (n=429), M. Tsai 2 (n=165) and 3 (n=23), M. Jensen (n=28), and D. Jacobs (n=26). A.Tall (n=61), M.Gross (n=65), B.Kestenbaum 2 (n=34), N.Jenny 1 (n=14) and 2 (n=18),	A. Tall, M. Gross, B. Kestenbaum 1 and 2, N. Jenny 1 and 2, Cushman/Jenny, M. Tsai 2 and 3, Candidate Gene Grp, M. Jensen, and D. Jacobs - complete.
EDTA	13	6704	6204	93%	0	5062	1142	1642	480	17	0			Cushman/Jenny (n=888), Candidate Gene Grp (n=200), M. Tsai 2 (n=354) and 3 (n=365) M. Jensen (n=68), and D. Jacobs (n=72). A.Tall (n=138), M.Gross (n=413), B.Kestenbaum 2 (n=18), N.Jenny 1 (n=25)	Jenny 1 and 2, Cushman/Jenny, M.
EDTA	14	6641	4716	71%	0	3923	793	2718	408	28	1			and 2 (n=31), Cushman/Jenny (n=278), Candidate Gene Grp (n=410), Fatty Acid drift (n=17), M. Tsai 2 (n=1359) and 3 (n=163), M. Jensen (n=182), and D. Jacobs (n=121). A.Tall (n=323), M.Gross (n=388), B.Kestenbaum 2 (n=37), N.Jenny 1 (n=49)	Jenny 1 and 2, Cushman/Jenny, M.
EDTA	15	6501	5798	89%	0	665	5133	5834	3479	106	2			and 2 (n=113), Cushman/Jenny (n=4778), Candidate Gene Grp (n=165), Fatty Acid drift (n=8), M. Tsai 2 (n=211) and 3 (n=2893), M. Jensen (n=425), and D. Jacobs (n=31). A.Tall (n=594), M.Gross (n=348), B.Kestenbaum 2 (n=431), N.Jenny 1 (n=91)	Jenny 1 and 2, Cushman/Jenny, M. Tsai 2 and 3, Candidate Gene Grp, Fatty Acid drift, M. Jensen, and D. Jacobs - complete. A. Tall, M. Gross, B. Kestenbaum 2,
EDTA	16	6173	3171	51%	0	477	2694	5694	2037	155	5			(n=1711), and D. Jacobs (n=34). A.Tall (n=5587), B.Kestenbaum 2 (n=1),	Candidate Gene Grp, M. Jensen, and D. Jacobs - complete.
EDTA REDCE	17	5593	5461	98%	0	0	5461	5589	5580	1486	113			N.Jenny 1 (n=822) and 2 (n=1520), Candidate Gene Grp (n=1589), M. Tsai 2 (n=1) and 3 (n=358), M. Jensen (n=2890).	1 and 2, M. Tsai 2 and 3, Candidate Gene Grp, and M. Jensen - complete.
LL	18	6777	0	0%	0	0	0	6777	0	0	0			Uminn Group 1 DNA Extraction (n=6777)	Uminn Group 1 - complete.
REDCE LL	19	6758	0	0%	0	0	0	6758	0	0	0			Uminn Group 1 Fatty Acid Membrane (n=6758)	Uminn Group 1 - complete.
SCAT	20	6773	4106	61%	0	0	4106	6773	20	0	0			UVM Group 2 (n=6773), sICAM on TT subjects (n=20)	UVM Group 2, and sICAM - complete.
SCAT	21	6769	6769	100%	0	6636	133	133	0	0	0			UVM Group 2 (n=133)	UVM Group 2 - complete.
SCAT	22	6764	6763	100%	0	6763	0	1	0	0	0			UVM Group 2 (n=1)	UVM Group 2 - complete.
SCAT	23	6738	6738	100%	0	6738	0	0	0	0	0				
Citrate	24	6776	6769	100%	0	0	6769	6776	439	0	0			UVM Group 2 (n=6776), and MF Mesa Classi PAI-1 (n=439)	cUVM Group 2, and MF Mesa Classic - complete.

Туре	Cryo	Received	, Available	Available	" Reserved	Frozen	Thawed	#1x Used	Used	Used	Used L	JsedU:	sed U	Jsed	Sample Selections	Sample Selection/Comments
Citrate	25	6775	6775	100%	0	6775	0	0	0	0	0					
Citrate	26	6771	6770	100%	0	5770	1000	1001	0	0	0				UVM Group 3 (n=999), and Mesa RV/Kawut (n=2)	UVM Group 3, and Mesa RV/Kawut - complete.
Citrate	27	6761	6761	100%	0	5423	1338	1338	0	0	0				Mesa RV/Kawut (n=1338)	Mesa RV/Kawut - complete.
Serum	28	6792	0	0%	0	0	0	6792	0	0	0				Uminn Group 1 Chem (n=6792) Uminn Group 2 (n=6792), M. Shlipak	Uminn Group 1 - complete.
Serum	29	6794	4212	62%	0	0	4212	6793	6789	6742	3165 \$	589 9	90		(n=6789), B. Kestenbaum Rpts (n=419), D.Majka 1 (n=858) & 2 (n=1532), R. Bradley (n=5885), J. lx (n=88), T. McCluskey (n=82), M. Tsai 4 (n=1693), and S. Bielinski (n=31).	Uminn Group 2, M. Shlipak, B. Kestenbaum, R. Bradley, J. Ix, T. McCluskey, D. Majka 1 and 2, M. Tsai 4, and S. Bielinski - complete.
Serum	30	6791	6592	97%	199	6592	0	0	0	0	0				Drift selection reserved (n=199)	Drift selection - reserved.
oorum					100		-		-	Ū					Uminn Group 3 (n=1030), R. Bradley (n=12), J. Ix (n=1), K. Shea (n=19), T. McCluskey (n=15), D. Majka 2 (n=232), B. Kestenbaum Rpts (n=4), M. Tsai 4 (n=229), and S. Bielinsk	Uminn Group 3, R. Bradley, J. Ix, K. Shea, T. McCluskey, D. Majka 2, B. Kestenbaum Rpts, M. Tsai 4, and S.
Serum	31	6790	6444	95%	1	5759	685	1030	351	219	29	1			(n=88). Drift selection (n=1) reserved.	reserved.
Serum	32	6785	6578	97%	200	6578	0	7	0	0	0				Drift selection reserved (n=200). P. Greenland (n=3) and S. Bielinski (n=4).	Drift selection - reserved. P. Greenland, and S. Bielinski - complete.
															UVM Group 3 (n=999), R. Bradley (n=4), K.	
Serum	33	6782	6533	96%	0	5570	963	1212	245	12	5				Shea (n=1), T. McCluskey (n=2), D. Majka 2 (n=229), M. Tsai 4 (n=12), P. Greenland (n=13), and S. Bielinski (n=214). Daniels/Bahrami (n=5597), D.Majka 1 (n=11)	UVM Group 3, R. Bradley, K. Shea, T. McCluskey, D. Majka 2, M. Tsai 4, P. Greenland, and S. Bielinski - complete.
Serum	34	6773	4653	69%	0	1116	3537	5657	5040	2107	1422	60	2		and 2 (n=5365), R. Bradley (n=877), J. Ix (n=2), K. Shea (n=39), T. McCluskey (n=614) B. Kestenbaum Rpts (n=373), M. Tsai 4 (n=1236), P. Greenland (n=54), and S. Bielinski (n=120). B. Kestenbaum Rpt Ca/Ph (n=464), Rpt1 VitD	Bradley, J. Ix, K. Shea, T. McCluskey, B. Kestenbaum Rpts, M. Tsai 4, P. Greenland, and S. Bielinski - complete.
Serum	35	6759	6263	93%	0	5885	378	874	142	42	18				(n=33), Rpt2 VitD (n=16) and 3 (n=2), Daniels/Bahrami (n=1), K. Shea (n=23), T. McCluskey (n=10), D. Majka 2 (n=76), Ex5 In Comparability (n=1), M. Tsai 4 (n=33), P. Greenland (n=155), and S. Bielinski (n=262). S. Gapstur (n=6), MF Mesa Classic Insulin (n=410), Glucose drift (n=9), MF Mesa Classi Panel A&B (n=3), J. Ix (n=3), K. Shea (n=12), B. Kestenbaum 3 (n=42) and Rpt2 VitD (n=17), D. Majka 2 (n=46), M. Tsai 4 (n=48),	B. Kestenbaum, Daniels/Bahrami, K. s Shea, T. McCluskey, D. Majka 2, High ins Comp, M. Tsai 4, P. Greenland, and S. Bielinski - complete.
Serum	36	6736	5866	87%	0	5506	360	1230	77	46	11				P. Greenland (n=295), and S. Bielinski (n=473).	Rpt2 VitD, D. Majka 2, M. Tsai 4, P. Greenland, and S. Bielinski - complete.

#

Percent # # Fresh

SEPTEMBER 17-18, 2014

#2x #3x #4x #5x #6x #7x

HILTON CRYSTAL CITY HOTEL, ARLINGTON, VA

Туре	Crvo	# Received /	# Available	Percent Available	# Reserved	# Fresh Frozen	# Thawed	l #1x Used	#2x Used	#3x Used		#5x #6x UsedUse	6x #7x Ised Used Sample Selections Sample Sample Selection/Comr	nents
Serum	37	6704	508	8%	0	508	0	6196	5	2	0		S. Gapstur (n=6165), J. Ix (n=1), K. Shea (n=1), B. Kestenbaum 3 (n=5), D. Majka 2 (n=4), M. Tsai 4 (n=5), P. Greenland (n=7), and S. Bielinski (n=15). S. Gapstur (n=2), B. Kestenbaum 1 (n=12), Rpts (n=1), Rpt1 VitD (n=5), 3 (110) and Rpt2 VitD (n=50), Glucose drift (n=187), MF Mesa S. Gapstur, B. Kestenbaum 1	I. Tsai 4, i -
Serum	38	6675	4960	74%	0	4507	453	2167	614	311	207	12	Classic Panel A&B (n=435), J. Ix (n=30), K. Rpt1 VitD, 3, and Rpt2 VitD, 0 Shea (n=182), T. McCluskey (n=114), Ex5 Ins drift, MF Mesa Classic, J. Ix, I Harmonization (n=1), D. Majka 2 (n=600), M. T. McCluskey, Ex5 Ins Harmon Tsai 4 (n=269), P. Greenland (n=583), and S. D. Majka 2, M. Tsai 4, P. Gree Bielinski (n=730). and S. Bielinski - complete. V. Shin 1 (n=400), I. DeBoer (n=14), MF Mesa Classic Panel A&B (n=1), R. Bradley (n=77), J. Ix (n=51), K. Shea (n=164), T. McCluskey V. Shin, I. DeBoer, MF Mesa	K. Shea, onization, enland,
Serum	39	6633	4407	66%	0	4059	348	2572	448	215	155	10	 (n=14), B. Kestenbaum 3 (n=195) and Rpt2 K. Bradley, J. Ix, K. Shea, T. VitD (n=57), Ex5 Ins Harmonization (n=10), Ex5 Ins Comparability (n=3), D. Majka 2 (425), VitD, Ex5 Ins Harmonization, M. Tsai 4 (n=201), P. Greenland (n=1137), and S. Bielinski (n=651). B. Kestenbaum 1 (n=200), Rpts (n=7), Rpt2 VitD (n=37), and 3 (n=299), I. DeBoer (n=998), R. Bradley (n=3), J. Ix (n=79), K. 	Ex5 Ins . Tsai, P. complete.
Serum	40	6557	2959	45%	0	2871	88	3679	190	120	32		 Shea (n=17), T. McCluskey (n=3), Ex5 Ins Harmonization (n=9), Ex5 Ins Comparability (n=3), D. Majka 2 (n=200), M. Tsai 4 (n=201), McCluskey, Ex5 Ins Harmoniz P. Greenland (n=781), and S. Bielinski (n=1240). B. Kestenbaum 1 (n=200), Rpts (n=12), 2 (n=278), 3 (338), and Rpt2 VitD (n=33), and I. DeBoer (n=984), R. Bradley (n=35), J. Ix B. Kestenbaum 1, 3, Rpts, an WitD, I. DeBoer, J. Ix, K. Shei 	a, T. zation, D. id, and S.
Serum	41	6398	2767	43%	0	1642	1125	4740	743	431	206	5	 (n=84), K. Shea (n=85), T. McCluskey (n=10), DeBoer, R. Bradley, J. Ix, K. S. Ex5 Ins Harmonization (n=7), D. Majka 2 (n=817), M. Tsai 4 (n=455), P. Greenland (n=1578), and S. Bielinski (n=1149). B. Kestenbaum 2 (n=278), Rpt VitD (n=34), Rpt2 VitD (n=103), and 3 (n=903), J. Ix (n=230), K. Shea (n=82), T. McCluskey (n=8), B. Kestenbaum 2, 3, Rpt VitD Ex5 Ins Harmonization (n=33), Ex5 Ins 	zation, D. nd, and S. , and rpt2
Serum	42	6116	941	15%	0	756	185	5319	408	279	16		Comparability (n=8), D. Majka 2 (n=416), M. Tsai 4 (n=345), P. Greenland (n=2494), and S. Bielinski (n=1088).	2, M. Tsai,

Туре	Crvo	# Received /	# ∆vailable	Percent Available	# Reserved	# Fresh Frozen	# Thawed	#1x Used	#2x	#3x Used		#5x Used		I Sample Selections	Sample Selection/Comments
Serum	43	5605	484	9%	0	105	379	5470	827	428	25	1	 	B. Kestenbaum 2 (n=278), Rpt VitD (n=1), Rpt2 VitD (n=171), and 3 (n=2484), I. DeBoer (n=2), R. Bradley (n=3), J. Ix (n=344), K. Shea (n=328), T. McCluskey (n=23), Ex5 Ins Harmonization (n=34), Ex5 Ins Comparability (n=2), D. Majka 2 (n=806), M. Tsai 4 (n=776), P. Greenland (n=897), and S. Bielinski (n=602). I. DeBoer (n=2), R. Bradley (n=15), J. Ix (n=2241), K. Shea (n=283), T. McCluskey (n=52), B. Kestenbaum 3 (n=2186), and Rpt2 VitD (n=153), Ex5 Ins Harmonization (n=6), D.	B. Kestenbaum 2, 3, Rpt VitD, and Rpt2 vitD, I. DeBoer, R. Bradley, J. Ix, K. Shea, T. McCluskey, Ex5 Ins Harmonization, D. Majka 2, M. Tsai, P. Greenland, and S. Bielinski - complete. I. DeBoer, R. Bradley, J. Ix, K. Shea, T. McCluskey, B. Kestenbaum 3, and Rpt2 VitD, Ex5 Ins Harmonization, D.
Serum	44	4858	571	12%	0	40	531	4815	2023	1853	76	2			Majka 2, M. Tsai 4, P. Greenland, and S. Bielinski - complete.
CPT	45	6769	6769	100%	0	6769	0	0	0	0	0				·
CPT	46	6770	6770	100%	0	6770	0	0	0	0	0				
CPT	47	6772	6772	100%	0	6772	0	0	0	0	0				
CPT	48	6769	6769	100%	0	6769	0	0	0	0	0				
CPT	49	6764	6764	100%	0	6764	0	0	0	0	0				
CPT	50	6766	6766	100%	0	6766	0	0	0	0	0				
CPT	51	6759	6759	100%	0	6759	0	0	0	0	0				
CPT	52	6745	6745	100%	0	6745	0	0	0	0	0				
CPT	53	6733	6733	100%	0	6733	0	0	0	0	0				
CPT	54	6700	6700	100%	0	6700	0	0	0	0	0				
CPT	55	6662	6662	100%	0	6662	0	0	0	0	0				
CPT	56	6632	6632	100%	0	6632	0	0	0	0	0				
CPT	57	6582	6582	100%	0	6582	0	0	0	0	0				
CPT	58	6505	6505	100%	0	6505	0	0	0	0	0				
CPT	59	6368	6368	100%	0	6368	0	0	0	0	0				
CPT CPT	60	6205	6205	100%	0	6205	0	0	0	0	0				
CELLS CPT	61	6759	6707	99%	0	6707	0	52	0	0	0			Uminn - Gene Expression (n=52)	Uminn - Gene Expression - complete.
CELLS FAHC	62	6625	6607	100%	0	6607	0	18	0	0	0			Mesa Family cell lines (n=18)	Mesa Family cell lines - complete.
Urine	63	6777	0	0%	0	0	0	6777	0	0	0			UVM Group 1 UMALB (n=6777)	UVM Group 1 UMALB - complete.

MESA STE	ERING (Committee	MEETING						SEI	PTEMBER	17-18,	2014		HIL	TON CRYSTAL CITY HOTEL, ARLINGTON, VA
Туре	Cryo	# Received	# Available	Percent Available	# Reserved	# Fresh Frozen		#1x Used	#2x Used	#3x Used			#6x #7x Used Used Sam	nple Selections	Sample Selection/Comments
URINE	64	6770	6763	100%	0	4	6759	6762	4420	829	43	1	Johr		Mesa Lung cotinine/G. Barr, C. 8), Johnson, B. Kestenbaum 3, and n Shlipak/Peralta - complete. A. Navas- Acien - in progress
ACETI C	65	6749	4976	74%	0	4682	294	2066	150	0	0			estenbaum (n=438) and 3 (n=6), C. tetuolo (n=1772)	B. Kestenbaum - complete. C. Ventetuolo - in progress
Totals:	65	431319	342936		800	279846	63090	150555	35626	15461	5535				

4.2.2 Exam 2

Туре	Cryo	# Rec'd	# Avail.	% Avail.	# Reserved	# Frozen	# Thawed	# 1X Used	# 2X Used	# 3X Used	Sample selections	Sample Selection Status/Comments
EDTA-whole blood	01	6181	0	0%	0	0	0	6181	0	0	Uminn Group 1 Homocysteine (n=6181)	Uminn Group 1 - complete.
											Uminn Group 1 Lipids (n=6186), M. Allison 1 (n=4) and 2	Uminn Group 1 and M. Alison 1 and 2, Mesa
EDTA	02	6192	2396	39%	0	5	2391	6186	3804	3	(n=305), Mesa Lung SHARE (n=1), and S. Bielinski (n=3497) Uminn Group 1 Lipids (n=5), and S. Bielinski (n=1). Drift	. Lung SHARE, and S. Bielinski - complete. Uminn Group 1, and S. Bielinski - complete.
EDTA	03	6187	5984	97%	200	5981	3	5	1	0	selection reserved (n=200)	Drift selection - reserved.
EDTA	04	6190	6190	100%	0	6187	3	2	0	0	Uminn Group 1 Lipids (n=2)	Uminn Group 1 - complete.
EDTA	05	6186	6185	100%	0	6184	1	1	0	0	S. Bielinski (n=1).	S. Bielinski - complete.
EDTA	06	6167	6126	99%	0	6121	5	45	1	0	Cushman/Jenny (n=4), M. Allison 1 (n=1), and S. Bielinski (n=41).	Cushman/Jenny, M. Allison 1, and S. Bielinski - complete
EDTA	07	6126	5782	94%	0	4934	848	1191	74	3	Cushman/Jenny (n=480), M. Allison 1 (n=6), and 2 (n=435), S. Bielinski (n=343), and Mesa Lung SHARE (n=4).	Cushman/Jenny, M. Allison 1 and 2, S. Bielinski, and Mesa Lung SHARE - complete.
EDTA	08	6108	3807	62%	0	3092	715	3015	316	10	Uminn Group 1 Lipids (n=2), M. Allison 1 (n=769) and 2	Uminn Group 1, M. Alison 1 and 2, S.
Citrate	08	6178	5007 6178	62% 100%	0	5092 6177	1	0	0	10 0	(n=304), S. Bielinski (n=2265), and Mesa Lung SHARE (n=3)	. Bielinski, and Mesa Lung SHARE - complete.
Citrate	10	6175	6175	100 %	0	6174	1	0	0	0		
Citrate	11	6177	6177	100 %	0	6176	1	0	0	0		
Citrate	12	6161	6161	100%	0	6160	1	0	0	0		
SCAT	13	6163	6163	100%	0	6162	1	0	0	0		
SCAT	14	6163	6163	100%	Õ	6162	1	0	0	Ő		
SCAT	15	6159	6159	100%	0	6158	1	0	0	0		
SCAT	16	6146	6146	100%	0	6145	1	0	0	0		
Buffy Coat	17	6191	5995	97%	0	5994	1	196	0	0	Sent to Uminn (n=196)	Sent to Uminn - complete.
Serum	18	6190	5872	95%	0	0	5872	6190	1071	0	Uminn Group 1 Chem (n=6190), M. Allison 2 (n=770), and B. Kestenbaum 3 (n=301)	Kestenbaum 3 - complete.
Serum	19	6187	5986	97%	200	5980	6	6	0	0	Uminn Group 1 Chem (n=6), Drift selection reserved (n=200)	Uminn Group 1 - complete. Drift selection -
Serum	20	6183	6183	100%	0	6181	2	1	Õ	Õ	Uminn Group 1 Chem (n=1)	Uminn Group 1 - complete.
Serum	21	6175	6175	100%	0	6173	2	1	0	0	Uminn Group 1 Chem (n=1)	Uminn Group 1 - complete.
Serum	22	6143	5838	95%	0	5833	5	309	0	0	A. Bertoni (n=56), and S. Bielinski (n=253).	A. Bertoni and S. Bielinski - complete.
											V. Shin 2 (n=762), Glucose Drift (n=3), A. Bertoni (n=190), S.	
Serum	23	6084	4095	67%	0	3325	770	2758	69	0	Bielinski (n=1804), M. Allison 2 (n=1), and B. Kestenbaum 3 (n=67)	M. Allison 2, and B. Kestenbaum 3 - complete.
Serum	24	6013	699	12%	0	497	202	5509	0	0	Uminn Grp1 Chem (n=5), Glucose Drift (n=195), A. Bertoni (n=4920), S. Bielinski (n=393), and B. Kestenbaum 3 (n=1).	Uminn Group 1, Glucose Drift, A. Bertoni, S. Bielinski, and B. Kestenbaum 3 - complete.
FAHC Urine	25	6199	0	0%	0	0	0	6199	0	0	UVM Group 1 UMALB (n=6199)	UVM Group 1 UMALB - complete.
Totals:	25	154024	126635		400	115801	10834	37795	5336	16	· · · · · · · · · · · · · · · · · · ·	· · · · · ·

4.2.3 Exam 3

						_ # .						
Type	Crvo	# Received	# Available	% Available	# Reserved	Fresh Frozen	# Thawed	# 1xUsed	# 2xUsed	# 3xUse	edSample Selections	Sample Selection Status/Comments
EDTA	01	5893	5827	99%	0	1	5826	5892	58	4	Uminn Group 1 Lipids (n=5892), M. Allison 1 (n=8) and 2 (n=54)	
EDTA	02	5890	5691	97%	199	5688	3	3	0	0	Uminn Group 1 Lipids (n=3), Drift selection reserved (n=199)	Uminn Group 1 - complete. Drift selection - reserved.
EDTA	03	5889	5888	100%	1	5886	2	2	0	0	Uminn Group 1 Lipids (n=2), Drift selection reserved (n=1)	Uminn Group 1 - complete. Drift selection - reserved.
EDTA	04	5884	5884	100%	0	5884	0	0	0	0		
EDTA	05	5866	5866	100%	0	5861	5	5	0	0	Cushman/Jenny (n=5)	Cushman/Jenny - complete.
EDTA	06	5833	5826	100%	0	4694	1132	1139	12	0	Cushman/Jenny (n=4), M. Allison 1 (n=91) and 2 (n=1056) Uminn Group 1 Lipids (n=5), Cushman/Jenny (n=448),	Cushman/Jenny and M. Allison 1 and 2 - complete. Uminn Group 1, Cushman/Jenny, and M.
										_	M. Allison 1 (n=1089) and 2 (n=125), and Mesa Lung	Allison 1 and 2, and Mesa Lung SHARE -
EDTA	07	5794	5779	100%	0	4245	1534	1546	124	5	SHARE (n=13)	complete.
Citrate	08	5875	5875	100%	0	5875	0	0	0	0		
Citrate	09	5874	5874	100%	0	5874	0	0	0	0		
Citrate	10	5870	5870	100%	0	5870	0	0	0	0		
Citrate	11	5852	5852	100%	0	5852	0	0	0	0		
SCAT	12	5803	5803	100%	0	5803	0	0	0	0		
SCAT	13	5801	5801	100%	0	5801	0	0	0	0		
SCAT	14	5791	5791	100%	0	5791	0	0	0	0		
SCAT	15	5746	5746	100%	0	5746	0	0	0	0		
Serum	16	5890	5855	99%	0	0	5855	5890	100	0	Uminn Group 1 Chem (n=5890), and J. Ix (n=100). Uminn Group 1 Chem (n=2), M. Shlipak (n=1); Drift	Uminn Group 1 and J. lx - complete. Uminn Group 1 and M. Shlipak - complete.
Serum	17	5886	5686	97%	200	5684	2	2	1	0	selection reserved (n=200)	Drift selection - reserved.
Serum	18	5883	5883	100%	0	5875	8	8	5	0	Uminn Group 1 Chem (n=8), M. Shlipak (n=5)	Uminn Group 1 and M. Shlipak - complete
Serum	19	5866	5866	100%	0	5864	2	2	1	0	Uminn Group 1 Chem (n=2), M. Shlipak (n=1)	Uminn Group 1 and M. Shlipak - complete
Serum	20	5830	5830	100%	0	5830	0	0	0	0		
Serum	21	5771	5771	100%	0	5673	98	98	70	0	Daniels/Bahrami (n=74), M. Shlipak (n=94)	Daniels/Bahrami and M. Shlipak - complete Uminn Grp 1, Glucose Drift,
Serum	22	5680	5676	100%	0	10	5666	5670	4606	0	Uminn Grp 1 Chem (n=4), Glucose Drift (n=196), Daniels/Bahrami (n=4629), M. Shlipak (n=5451)	Daniels/Bahrami and M. Shlipak - complete.
FAHC Urine	23	5886	0	0%	0	0	0	5886	0	0	UVM Group 1 UMALB (n=5886)	UVM Group 1 UMALB - complete.
Totals:	23	134353	127940		400	107807	20133	26143	4977	9		

4.2.4 Exam 4

Туре	Cryo	# Received A	# Available	% Available l	# Reserved	# Fresh Frozen	# Thawed	# 1X Used	# 2X Used	Sample Selections	Sample Selection Status/Comments
01	5635	5626	100%	0	0	5626	5635	0	Uminn Group 1 Lipids (n=5635) Uminn Group 1 Lipids	Uminn Group 1 - complete.	01
02 03	5633 5628	5432 5628	96% 100%	200 0	5432 5628	0 0	1 0	0 0	(n=1), Drift selection reserved (n=200)	Uminn Group 1 - complete. Drift selection - reserved.	02 03
03	5622	5622	100%	0	5622	0	0	0			04
04 05	5594	5594	100%	0	5594	0	0	0			05
06	5567	5567	100%	0	5513	54	54	1	Cushman/J enny (n=4), Mesa Air (n=44), and Mesa Lung SHARE (n=7) Cushman/J enny (n=429), Mesa Air (n=412), and Mesa Lung	Cushman/Jenny, Mesa Air, and Mesa Lun SHARE - complete.	
07	5549	5549	100%	0	4579	970	969	10	SHARE	Cushman/Jenny, Mesa Air, and Mesa Lung	g 07
07 08	5549 5625	5549 5625	100%	0 0	4579 5625	970 0	969 0	12 0	(n=140)	SHARE - complete.	07 08
08	5625 5625	5625 5625	100%	0	5625	0	0	0			09
09 10	5625 5617	5625 5617	100%	0	5617	0	0				10
		5596	100%	0	5596	0	0	0 0			10
11 12	5596 5583	5583	100%	0	5583	0	0	0			12
12	5583	5583	100%	0	5583	0	0	0			12
13 14	5565 5572	5572	100%	0	5565 5572	0	0	0			13
14	5572 5549	5549	100%	0	5572 5549	0	0	0			14
()	0049	0049	100%	U	0049	U	U	0			10

Tuna	Crive	# Received	# Availabla	% Available	# Becomvod	# Fresh	# Thowad	# 1X Used	# 2X Used	Sample Selections	Sample Selection Status/Comments
Туре	Cryo	Receiveu	Available	Available	Reserveu	FIOZell	Thaweu	Useu	Uminn	Sample Selections	Sample Selection Status/Comments
									Group 1		
16	5624	5627	100%	0	0	5627	5634	0	Chem		16
16	5634	3027	100%	0	0	3027	2034	U	(n=5634) Umin Group	Uminn Group 1 - complete.	10
									1 Chem)	
									(n=1), Drift		
									selection		
47	5004	5404	000/	000	F 400		0	•	reserved	Uminn Group 1 - complete. Drift selection	17
17	5631	5431	96%	200	5430	1	0	0	(n=200)	- reserved.	17
18	5622	5622	100%	0	5622	0	0	0			18
									Umin Group	0	
19	5605	5605	100%	0	5604	1	1	0	1 Chem	Uming Crown 1. complete	19
19	5005	5005	100 /0	0	5004	I	I	0	(n=1) Mesa Air	Uminn Group 1 - complete	19
									Cotinines		
20	5550	5550	100%	0	5549	1	1	0	(n=1)	Mesa Air Cotinines - complete.	20
									Glucose		
									Drift (n=3),		
									M. Shlipak (n=56), and		
									Mesa Air		
									Cotinines	Glucose Drift, M. Shlipak, and Mesa Air	
21	5484	5482	100%	0	5248	60	61	0	(n=2)	Cotinines - complete	21
									Glucose		
									Drift		
									(n=191), M. Shlipak		
									(n=5208),		
									Mesa Air		
									Cotinines	Glucose Drift, M. Shlipak, and Mesa Air	
22	5426	5413	100%	0	23	5390	5400	179	(n=180)	Cotinines - complete	22
22	122930	122498		400	104594	17730	17756	192			22

HILTON CRYSTAL CITY HOTEL, ARLINGTON, VA

4.2.5 Exam 5

Turne	0	# Deceived	#	%	#	# Fresh	# These d	#1X	#2X	Comula Calcotiana	Commiss Colortion Status/Comments
Type EDTA-	Cryo	Received	Available	Available R	eservea	Frozen	Thawed	Used	Used	Sample Selections	Sample Selection Status/Comments
whole											
blood(HbA1	04	4500	0	00/	0	0	0	4500	0		
c)	01	4582	0	0%	0	0	0	4582	0	Uminn Group 1 HbA1c (n=4582)	Uminn Group 1 - complete
EDTA	02	4584	4584	100%	0	0	4584	4584	0	Uminn Group 1 Lipids (n=4584)	Uminn Group 1 - complete
EDTA	03	4584	4584	100%	0	4584	0	0	0		
EDTA	04	4583	4583	100%	0	4583	0	0	0		
EDTA	05	4583	4583	100%	0	4583	0	0	0		
EDTA	06	4583	4583	100%	0	4583	0	0	0		
EDTA	07	4580	4580	100%	0	4580	0	0	0		
EDTA	08	4579	4579	100%	0	4578	1	1	0	Mesa Air (n=1)	Mesa Air - in progress
EDTA	09	4572	4572	100%	0	4571	0	1	0	Mesa Air (n=1)	Mesa Air - in progress
EDTA	10	4557	4557	100%	0	4555	0	2	0	Mesa Air (n=2)	Mesa Air - in progress
EDTA	11	4540	4540	100%	0	4539	0	1	0	Mesa Air (n=1)	Mesa Air - in progress
EDTA	12	4531	4531	100%	0	4529	0	2	0	Mesa Air (n=2)	Mesa Air - in progress
EDTA	13	4524	4524	100%	0	4522	0	2	0	Mesa Air (n=2)	Mesa Air - in progress
EDTA	14	4504	4504	100%	0	4498	0	6	0	Mesa Air (n=6)	Mesa Air - in progress
EDTA	15	4466	4466	100%	0	4456	0	10	0	Mesa Air (n=10)	Mesa Air - in progress
EDTA	16	4418	4418	100%	0	4398	0	20	0	Mesa Air (n=20)	Mesa Air - in progress
EDTA	17	4299	4297	100%	0	4254	0	45	0	Mesa Air (n=45) Uminn Group 1 Lipids (n=1) and Mesa Air	Mesa Air - in progress
EDTA	18	4069	4059	100%	0	3641	1	428	0	(n=427)	Uminn Group 1 - complete. Mesa Air - in progress
Red Cells	19	4582	3287	72%	0	3287	0	1295	0	Mesa Stress (n=1295)	Mesa Stress - in progress.
SCAT	20	4496	4496	100%	0	4496	0	0	0		
SCAT	21	4496	4496	100%	0	4496	0	0	0		
SCAT	22	4486	4486	100%	0	4486	0	0	0		
SCAT	23	4428	4428	100%	0	4428	0	0	0		
Citrate	24	4575	4575	100%	0	4575	0	0	0		
Citrate	25	4575	4575	100%	0	4575	0	0	0		
Citrate	26	4573	4561	100%	0	4561	0	12	0	Mesa Stress (n=12)	Mesa Stress - in progress.
Citrate	27	4528	3594	79%	0	3594	0	934	0	Mesa Stress (n=934) Uminn Group 1 Chem and Cystatin C	Mesa Stress - in progress.
Serum	28	4589	4589	100%	0	0	4589	4589	0	(n=4589).	Uminn Group 1 - complete

MESA STEER	ING COMM	ITTEE MEETING	3				SEPT	EMBER 17-1	18, 2014		HILTON CRYSTAL CITY HOTEL, ARLINGTON, VA
Туре	Cryo	# Received	# Available	% Available R	# eserved	# Fresh Frozen	# Thawed	#1X Used	#2X Used	Sample Selections	Sample Selection Status/Comments
Serum	29	4589	4589	100%	0	4589	0	0	0		
Serum	30	4587	4587	100%	0	4587	0	0	0		
Serum	31	4587	4587	100%	0	4587	0	0	0		
Serum	32	4587	4586	100%	0	4586	0	1	0	Mesa Stress (n=1)	Mesa Stress - in progress.
Serum	33	4587	4587	100%	0	4587	0	0	0		
Serum	34	4580	4580	100%	0	4580	0	0	0		
Serum	35	4577	4573	100%	0	4573	0	4	0	Mesa Stress (n=4)	Mesa Stress - in progress.
Serum	36	4557	4551	100%	0	4551	0	6	0	Mesa Stress (n=6)	Mesa Stress - in progress.
Serum	37	4538	4532	100%	0	4532	0	6	0	Mesa Stress (n=6)	Mesa Stress - in progress.
Serum	38	4512	4503	100%	0	4503	0	9	0	Mesa Stress (n=9)	Mesa Stress - in progress.
Serum	39	4492	4473	100%	0	4473	0	19	0	Mesa Stress (n=19)	Mesa Stress - in progress.
Serum	40	4442	4400	99%	0	4400	0	42	0	Mesa Stress (n=42)	Mesa Stress - in progress.
Serum	41	4335	4263	98%	0	4263	0	72	0	Mesa Stress (n=72)	Mesa Stress - in progress.
Serum	42	4122	4034	98%	0	4034	0	88	0	Mesa Stress (n=88)	Mesa Stress - in progress.
Serum	43	3809	3672	96%	0	3672	0	137	0	Mesa Stress (n=137)	Mesa Stress - in progress.
Serum Whole	44	3227	2662	82%	0	2662	0	565	0	Mesa Stress (n=565)	Mesa Stress - in progress.
Blood Whole	45	4454	4454	100%	0	4454	0	0	0		
Blood FAHC	46	4339	4339	100%	0	4339	0	0	0		
Urine	47	4553	0	0%	0	0	0	4553	0	UVM Group 1 UMALB (n=4553)	UVM Group 1 - complete
Urine	48	4548	4548	100%	0	1128	3420	3420	0	Mesa Lung Cotinine / G. Barr (n=3420) UVM Group 1 UMALB (n=1) and C. Curl	Mesa Lung Cotinine / G. Barr - complete
Urine Urine/Ac	49	4527	4527	100%	0	4525	2	2	0	(n=1)	UVM Group 1 and C. Curl - complete
etic Acid Urine/Ac	51	4410	4410	100%	0	4409	1	0	0	(Recd in cracked tube)	(Sample transferred to new tube)
etic Acid	52	4277	4277	100%	0	4277	0	0	0		
Totals:	52	227702	215365		0	202263	12598	25438	0		

4.3 MESA Repository Report, as of August, 2014

4.3.1 MESA Repository Availability, by Category

4.3.1.1 Table: Baseline

Baseline N =6806 (baseline cohort IDs N = 6814; received samples on only 6806 cohort Ids)

Baseline

Baseline - EDTA	# cryos	Volume	# FreshCryos Available	% of 6806
Available	3 - 17	<u>></u> 1.0 mL	6795	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	4	0%
No Sample	0	0	7	0%
Baseline - SCAT	# cryos	Volume	# FreshCryos Available	% of 6806
Available	3 - 4	> 1.0 mL	6602	97%
Critical	1 - 2	_ > 0 and < 1.0 mL	169	2%
No Sample	0	0	35	1%
Baseline - SERUM	# cryos	Volume	# FreshCryos Available	% of 6806
Available	3 - 17	<u>></u> 1.0 mL	6781	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	12	0%
No Sample	0	0	13	0%
Baseline - CITRATE	# cryos	Volume	# FreshCryos Available	% of 6806
Available	3 - 4	<u>></u> 1.0 mL	4475	66%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	2301	34%
No Sample	0	0	30	0%

(Table continues on following page)

Baseline Selected 1000 (Group3) n=999

				% of
Baseline - EDTA	# cryos	Volume	# FreshCryos Available	% 01 999
Available	3 - 17		999	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	0	0%
Baseline - SCAT	# cryos	Volume	# FreshCryos Available	% of 999
Available	3 - 4	<u>></u> 1.0 mL	961	96%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	38	4%
No Sample	0	0	0	0%
Baseline - SERUM	# crvos	Volume	# FreshCryos Available	% of 999
Available	3 - 17	<u>></u> 1.0 mL	999	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	0	0%
Baseline - CITRATE	# cryos	Volume	# FreshCryos Available	% of 999
Available	3 - 4	<u>></u> 1.0 mL	0	0%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	999	100%
No Sample	0	0	0	0%

4.3.1.2 Table: Exam 2

Exam 2 N=6211 (based on baseline defined cohort with Exam 2 samples received at Vermont)

Exam 2 n= 6211*				
Exam 2 - EDTA	# cryos	Volume	# FreshCryos Available	% of 6211
Available	2 - 7	> 1.0 mL	6190	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	20	0%
				% of
Exam 2 - SCAT	# cryos	Volume	# FreshCryos Available	% of 6211
Available	3 - 4	<u>></u> 1.0 mL	6158	99%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	5	0%
No Sample	0	0	48	1%
			# FreshCryos	% of
Exam 2 - SERUM	# cryos	Volume	Available	6211
Available	2 - 7	<u>></u> 1.0 mL	6183	100%
Critial	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	3	0%
No Sample	0	0	25	0%
Exam 2 - CITRATE	# cryos	Volume	# FreshCryos Available	% of 6211
Available	3 - 4	<u>></u> 1.0 mL	6175	99%
Critial	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	2	0%
No Sample	0	0	34	1%

(Table continues on following page)

Exam 2 Selected 1000 (Group3) n=926

(Group3) n=926				
Exam 2 - EDTA	# cryos	Volume	# FreshCryos Available	% of 926
Available	2 - 7	<u>></u> 1.0 mL	925	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	1	0%
Exam 2 - SCAT	# cryos	Volume	# FreshCryos Available	% of 926
Available	3 - 4	<u>></u> 1.0 mL	922	100%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	4	0%
			# FreshCryos	% of
Exam 2 - SERUM	# cryos	Volume	Available	926
Available	2 - 7	<u>></u> 1.0 mL	924	100%
Critial	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	1	0%
			# FreshCryos	% of
Exam 2 - CITRATE	-	Volume	Available	926
Available	3 - 4	<u>></u> 1.0 mL	922	100%
Critial	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	4	0%

4.3.1.3 Table: Exam 3

Exam 3 N=5913 (based on baseline defined cohort with Exam 3 samples received at Vermont)

Exam 3				
Exam 3 - EDTA	# cryos	Volume	# FreshCryos Available	% of 5913
Available	<u>2 - 7</u>	> 1.0 mL	5891	100%
Critical	1	<u>></u> 0 and <u><</u> 1.0 mL	2	0%
No Sample	0	0	20	0%
Exam 3 - SCAT	# cryos	Volume	# FreshCryos Available	% of 5913
Available	3 - 4	<u>></u> 1.0 mL	5791	98%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	13	0%
No Sample	0	0	109	2%
Exam 3 - SERUM	# cryos	Volume	# FreshCryos Available	% of 5913
Available	2 - 7	<u>></u> 1.0 mL	5880	99%
Critical	1	<u>></u> 0 and <u><</u> 1.0 mL	6	0%
No Sample	0	0	27	0%
Exam 3 - CITRATE	# cryos	Volume	# FreshCryos Available	% of 5913
Available	3 - 4	<u>></u> 1.0 mL	5870	99%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	5	0%
No Sample	0	0	38	1%

(Table continues on following page)

٦

Exam 3 Selected 1000 (Group3) n=890

Exam 3 - EDTA Available Critical No Sample	<u># cryos</u> 2 - 7 1 0	Volume ≥ 1.0 mL ≥ 0 and ≤ 1.0 mL 0	# FreshCryos Available 884 0 6	% of 890 99% 0% 1%
Exam 3 - SCAT	<u># cryos</u>	Volume	# FreshCryos Available	% of 890
Available	3 - 4	<u>></u> 1.0 mL	871	98%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	19	2%
Exam 3 - SERUM	# cryos	Volume	# FreshCryos Available	% of 890
Available	2 - 7	<u>></u> 1.0 mL	885	99%
Critical	1	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	5	1%
Exam 3 - CITRATE	# cryos		# FreshCryos Available	% of 890
Available	3 - 4	<u>></u> 1.0 mL	882	99%
Critical	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	7	1%

4.3.1.4 Table: Exam 4

Exam 4 N = 5637

Exam 4

				% of
			# FreshCryos	
Exam 4 - EDTA	# cryos	Volume	Available	5637
Available	2 - 7	<u>></u> 1.0 mL	5628	100%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	5	0%
No Sample	0	0	4	0%
				% of
Exam 4 - SCAT	# cryos	Volume	# FreshCryos Available	5637
Available	3 - 4	<u>></u> 1.0 mL	5573	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	12	0%
No Sample	0	0	52	1%
				% of
Exam 4 - SERUM	# cryos	Volume	# FreshCryos Available	5637
Available	2 - 7	<u>></u> 1.0 mL	5620	100%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	11	0%
No Sample	0	0	6	0%
				% of
Exam 4 - CITRATE	# cryos	Volume	# FreshCryos Available	5637
Available	3 - 4	<u>></u> 1.0 mL	5617	100%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	8	0%
No Sample	0	0	12	0%

(Table continues on following page)

Exam 4 Selected 1000 (Group3), (n=847)

				% of
Exam 4 - EDTA	# cryos	Volume	# FreshCryos Available	847
Available	2 - 7	<u>></u> 1.0 mL	846	92%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	7%
No Sample	0	0	1	0%
				% of
Exam 4 - SCAT	# cryos	Volume	# FreshCryos Available	847
Available	3 - 4	<u>></u> 1.0 mL	841	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	6	1%
				% of
Exam 4 - SERUM	# cryos	Volume	# FreshCryos Available	847
Available	2 - 7	<u>></u> 1.0 mL	846	100%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	0	0%
				% of
Exam 4 - CITRATE	# cryos	Volume	# FreshCryos Available	847
Available	3 - 4	<u>></u> 1.0 mL	845	100%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	1	0%

4.3.1.5 Table: Exam 5

Exam 5 n = 4626

Exam 5

				% of
			# FreshCryos	
Exam 5 - EDTA	# cryos	Volume	Available	4626
Available	3 - 17	<u>></u> 1.0 mL	4583	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	42	1%
				% of
Exam 5 - SCAT	# cryos	Volume	# FreshCryos Available	4626
Available	3 - 4	<u>></u> 1.0 mL	4486	97%
Borderline	1 - 2	_ <u>></u> 0 and <u><</u> 1.0 mL	11	0%
No Sample	0	0	129	3%
				% of
			# FreshCryos	
Exam 5 - SERUM	# cryos	Volume	Available	4626
Available	3 - 17	<u>></u> 1.0 mL	4587	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	2	0%
No Sample	0	0	37	1%
				% of
			# FreshCryos	
Exam 5 - CITRATE	# cryos	Volume	Available	4626
Available	3 - 4	<u>></u> 1.0 mL	4561	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	14	0%
No Sample	0	0	51	1%

(Table continues on following page)

Exam 5 Selected 1000 (Group3), (n=728)

				% of
			# FreshCryos	700
Exam 5 - EDTA		Volume	Available	728
Available	3 - 17	<u>></u> 1.0 mL	719	99%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	0	0%
No Sample	0	0	9	1%
				% of
			# FreshCryos	
Exam 5 - SCAT	# cryos	Volume	Available	728
Available	3 - 4	<u>></u> 1.0 mL	698	96%
Borderline	1 - 2	<u>></u> 0 and <u><</u> 1.0 mL	2	0%
No Sample	0	0	28	4%
				% of
Exam 5 - SERUM	# crvos	Volume	# FreshCryos Available	728
Available	3 - 17	> 1.0 mL	722	99%
Borderline	1 - 2	_ <u>></u> 0 and <u><</u> 1.0 mL	1	0%
No Sample	0	0	5	1%
				% of
Exam 5 - CITRATE	# cryos	Volume	# FreshCryos Available	728
Available	<u># cryos</u> 3 - 4	> 1.0 mL	718	99%
Borderline	3 - 4 1 - 2	\ge 0 and \le 1.0 mL	0	0%
	0	<u>2 0 and 5 1.0 mL</u> 0	10	0% 1%
No Sample	U	U	10	1 70

MESA Repository Report, as of August, 2014

4.3.2 MESA DNA Repository Availability, by Category

The following tables show the status of DNA in the MESA repository, as provided by the Clinical Laboratory at the University of Minnesota. Table 1 represents the distribution of DNA remaining in the repository, and Table 2 lists the amount of DNA sent to various laboratories.

4.3.2.1 Table: Distribution of quantities of DNA remaining in MESA Repository

Quantity category	n
<u><</u> 15 ug	36*
16 - 25 ug	12
26 - 50 ug	53
51 - 100 ug	436
101 - 150 ug	724
151 - 200 ug	1023
201 - 300 ug	2202
301 - 400 ug	1299
401 - 500 ug	516
> 500 ug	265
Total	6566

*There is 1 specimen with no DNA.

4.3.2.2 Table: MESA DNA Released

Date Sent	Sent to	Population	Amount Sent	Total sent
				ug DNA
Feb, 2004	Crider/Dries Laboratory	entire cohort	25 uL of 10 ng/uL	0.25
May, 2005	Illumina	MESA Family Candidate Gene Part 1	80 uL of 50 ng/uL	4.00
May, 2006	Kent Taylor@CS	MESA Family Candidate Gene Part 1	200 uL of 10 ng/uL	2.00
May, 2006	Don Bowden@ WF	MESA Family Candidate Gene Part 1	200 uL of 10 ng/uL	2.00
March, 2006	Dan Arking	entire cohort	17uL of 5.2 ng/uL	0.09
Jan, 2007	Diez Roux Telomere Study	selected cohort of 982	10 uL of 26-28ng/uL	0.27
Dec, 2007	CARe	entire cohort	40 uL of 50 ng/uL	2.00
Jan, 2008	Steve Rich/Michele Sale	MESA Family Candidate Gene Part 1	40 uL of 50 ng/uL	2.00
March, 2008	Barry Freedman	308 African Americans	40 uL of 100 ng/uL	4.00
March, 2008	Mike Tsai ApoE/ACE	MESA Family Candidate Gene Part 1	10 uL of 10 ng/uL	0.01
Aug, 2008	SEA, David Herrington	entire cohort	20 uL of 50 ng/uL	1.00
Nov, 2008	Kent Taylor	MESA Family Candidate Gene Part 2	40 uL of 100 ng/uL	4.00
Nov, 2008	Steve Rich/Michele Sale	MESA Family Candidate Gene Part 2	40 uL of 100 ng/uL	4.00
June, 2009	Affymetrix	MESA Classic less AFA	30 uL of 50 ng/uL	1.50
July, 2009	Rick Pilsner/MESA Epigenetics	991 MESA Stress	50 uL of 20 ng/uL	1.00
March, 2010	Jerry Rotter	entire cohort	20 uL of 100 ng/uL	2.00
August 2010- 11	MESA Exome Heart Go	selected cohort of 1000	50 uL of 100 ng/uL	5.00
Aug, 2011	MESA Exome Heart Go	20 selected cohort of 1000	50 uL of 200 ng/uL	10.00
Nov, 2011	MESA Exome Heart Go	25 selected cohort of 1000	50 uL of 200 ng/uL	10.00

Feb, 2012	Jerry Rotter/Kent Taylor	MESA Classic cohort	50 uL of 40 ng/uL	2.00
Feb, 2012	Steve Rich/Michele Sale	MESA Classic cohort	50 uL of 40 ng/uL	2.00
April, 2012	Mike Tsai Alox 5 project	MESA Classic cohort	10 uL of 25 ng/uL	0.25
Total				55.12

Section 5: Datasets

Sect	tion 5: Datasets	101
Intro	oduction	103
5.1	Exam 1 Data	. 103
	5.1.1 Update Status	. 103
5.2	Exam 2 Data	. 104
	5.2.1 Posted Exam 2 Datasets	. 104
	5.2.2 Update Status	. 104
5.3	Exam 3 Data	. 105
	5.3.1 Posted Exam 3 Datasets	. 105
	5.3.2 Update Status	. 105
5.4	Exam 4 Data	. 106
	5.4.1 Posted Exam 4 Datasets	. 106
	5.4.2 Update Status	. 106
5.5	Ancillary Study Data	. 107
5.6	Events Datasets	. 107
5.7	Exam 5 Data	. 108
	5.7.1 Posted Exam 5 Datasets	. 108
	5.7.2 Update Status	. 108
	5.7.3 Exam 5 Descriptive Summary	. 109
5.8	Longitudinal Data Availability (select variables)	. 111

BLANK

102

Introduction

Datasets, documentation and other useful information can be found by following the appropriate Exam Datasets link in the internal MESA website (<u>http://www.mesa-nhlbi.org/Mesa-Internal/mesaData1.asp</u>) and following the Navigation bar for further exams. A password, which is changed every week, is required to access the data files. In addition, people affiliated with MESA must complete the Data Distribution Agreement posted on the MESA web site, under Exam Datasets, and fax (or e-mail) it to David Vu at the Coordinating Center. To obtain the current password, send an email request to David Vu at <u>voodoo@u.washington.edu</u>, and he will contact you by phone with the password. For security reasons, the password will not be given via email.

5.1 Exam 1 Data

Exam 1 (clinic data collected July 17, 2000, to August 29, 2002):

The Exam 1 MESA data was made available May 13, 2003. Datasets are in SPSS, STATA, and SAS formats. In each format, the following files exist:

- Main data file includes variables from clinic procedures and questionnaires, created analytic variables (e.g., body mass index), and key reading center (RC) variables (e.g., average total calcium score).
- **RC and Questionnaire data files**: ECG, CT, MRI, US IMT, US Distensibility, US Endothelial Function, Lipid Blood Groups 1, 2, 3, Urine, sICAM, Sphyngomyelin, Pulsewave, Aortic Valvular Calcium, Physical Activity, and Diet data,. Note that the CT files contain up to two scans per enrollee.

The following MS Word files are posted and contain descriptions of all variables included in the Main and RC datasets:

- main data variables file (sorted by completion form and RC)
- RC variables file (sorted by RC), with additional files for certain data sets
- created variables data dictionary (organized by exam procedure)
- additional individual data sets have further documentation files

5.1.1 Update Status

Updates and changes to the Exam 1 datasets since February 2014 include:

- Assays: Apolipoprotein E data added.
- Cardiac MRI: "Mean LV Wall Thickness, End-Diastole (mm)" variable added
- Commercial Use of Data Consent: Updated with Exam 5 consent information.
- ECG: "Cornell Voltage" variable computed by Reading Center
- ECG: "Left Ventricular Hypertrophy, by Cornell Voltage" variable computed by Reading Center
- Medications: All medication category variables updated to reflect revised category definitions
- "Estimated 10-Year ASCVD Risk Rate" variable added

The complete history of Exam 1 data updates can be found at: http://www.mesa-nhlbi.org/MesaInternal/Exam1 Data/Exam1 Data Updates completed.doc

5.2 Exam 2 Data

Exam 2 (Clinic data collected from September 9, 2002, to February 2004):

The following Exam 2 MESA data is available. Similar to Exam 1, datasets are produced in SPSS, STATA and SAS formats. The SAS files include syntax (.sas), data (.sas7bdat), and contents (.lst) files.

5.2.1 Posted Exam 2 Datasets

- Main
- Anthropometry
- Seated Blood Pressure
- Medical History
- Phlebotomy
- Demographics
- Lipids and Urine
- Family History
- Family History of Diabetes Mellitus
- Health & Life
- Medications
- Personal History
- Sleep History
- CT on 50% of cohort at Exam 2
- CT Wide Exam 2 data with 1 record per participant
- Physical Activity

The Main data file includes commonly used analytic variables from all of these datasets.

5.2.2 Update Status

Updates and changes to the Exam 2 datasets since February 2014 include:

- Medications: All medication category variables updated to reflect revised category definitions
- "Estimated 10-Year ASCVD Risk Rate" variable added

The complete history of Exam 2 data updates can be found at:

http://www.mesa-nhlbi.org/MesaInternal/Exam2Data/Exam2_Data_Updates_completed.doc

5.3 Exam 3 Data

Exam 3 (Clinic data collected from March 2004, to September 2005):

The following Exam 3 MESA data is available. Similar to Exam 1, datasets are produced in SPSS, STATA and SAS formats. The SAS files include syntax (.sas), data (.sas7bdat) and contents (.lst) files.

5.3.1 Posted Exam 3 Datasets

- Main
- Demographics
- Lipids and Urine
- Anthropometry
- CT on 50% of cohort at Exam 3
- CT Wide Exam 3 data with 1 record per participant
- Personal History
- Seated BP
- Medical History
- Medications
- ABI
- Health & Life
- Physical Activity

The Main data file includes commonly used analytic variables from all of these datasets.

5.3.2 Update Status

Updates and changes to the Exam 3 datasets since February 2014 include:

- Medications: All medication category variables updated to reflect revised category definitions
- "Estimated 10-Year ASCVD Risk Rate" variable added

The complete history of Exam 3 data updates can be found at: http://www.mesa-nhlbi.org/MesaInternal/Exam3Data/Exam3 Data Updates completed.doc

5.4 Exam 4 Data

Collection of Exam 4 data began in September 2005 and continued through May 2007:

Preliminary cleaning began 1st quarter 2007 and was completed and posted in 4th quarter 2007. The following Exam 4 MESA data is available. Similar to Exam 1, datasets are produced in SPSS, Stata and SAS formats. The SAS files include syntax (.sas), data (.sas7bdat) and contents (.lst) files.

5.4.1 Posted Exam 4 Datasets

- Main
- Demographics
- Phlebotomy/Lipids
- Anthropometry
- CT on 25% of cohort at Exam 4
- CT Wide Exam 4 data with 1 record per participant
- Personal History
- Sleep History
- Seated BP
- Medical History
- Medications
- Blood Potassium
- Health & Life

The Main data file includes commonly used analytic variables from all of these datasets.

5.4.2 Update Status

Updates and changes to the Exam 4 datasets since February 2014 include:

- Medications: All medication category variables updated to reflect revised category definitions
- "Estimated 10-Year ASCVD Risk Rate" variable added

The complete history of exam 4 data updates can be found at: http://www.mesa-nhlbi.org/MesaInternal/Exam4Data/Exam4 Data Updates completed.doc

5.5 Ancillary Study Data

Thirteen ancillary studies have produced and posted data since February 2014. For the MESA Candidate Gene study, a total of thirty four data sets are available; numerous changes were made to existing datasets.

The complete history of ancillary data updates can be found at: http://www.mesa-nhlbi.org/MesaInternal/ASData/Ancillary Data Updates completed.doc

Note that access to the current ancillary studies requires authorization from the Study PI, and each dataset is posted with its own unique password. This password can also be obtained from David Vu.

5.6 Events Datasets

The Events data sets were updated in January 2014, and now include data through calendar year 2011. See Section 3 for a description of the data sets and further information on the status of Events surveillance, data collection and adjudication.

5.7 Exam 5 Data

Collection of Exam 5 data began in April 2010 and continued through April 2013.

Preliminary cleaning began 2nd quarter 2011 and was completed and posted in 3rd quarter 2012. The following Exam 5 MESA data is available. Similar to Exam 1, datasets are produced in SPSS, Stata and SAS formats. The SAS files include syntax (.sas), data (.sas7bdat) and contents (.lst) files.

5.7.1 Posted Exam 5 Datasets

- Main
- Demographics
- Cardiac CT
- ECG
- MRI
- Ankle-Brachial Index
- Anthropometry
- Lipids (includes Phlebotomy and Urine data)
- Seated BP
- Cognitive Assessment
- Digit Span and Symbol
- Erectile Dysfunction
- Health and Life Questionnaire
- Medical History Questionnaire
- Medications
- Personal History Questionnaire
- Physical Activity

Availability of ancillary data collected during Exam 5 will be at the discretion of ancillary study investigators.

5.7.2 Update Status

Updates and changes to the Exam 5 datasets since February 2014 include:

- CT Cardiac: recomputed to exclude QC cases
- ECG: "Any Major or Minor ECG Abnormalities per Minnesota Code" variable computed
- ECG: "Cornell Voltage" variable computed by Reading Center
- ECG: "Left Ventricular Hypertrophy, by Cornell Voltage" variable computed by Reading Center
- ECG: P-Wave continuous waveform variables updated by Reading Center
- Medications: All medication category variables updated to reflect revised category definitions
- MRI Myocardial Scarring: data posted.
- MRI Tagging: data posted.
- "Estimated 10-Year ASCVD Risk Rate" variable added

The complete history of exam 5 data updates can be found at: <u>http://www.mesa-nhlbi.org/MesaInternal/Exam5Data/Exam5_Data_Updates_completed.doc</u>

5.7.3 Exam 5 Descriptive Summary

	N	Mean	SD	Minimum	Median	Maximum
DEMOGRAPHICS						
SITE						
WAKE FOREST	813 (17%)					
COLUMBIA	810 (17%)					
JOHNS HOPKINS	658 (14%)					
MINNESOTA	771 (16%)					
NORTHWESTERN	876 (19%)					1
UCLA	788 (17%)					1
RACE / ETHNCITY						1
WHITE, CAUCASIAN	1926 (41%)					
CHINESE AMERICAN	541 (11%)					
BLACK, AFRICAN-AMERICAN	1250 (27%)					
HISPANIC	999 (21%)					
GENDER						
FEMALE	2514 (53%)					
MALE	2202 (47%)					
AGE AT EXAM 5	4655	70	9	53	69	94
CHD RISK		-				
NCEP 10-YEAR HARD CHD RISK (fmcep5c)	3633	.09	.07	.00	.08	.30
JAMA 2001 10-YEAR HARD CHD RISK (frjama5c)	4532	.09	.08	.01	.06	.76
CIRCULATION 1998 10-YEAR ALL CHD RISK	4532	.10	.08	.02	.08	.77
METABOLIC SYNDROME BY NCEP (mtsy035c)			.00		.00	
NO	2901 (63%)					1
YES	1673 (37%)					1
DIABETES (2003 ADA FASTING CRITERIA)						
NORMAL	2726 (59%)					1
IMPAIRED FASTING GLUCOSE	948 (21%)					1
UNTREATED DIABETES	85 (2%)					1
TREATED DIABETES	836 (18%)					1
ANTHROPOMETRY						1
WEIGHT (lb)	4643	172.1	39.3	76.0	168.9	352.2
HEIGHT (cm)	4646	165.3	10.0	136.0	164.9	198.0
BODY MASS INDEX	4642	28.48	5.66	14.58	27.71	56.01
ANKLE-BRACHIAL INDEX						
ANKLE-BRACHIAL INDEX	4436	1.12	.15	.35	1.13	3.45
BLOOD PRESSURE	1100		.10	.00	1.10	0.10
SEATED SYSTOLIC BLOOD PRESSURE (mmHg)	4653	124.13	20.92	62.00	120.50	250.00
SEATED DIASTOLIC BLOOD PRESSURE (mmHg)	4653	68.25	10.07	36.50	68.00	123.00
SEATED PULSE PRESSURE (mmHg)	4653	55.9	17.4	15.0	53.0	152.0
SEATED HEART RATE (BEATS PER MINUTE)	4653	64.37	10.72	28.50	63.50	123.00
HYPERTENSION BY JNC VI (1997) CRITERIA	+000	04.07	10.72	20.00	00.00	120.00
NO	1875 (40%)					
YES	2778 (60%)					
HYPERTENSION	2110 (0070)					-
OPTIMAL	2193 (47%)					-
NORMAL	781 (17%)					-
HIGH-NORMAL	657 (14%)					1
STAGE 1 HYPERTENSION	722 (16%)					+
STAGE 2 HYPERTENSION	204 (4%)					+
STAGE 3 HYPERTENSION	65 (1%)					+
CARDIAC CT	03(1/0)			1		1
ADJUSTED CORONARY CALCIUM SCORE	3300	297 70	505.62	00	42.97	6388.93
	3300	287.70	595.62	.00	42.97	0366.93
COGNITIVE ASSESSMENT	4500	07	44	4	00	100
TOTAL COGNITIVE ASSESSMENT SCORE	4588	87	11	1	89	100

Exam 5 Descriptive Summary (continued)

	N	Mean	SD	Minimum	Median	Maximum
LAB ASSAY		mean	00	winner	median	Maximum
SERUM INSULIN (mIU/L)	4162	60.26	49.12	3.00	48.00	1039.00
HEMOGLOBIN A1C	4558	6.0	.9	3.2	5.8	16.0
FASTING GLUCOSE (mg/dl)	4587	102	29	38	95	448
TOTAL CHOLESTEROL	4582	183		75	181	372
DESIRABLE, <200	3128 (68%)					
BORDERLINE HIGH, 200-239	1134 (25%)					
HIGH, 240+	320 (7%)					
LDL CHOLESTEROL (mg/dl)	4559	105	37	12	103	310
OPTIMAL, <100	2106 (46%)		-			
NEAR OPTIMAL, 100-129	1427 (31%)					
BORDERLINE HIGH, 130-159	767 (17%)					
HIGH, 160-189	214 (5%)					
VERY HIGH, 190+	45 (1%)					
HDL CHOLESTEROL (mg/dl)	4581	56	17	22	53	187
HIGH, 60+	1583 (35%)					
40-59	2358 (51%)					
LOW, <40	640 (14%)					
TRIGLYCERIDES (mg/dl)	4582	109	62	21	95	931
NORMAL, <150	3782 (83%)					
BORDERLINE HIGH, 150-199	489 (11%)					
HIGH, 200-499	302 (7%)					
VERY HIGH, 500+	9 (0%)					
CREATININE (mg/dl)	4587	.923	.405	.270	.870	12.200
GLOMERULAR FILTRATION RATE (MDRD)	4587	80.05	21.30	3.15	79.14	246.95
GLOMERULAR FILTRATION RATE (CKD-EPI)	4587	79.08	18.22	2.98	81.58	141.85
MEDICATIONS / SUPPLEMENTS						
HYPERTENSION MEDICATION	2609 (55%)					
INSULINS	147 (3%)					
ORAL HYPOGLYCEMIC AGENTS	672 (14%)					
LIPID-LOWERING MEDICATION	1834 (39%)					
MULTI-VITAMINS	1023 (35%)					
MRI						
LV END DIASTOLIC VOLUME	3013	119.23	31.71	37.40	115.40	310.20
LV END SYSTOLIC VOLUME	3012	46.12	18.18	11.90	43.00	210.90
LV EJECTION FRACTION (%)	3012	61.92	7.32	23.70	62.30	83.30
LV STROKE VOLUME (mL)	3012	73.11	18.46	23.30	71.00	161.60
LV END-DIASTOLIC MASS (g)	3013	123.01	33.84	51.10	117.70	285.50
PERSONAL HISTORY						
CIGARRETTE SMOKING STATUS						
NEVER	2098 (45%)					
FORMER	2188 (47%)					
CURRENT	365 (8%)					
CIGARRETTE SMOKING PACK-YEARS	4604	10.92	20.55	.00	.00	272.24
PHYSICAL ACTIVITY						
TOTAL INTENTIONAL EXERCISE (MET-MIN/WK)	3498.34	4638	2702.68	.00	1650.00	69367.50
MODERATE & VIGOROUS PA TOTAL (MET-MIN/WK)	4638	4298.43	4889.00	.00	2883.75	97110.00
ULTRASOUND IMT						
RIGHT CCA MEAN (mm)	3405	.8666	.2151	.4320	.8310	3.0680
LEFT CCA MEAN (mm)	3383	.8665	.2342	.3860	.8250	3.1400
URINE						
URINARY ALBUMIN (mg/dl)	4552	3.38	16.01	.10	.60	380.00
URINARY CREATININE (mg/dl)	4552	109.34	69.28	4.00	96.40	573.50
URINARY ALBUMIN/CREATININE (mg/g)	4552	36.35	177.55	.40	6.10	3643.40
					*	
NORMAL	3942 (87%)					
MICROALBUMINURIA	511 (11%)					
MACROALBUMINURIA	99 (2%)					
	(=, •,					

5.8 Longitudinal Data Availability (select variables)

	Exam 1	Exam 2	Exam 3	Exam 4	Exa	n 5 *
Measurement	Count	Count	Count	Count	Count	% exam 1 count
BMI1C: body mass index (kg)/(m^2)	6814	6226	5939	5702	4642	68%
SBP1C: seated systolic blood pressure (mmHg)	6811	6221	5936	5698	4653	68%
DM971C: diabetes mellitus by 1997 ADA fasting criteria	6790	5923	5912	5662	4595	68%
OLVEDM1: LV End-Diastolic Mass (g)	5004	-	-	-	3013	60%
AGATPM1C: Agatston calcium score, phantom-adjusted (mean)	6814	2954	2804	1406	3300	48%
RDCCAMNAVG5: Right Common Carotid Mean (mm)	3220	-	-	-	3405	106%
QTDUR1: QT Interval (msec)	6765	-	-	-	4613	68%
CHOL1: total cholesterol (mg/dl)	6791	6183	5892	5634	4582	67%
LDL1: LDL total cholesterol (mg/dl)	6701	6112	5810	5577	4559	68%
GLUCOSE1: fasting glucose (mg/dl)	6789	6182	5887	5634	4587	68%
HBA1C2: Serum Hemoglobin A1c	-	6142	-	-	4162	68%
UALBCRE1:urinary abumin/creatinine (mg/g)	6775	6145	5885	NA	4552	67%
ABI1C: Ankle-Brachial Index	6735	-	5885	-	4436	66%

BLANK

112

Section 6: Ancillary Studies

Sect	tion 6: Ancillary Studies	. 113
6.1	New and Revised Proposals	115
6.3	Ancillary Study Proposals of Ancillary Studies (none)	116
6.6	MESA Ancillary Studies Status Tables	117

BLANK

6.1 New and Revised Proposals

Since the last report in February, 2014, the Ancillary Studies Committee (ASC) has reviewed seventeen new proposals. Sixteen of the new proposals were subsequently approved for review by the Steering Committee.

The following ASC reviews were conducted either by conference call or by email:

New Approved Proposals:

- A249 Age-associated Vascular and Cardiac Changes. Joao Lima, Eliseo Guallar, So Yeon Lim, Russell Tracy, Myron Gross, Kiang Liu, Donald Lloyd-Jones, Colin Wu, Erin P. Ricketts, David Jacobs, David Bluemke, Alban Redheuil, Yoshiaki Ohyama.
- A250 Epigenetic roles in regulation of cholesterol metabolism and CVD risk. Yongmei Liu, David Herrington, Jingzhong Ding, John Parks, Jennifer Van Eyk, Russell P. Tracy, Ina Hoeschele.
- A251 The Insulin Axis and Diabetes Risk: Effects of Microbiome Diversity and Host Genome in a Multiethnic Cohort. Mark Goodarzi, Steve Rich, Martin Wu, Joe Mychaleckyj, Ani Manichaikul, Suna Onengut (UVA), Lekki Wood (Baylor), Jim Pankow, Aaron Folsom, Alain Bertoni, Karol Watson, Mike Tsai, Jerome Rotter, Yii-Der Ida Chen, Kent Taylor, Xiuqing Guo.
- A252 Epigenomics and transcriptomics of cognitive decline Jingzhong Ding, Yongmei Liu, Annette Fitzpatrick, Steve Rapp, Ina Hoeschele, Teresa Seeman, Jose Luchsinger, Constantine Lyketsos, Alvaro Alonso.
- A253 Obesity, Immunity and Epigenetic Changes in a Cholesterol Metabolism Network. Jingzhong Ding, Yongmei Liu, Russell Tracy, Bruce Psaty, Ina Hoeschele, David Herrington, Wendy Post, David Jacob, Steve Shea, .Gregory Burke.
- A254 Atrial fibrillation, cardiac MRI, and vascular disease of the brain in MESA. Susan Heckbert, David Bluemke, Nick Bryan, Greg Burke, Lin Yee Chen, Aaron Folsom, Phil Greenland, Tamara Horwich, Dick Kronmal, João Lima, Kiang Liu, Robyn McClelland, Wendy Post, Bruce Psaty, Steve Shea, Sayed Soliman, Preethi Srikanthan, Russ Tracy, Karol Watson.
- A255 From Risk Factors to Early Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Alain Bertoni, Sanjiv Shah, Gregory Burke, Joseph Yeboah, Haiying Chen, Carlos Rodriquez, Sylvia E. Rosas, Rahul Deo, Julio Chirinos.
- A256 Determinants of Mobility, Usual Physical Activity and Quality of Life in an Elderly Multi-Ethnic Cohort. Matthew Allison, Michael Criqui, Mary Cushman, Mary McDermott, Robyn McClelland.
- A257 Coronary Atherosclerosis and the effects of Intestinal Microbiota, Diet and Genetics in MESA. Matthew Budoff, Stephen Rich, Jerome Rotter, Wendy Post, Jeff Carr, Robyn McClelland, Joao Lima, Alexis Frazier-Wood, Martin Wu, Kent Taylor, Xiuqing Guo.
- A258 Pulmonary Perfusion in MESA. The MESA Lung Study III. Graham Barr, Matt Budoff, Aaron Folsom, John Hankinson, Eric Hoffman, David Jacobs, Richard Kronmal, Kiang Liu, Wendy Post, Daniel Rabinowitz, Steven Shea, Russ Tracy, Karol Watson.

- A259 Vitamin D pharmacogenomics. Ian de Boer, Bryan Kestenbaum, David Siscovick, Russ Tracy, Jerry Rotter, Steve Rich.
- A260 Urinary KNOWledge study (U-KNOW). Holly Kramer, Kiang Liu, Linda Brubaker, Sue Penckhofer, Kate Wolin, Alan Wolf.
- A261 HDL-mediated cholesterol efflux and carotid FDG PET in MESA Steven Shea, Alan Tall, Wendy Post, Joao Lima, David Bluemke, James Stein, Zahi Fayad, Mani Vankatesh, Daniel Rabinowitz.
- A262 The Spectrum of Non-Esterified Fatty Acids and Cardiometabolic Disease in Older Adults. Luc Djousse, Kenneth J Mukamal, David Siscovick, Michael Tsai, Alice Arnold, Mary Lou Biggs, Jorge Kizer, Joachim Ix.
- A263 Defining A Reference Profile of Circulating Extracellular RNA. Kenneth Mukamal, Nancy Jenny, Jane Freedman, Chris O'Donnell.
- A264 Idiopathic Hypoglycemic Symptoms and Incident Cardiovascular Disease. Morgana Mongraw-Chaffin, Matthew Allison, Cheryl Anderson, Andrea LaCroix, Dorothy Sears.

Proposals Not Approved (none)

6.3 Ancillary Study Proposals of Ancillary Studies (none)

6.6 MESA Ancillary Studies Status Tables

Table 1: All Ancillary studio

	N (%)
Proposals ^[1]	269 (100%)
Withdrawn ^[2]	47 (15%)
Funding pending ^[3]	87 (32%)
Funded/active ^[4]	102 (40%)
Completed ^[5]	33 (13%)

The full status table can be viewed online at the following link: <u>http://www.mesa-nhlbi.org/Mesa-Internal/AncillaryS/</u>

^[1] Proposals include all ancillary study proposals but not proposals designated as substudies (procedure or questionnaire included in an exam without separate funding).

^[2] Withdrawn are approved ancillary study proposals that were never funded and officially declared as no longer being pursued by the ancillary study PI.

^[3] Funding pending indicates ancillary studies that have not yet been funded (yet).

^[4] Funded active indicate ancillary studies that have received notice of funding award or work on the study has begun (if no funding involved).

^[5] Complete indicates an ancillary study whose work has officially ended.

BLANK